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Abstract 
 
The liver is a common target for xenobiotic-induced toxicity. Of importance, synthesis of soluble 
coagulation factors by the liver plays an essential role in hemostasis.  Blood coagulation cascade 
activation is evident in both human patients and in animal models of liver injury.  Several studies have 
shown that coagulation is not merely a process reactive to toxicity, but rather a critical determinant of 
liver disease pathogenesis. Previous studies have utilized global anticoagulation as a strategy to 
investigate the role of coagulation in liver injury.  Currently, our understanding of the mechanisms 
whereby individual coagulation proteases contribute to hepatotoxicity is inadequate.   
 Blood coagulation is initiated by tissue factor (TF), a transmembrane cellular receptor for the 
coagulation factor VII/VIIa.  The TF:VIIa complex initiates a serine protease cascade, which culminates 
in the generation of the serine protease thrombin.  Thrombin cleaves circulating fibrinogen to initiate 
fibrin clot formation.  Additionally, thrombin signals to multiple cell types through activation of protease 
activated receptors (PARs), which can promote inflammation and platelet aggregation.  The procoagulant 
response is balanced by several anticoagulant proteins and fibrin clot degradation is catalyzed by plasmin, 
the main endogenous fibrin degradation enzyme.  The aim of this dissertation was to determine the role of 
several blood coagulation cascade components in the responses elicited by two model hepatotoxicants; α-
naphthylisothiocyanate (ANIT) a toxicant that damages bile duct epithelial cells (BDECs), and 
acetaminophen (APAP), a common analgesic that causes centrilobular hepatocellular necrosis at high 
doses.   
We found that TF-dependent generation of thrombin contributed to the progression of chronic 
ANIT-induced hepatic inflammation and fibrosis by a mechanism requiring PAR-1. PAR-1 activation 
amplified TGF-β1-induced αVβ6 integrin expression by BDECs, and activation of TGF-β signaling in 
vivo. This suggests a novel feed-forward mechanism whereby coagulation can promote fibrogenesis. In 
contrast, PAR-1 was not required for the acute hepatotoxic effects of ANIT. Rather, ANIT-induced liver 
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injury occurred by a mechanism involving activation of PAR-4 on platelets and fibrin(ogen). The results 
highlight a differential contribution of thrombin signaling in acute and chronic cholestatic liver injury.  
Previous studies identified the primary inhibitor of fibrinolysis, plasminogen activator inhibitor-1 
(PAI-1), as a key hepatoprotective factor in APAP-induced liver injury. Indeed, hepatic fibrin deposition 
is a prominent feature of APAP-induced hepatocellular necrosis. To our surprise, fibrin(ogen) did not 
contribute to acute APAP-induced liver injury. Of importance, plasminogen deficiency reduced APAP 
hepatotoxicity. Taken together, the results suggest that plasmin(ogen) promotes APAP-induced liver 
injury in a fibrin independent manner.   
 Overall, these studies revealed novel pathways whereby elements of the coagulation cascade 
promote liver injury induced by two classical hepatotoxicants.  The results suggest that individual 
coagulation cascade components may play divergent roles in different models of liver injury and 
potentially at different time points during injury development.  Further studies systematically evaluating 
individual coagulation factors in animal models and human disease are required to fully understand the 
dynamic contribution that coagulation cascade proteins play in liver injury.   
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Chapter 1 
Introduction 
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1.1 Background  
The liver plays an essential role in the homeostasis of multiple biological processes and is a major 
site of metabolism for both endogenous and exogenous (xenobiotic) molecules (Casarett et al., 2008).  A 
majority of this metabolic capacity is generated by the high expression levels of metabolizing enzymes 
such as cytochrome P450 enzymes, conjugation enzymes, and transport proteins expressed by hepatocytes 
(HPCs).  HPCs are also known as liver parenchymal cells and represent approximately 80% of the liver 
mass (Casarett et al., 2008).  The expression of these particular proteins in HPCs allows for the rapid 
transport, exchange, and metabolism of compounds into and out of the blood plasma.  As the liver is the 
first organ to receive blood from the intestine via the portal vein, this extensive metabolic capacity serves 
as an effective protective mechanism to eliminate hazardous compounds out of the diet before they enter 
systemic circulation (Jacquot, 1978).  However, these same features also make the liver more susceptible 
to some drug-induced hepatotoxicities, resulting in a major factor for molecule abandonment during the 
drug development process and various drug-drug interactions that can lead to withdrawal of therapeutic 
treatment in the clinic (Navarro and Senior, 2006).   
1.2 Functions and zonation of the liver 
   Examining the basic functional architecture of the liver can serve as a good reference point to 
help illuminate some features and mechanisms of drug-induced liver injury.  The most basic unit of the 
liver is the hepatic sinusoid, which resembles a large complex capillary lined by sinusoidal endothelial 
cells, which separate the HPCs from blood.  In contrast to other organs, the hepatic sinusoidal endothelial 
cells create a fenestrated (porous) barrier (McCuskey, 2000), which allows for HPCs to be chronically 
bathed in plasma proteins from the blood and creates a site that allows for relatively free exchange of 
molecules and proteins between HPCs and blood.  Additionally, there are other non-parenchymal cells 
dispersed throughout the liver such as kupffer cells, stellate cells, bile duct epithelial cells (BDEC), and 
other resident immune cells that perform various functions (Casarett et al., 2008).  Blood enters the 
sinusoid from the hepatic portal vein and the hepatic artery.  These two sources meet in the sinusoid at a 
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region called the portal area, also known as zone 1 within the liver lobule, and directional perfusion 
proceeds through the midzonal (zone 2) and centrilobular (zone 3) regions exiting the liver through the 
central vein (Casarett et al., 2008).  This unidirectional blood flow in the hepatic sinusoid creates an 
oxygen tension gradient between these three zones, having the highest oxygen levels in zone 1 and the 
least in zone 3.  Additionally, intracellular levels of glutathione and expression of conjugation enzymes 
are highest in zone 1 of the hepatic lobule.  Interestingly, zone 3 has the highest expression levels of 
cytochrome P450, which makes this region of the liver lobule more susceptible to injury from compounds 
requiring bioactivation by these enzymes (Lindros, 1997).   
Another function of HPCs is the synthesis and secretion of bile, which is used to aid in absorption 
of fat and fat soluble compounds (Casarett et al., 2008).  As blood perfuses the liver, bile acids are 
actively taken up from HPCs and transported into the biliary tree.  The biliary tree is made up of both 
small and large bile ducts, which are channels that guide bile out of the liver emptying into a storage 
vessel called the gall bladder.  After a meal, bile leaves the gall bladder through the common bile duct 
where it drains into the intestine to help break down lipid droplets by forming smaller micelles.  The 
micelles can then be readily taken up into the small intestine and transported to the liver via the hepatic 
portal vein completing the cycle.  Disruption of this bile flow out of the liver is termed cholestasis and can 
occur through multiple mechanisms.   One mechanism whereby cholestasis can occur is through a 
decrease in bile acid uptake transporter expression and/or activity on the sinusiodal membrane of HPCs.  
Alternatively, several mechanisms exist whereby biliary excretion may be disrupted at the canalicular 
membrane in HPCs (Glaser et al., 2010; Wagner et al., 2010; Padda et al., 2011).  Additionally, direct 
injury to BDECs causes an increase in bile duct permeability and subsequently causes cholestasis 
originating from the portal area.     
4 
 
1.3 Mechanisms and models of liver injury 
1.3.1 Mechanisms of liver injury  
Exposure to some xenobiotics can cause direct cellular injury, which can be exemplified in 
APAP-induced hepatotoxicity.  Treatment of purified cultured HPCs with APAP causes direct 
cytotoxicity as indicated by increase release of intracellular enzymes such as lactose dehydrogenase into 
the cellular medium (Yan et al., 2010).  Similarly, high exposure of other compounds such as bile acids 
can cause cell death by apoptosis in cultured HPCs (Reinehr et al., 2003).  However, during in vivo 
pathogenesis of liver injury, additional factors are present that can promote injury secondary to the 
original insult.  For example, in bile duct ligation (BDL), primary injury is mediated by increased biliary 
pressure and spilling of bile acids into the liver parenchyma; however, the injury during the secondary 
injury progression stage is reduced in mice that are deficient in CD18, an essential cellular receptor for 
neutrophils (Gujral et al., 2003).  This secondary injury can also be seen in models of hepatic ischemic 
reperfusion injury, where initial injury is limited, but secondary inflammation associated with this model 
promotes further hepatocellular death (Eltzschig and Eckle, 2011).  Insofar as human patients enter the 
clinic at different stages of injury development, the ability to separate primary and secondary drug-
induced liver injuries may help predict the overall outcome of hepatoxicity and may help to improve 
recovery by pharmacologically targeting specific key players during different phases of the injury 
progression.     
Another contributor to the extent of liver injury is the ability of healthy HPCs to proliferate and 
replenish damaged or dying parenchymal cells.  This is classically exemplified in partial hepatectomy, 
where 3/5 of a mouse liver is removed and the subsequent cellular division causes the liver to “grow” 
back to its normal size in several weeks (Rabes, 1976).  This is also true for xenobiotic-induced liver 
injury such as in APAP-hepatotoxicity where complete resolution of APAP-induced liver injury can be 
observed in a matter of days for mice and a matter of weeks for surviving patients (Bernal et al., 2010; 
Jaeschke et al., 2011).  Inhibition of key components that promote HPC proliferation can lead to severe 
liver injury and delayed normalization of liver function. 
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Several liver diseases and drugs such as ethyl alcohol, methotrexate, isoniazid, and others can 
chronically injure the liver, which can cause a viscous cycle of tissue injury, inflammation, and repair.  
During acute wound healing, several profibrotic genes, such as transforming growth factor beta-1 (TGF-
B1) and Type-I collagen help stabilize the damaged area and provide a temporary "Band-aid" by 
increasing the deposition of extracellular matrix (ECM) in the injured area.  Additionally, ECM 
remodeling proteins such as matrix metalloproteinases (MMPs), and tissue inhibitor of metalloprotinases 
(TIMPs), help coordinate the breakdown and reconstruction of the ECM during the recovery phase of 
injury.  During chronic liver injury, this beneficial Band-aid can eventually develop into excessive ECM 
deposition termed fibrosis.  Uncontrolled fibrosis can limit hepatic function by developing into cirrhosis 
through constant synthesis and deposition of ECM proteins and by inhibiting the pathways that naturally 
break down and remodel the ECM (Bataller and Brenner, 2005).  Generally, the activated myofibroblast 
is considered the main cell type responsible for liver fibrosis as it contributes substantially to the 
production of type-I collagen, a main fibrotic component of extracellular matrix (Bataller and Brenner, 
2005; Friedman, 2008).  Within the liver, activated myofibroblasts may come from several pools of cells 
including quiescent stellate cells, portal fibroblasts, and fibroblast like cells of bone marrow origin 
(Bataller and Brenner, 2005; Friedman, 2008; Dranoff and Wells, 2010).  Importantly, several key 
profibrogenic molecules that promote liver fibrosis have been identified.  One of which is platelet derived 
growth factor B (PDGF-B), which is a potent mitogen for stellate cells (Bataller and Brenner, 2005; 
Friedman, 2008).  Additionally, transforming growth factor beta (TGF- ) has been shown to stimulate 
quiescent stellate cells and portal fibroblasts to promote their transition into activated myofibroblasts and 
is one of the most potent inducers of ECM synthesis in activated myofibroblasts (Friedman, 2008).   
Identifying ways to limit liver fibrosis could help delay the development of cirrhosis in some patients and 
may be beneficial in limiting the number of liver transplantations needed in patients with chronic liver 
diseases. 
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1.3.2 Examples of drug-induced liver injury in zone 1 
Injury initiating in zone 1 of the liver is frequently associated with cholestasis and can be seen 
after exposure to several xenobiotics including 4,4’methylene dianyline (MDA), flucloxacillin, and alpha-
naphthylisothiocyanate (ANIT) (Becker and Plaa, 1965; Kopelman et al., 1966; McNeil et al., 1999; 
Dietrich et al., 2001; Giouleme et al., 2011).  MDA is a curing agent for epoxy resins for the use in 
manufacture of polyurethane foams and has occupational exposure relevance.  MDA toxicity was first 
observed in 1965 when 84 people consumed MDA contaminated bread in Great Britain, which resulted in 
jaundice and liver injury (Kopelman et al., 1966).  Similarly, ANIT is also toxic to BDECs causing 
cholestasis, which is dependent upon ANIT transport into the bile to exert its toxic affect (Dietrich et al., 
2001).  This model toxicant has been used to identify mechanisms and mediators of liver injury initated 
by BDEC injury.  Injury to BDECs can also be seen in patients with an acute biliary obstruction or in 
rodents subject to bile duct ligation due to an increase in biliary pressure.  In response to BDECs injury, 
bile ducts begin to lose integrity, which allows high concentrations of bile acids to seep out into the 
surrounding liver parenchyma, which promotes local inflammation and injury (Stang-Voss and Appell, 
1981; Dietrich et al., 2001). 
In contrast to acute drug-induced liver injury, chronic injury to BDECs by ANIT or extended 
BDL also can elicit cholestasis, inflammation, and can promote biliary fibrosis.  Similarly, several liver 
diseases also promote chronic BDEC injury, cholestasis, and fibrosis such as in patients presenting with 
primary billiary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and patients with genetic 
polymorphisms in the phospholipid transporter multidrug resistance protein 3 (familial cholestasis) 
(Bhandari et al., 2011; Lindor, 2011; Morotti et al., 2011).  Understanding the mechanisms of chronic 
BDEC injury on the development of fibrosis could play an essential role in developing drug targets to 
prevent cirrhosis and liver failure in these patients.   
1.3.2 Examples of drug-induced liver injury in zone 3 
APAP is a classical hepatotoxicant, which is estimated to be responsible for more than 24,000 
hospitalizations and approximately 500 deaths per year.  Overdose of this drug also represents the most 
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common cause of drug-induced liver failure in the United States (Blackford et al., 2011).  The toxicity of 
this compound is completely dependent on the ability of cytorchrome P450s to metabolize this drug into 
the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) which is rapidly detoxified through 
sulfation, glucuronidation, and glutathionylation conjugation pathways at therapeutic doses (Jaeschke et 
al., 2011).  At supratherapeutic doses, the sulfation and glucuronidation detoxification pathways are 
overwhelmed and glutathione conjugation becomes the dominant detoxification pathway.  In APAP 
poisoning, the depletion of hepatocellular glutathione levels becomes the rate limiting step required for 
hepatotoxicity.  Subsequently, as centrilobular HPCs have the highest expression levels of CYP450 
enzymes, zone 3 hepatocytes are the most susceptible to develop hepatocellular necrosis after APAP 
poisoning (Lindros, 1997).  Injury initiating from this zone can also be seen in exposure to several other 
compounds such as the model toxicant carbon tetrachloride and the anti-cancer agent cyclophosphamide, 
which both require CYP450 bioactivation (Raucy et al., 1993; Gut et al., 2000).   
APAP-induced hepatotoxicity can be modeled in rodents, of which mice are the predominant 
species due to the increased availability of genetically modified animals and a higher sensitivity to the 
toxic effects of APAP poisoning when compared to rats (Jaeschke et al., 2011).  In relationship to human 
patients, the mouse model of APAP-induced hepatotoxicity develops much faster.  Human patients begin 
to develop clinical signs of liver injury such as elevated serum transaminase levels around 24 hours after 
ingestion and peak injury is generally seen between 24-72 hours in surviving patients.  Depending on 
dose, liver injury assessed by both histology and serum transaminase activity levels in most mouse 
models of APAP-induced toxicity can be seen as early as 2 hours and peak injury is observed between 16-
24 hours after administration.  Additionally, complete recovery in surviving mice is generally seen by 72 
hours, whereas human patients that are treated in the clinic receiving therapies such as N-actetylcysteine 
to limit liver injury, may take 96 hours or more to fully recover (Ganey et al., 2007; Blackford et al., 
2011; Jaeschke et al., 2011).  These time course discrepancies between humans and mice are important 
observations to consider when trying to translate animal data into human relevance. 
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In addition to HPC cell death, other cell types have also been suggested to be a direct target of 
APAP-induced hepatotoxicity.  One such cell type is the sinusoidal endothelial cell.  Patients presenting 
with APAP-overdose have elevated serum levels of hylauronic acid, a molecule generally cleared by the 
SECs and considered a general marker of SEC injury in some models (Williams et al., 2003).  
Interestingly, APAP-toxicity in mice is associated with red blood cell infiltration into the Space of Disse 
in areas adjacent to injured hepatocytes.  Sinusiodal hemorrhage has been suggested to be a consequence 
of SEC damage, as similar hemorrhage is seen in several classical models of SEC toxicity such as in 
monocrotaline- and cyclophosphamide-induced liver injury (Gismondi et al., 1980; Copple et al., 2006).  
Furthermore, SECs have been shown to express CYP450 enzymes, and APAP can be directly toxic to 
SECs that express high levels of CYP450 in cell culture models (DeLeve et al., 1997).  However, the 
affect of APAP on SECs and the role that these cells and others may play in the progression of APAP-
induced liver is still a field of intense study.     
1.4 Blood coagulation in liver disease 
1.4.1 Overview of the blood coagulation cascade  
The blood coagulation cascade is an essential pathway composed of several serine proteases, 
cellular receptors, and soluble mediators (Fig. 1.1).  In healthy subjects, blood coagulation is regulated at 
the level of activation, as most coagulation proteins are synthesized as zymogens and require an activation 
step to reveal enzymatic activity.  Normally, the coagulation cascade pathway is kept in an inactive, but 
“ready to go” state so that in response to harmful stimuli such as tissue damage, the blood coagulation 
cascade can be rapidly activated to prevent hemorrhage (Mackman, 2004).  The coagulation cascade is 
composed of two procoagulant pathways, the intrinsic and the extrinsic pathways, the latter acting as the 
major activator of blood coagulation.  The extrinsic pathway is initiated by tissue factor (TF), a cell 
surface receptor for the coagulation factor VII/VIIa (Mackman, 2004).  The physical expression pattern of 
TF represents a unique regulatory mechanism to keep hemostasis in balance (Drake et al., 1989; 
Mackman, 2004).  Expression of TF has been described as a “hemostatic envelope” having high 
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expression levels on cells adjacent to, but not on endothelial cells, therefore restricting the contact of TF 
with blood (Drake et al., 1989).  When tissue injury occurs, loss of vascular integrity and increased 
vascular permeability can cause blood and coagulation factors to leak out of the vasculature, which brings 
TF into contact with its ligand; coagulation factor VIIa.  The TF:VIIa complex initiates the coagulation 
serine protease cascade activating several proteases culminating in the generation of thrombin, the distal 
serine protease (Mackman, 2004).   
As TF expression is a major contributor to the regulation of its pro-coagulant activity, it is 
interesting to note that the expression of TF activity is present in liver, albeit relatively low levels when 
compared to other organs such as the brain and heart (Drake et al., 1989; Ganey et al., 2007).  A recent 
study has shown that BDECs express TF, which contributes to TF-dependent coagulation cascade 
activation during liver injury in ANIT-induced toxicity (Luyendyk et al., 2009).  Of importance, previous 
studies have also shown that purified HPCs express a procoagulant form of TF (Stephenne et al., 2007).  
This poses a unique regulatory challenge to the liver microcirculation as the liver both receives a large 
volume of blood and is also the primary site of coagulation factor synthesis (Casarett et al., 2008).  This 
suggests that TF activity must be regulated by a secondary mechanism within the liver to prevent 
pathologic clot formation.   
A previous study suggested that the majority of TF staining in HPCs was intracellular, suggesting 
a physical division between TF and coagulation factors within the perfusing plasma.  However, additional 
intracellular barriers would also have to be in place to prevent TF-VIIa interactions within the cell at the 
site of protein synthesis.  However, an alternative hypothesis would be that TF is held in an inactive non-
procoagulant state until some “trigger” activates this protein.  This has been shown in several cell culture 
models where TF expression is not procoagulant until cells are stimulated with a calcium ionophore, 
which reveals TF-dependent procoagulant activity suggesting an additional mechanism of regulation in 
addition to expression levels (Bach, 2006).  Other studies have suggested that modification of certain 
amino acids in TF can render it incapable of initiating a procoagulant response, however, the localization 
and regulation of TF in HPCs is not completely understood.     
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In addition to regulating the expression and activation of TF to control blood coagulation cascade 
activation, the procoagulant response is also balanced by anticoagulant pathways in order to prevent 
excessive pathologic clotting and to localize the procoagulant response at the site of injury.  These 
pathways are initiated by several endogenous inhibitors and feedback loops.  One such example of an 
endogenous feedback inhibitory pathway is initiated by the interaction of the procoagulant serine protease 
factor X and tissue factor pathway inhibitor (Mackman, 2004; Mackman, 2005).  Together these two 
proteins can limit coagulation by locally inhibiting the action of the TF:VIIa complex and therefore 
limiting the procoagulant response.  In similar fashion, the procoagulant serine protease thrombin can also 
activate protein C, another anticoagulant protein.  When bound to thrombomodulin, this complex can 
inhibit activated factors V and VIII (Mackman, 2004; Mackman, 2005).  Furthermore, thrombin and to a 
lesser extent factor X has its own direct inhibitor, anti-thrombin III, which can bind both of these proteins 
rendering them inactive (Mackman, 2004; Mackman, 2005).  Anti-thrombin III is a clinically relevant 
target for anticoagulant therapy and can be targeted by the use of heparins, another class of anticoagulants 
that act by increasing the affinity of anti-thrombin III for thrombin and factor X (Soff, 2012).  
Additionally, thrombin anti-thrombin complexes are commonly used as a stable clinical marker of 
coagulation cascade activation, as the half life of activated thrombin is relatively short in plasma (~30 
seconds) due to its high affinity and rapid binding to anti-thrombin III (Abildgaard, 1969; Abildgaard et 
al., 1974).  Together, these anticoagulant pathways help modulate and fine tune the extent of coagulation 
in response to injury and help limit coagulation to the local site of injury (Mackman, 2004; Mackman, 
2005). 
1.4.2 Downstream functions of coagulation cascade activation 
A main downstream effect of coagulation is the formation of a rigid fibrin clot, which forms a 
physical barrier in the injured tissue and prevents hemorrhage.  In addition to being a physical barrier, 
several proteins have also been shown to physically bind fibrin clots such as the gpIIb/ 3 (GPIIb/IIIa), 
MAC-1 (αMβ2) and V 3 integrins, which can contribute to local infiltration of platelets and 
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inflammatory cells in the injured tissue (Kubo et al., 2001; Mosesson, 2003).  The stability of these fibrin 
clots are regulated by several mechanisms including their size, density, the extent of crosslinking of the 
fibrin polymers, which is performed by a transglutaminase factor XIII (Mackman, 2004; Mackman, 
2005).  Additionally, the stability of these clots are also determined by the activity of the fibrinolytic 
pathway, a series of enzymes responsible for fibrin degradation (Schaller and Gerber, 2011).  Plasmin is 
the main enzyme responsible for direct dissolution of fibrin clots (Schaller and Gerber, 2011).  Plasmin, 
similar to most other coagulation factors, is a zymogen and is kept in an inactive state (plasminogen), but 
can be converted to an active protease by cleavage from the plasminogen activators: urokinase-type 
plasminogen activator (uPA) and tissue-type plasminogen activatior (tPA) (Schaller and Gerber, 2011).  
The fibrinolytic pathway is also regulated by inhibitory pathways, and can be inhibited at the level of the 
plasminogen activators by plasminogen activator inhibitor 1 (PAI-1) while plasmin can be directly 
inhibited by 2-macroglobulin and 2-antiplasmin (Schaller and Gerber, 2011).  In addition to fibrin clot 
dissolution, components of the fibrinolytic pathway have been shown to contribute to several repair 
mechanisms during wound healing.  For example, cleavage of plasminogen creates two products, active 
plasmin and a peptide called angiostatin; the latter is a potent inhibitor of angiogenesis (O'Reilly et al., 
1994).  Additionally, fibrin degradation products produced by plasmin have also been shown to promote 
angiogenesis in endothelial cells (Bootle-Wilbraham et al., 2001).  Furthermore, additional targets have 
been identified for the protease tPA, such as hepatocyte growth factor, an essential molecule in liver 
regeneration, (Mars et al., 1993) further suggesting that the fibrinolytic pathway is essential in proper 
resolution of liver injury.   
Outside of classical clot formation, thrombin can contribute to hemostasis by regulating the 
activity of platelets by activating the cell surface G-protein coupled receptors protease activated receptor 
1 (PAR-1) and PAR-4 (Kahn et al., 1998; Coughlin, 1999).  Importantly, a species difference exists on 
the expression pattern of PAR receptors between humans and mice.  Humans express both the high 
affinity thrombin receptor PAR-1 and the lower affinity PAR-4 on platelets whereas mouse platelets 
express PAR-4 and PAR-3; the latter acts as a high affinity co-receptor for thrombin/PAR-4 interaction 
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(Kahn et al., 1998; Coughlin, 1999; Sambrano et al., 2001).  Activation of these PARs on platelets 
enhances their activation and aggregation capacity.  Importantly, PAR stimulation on platelets causes a 
conformational change in the fibrin/fibrinogen receptor gpIIb/ 3 to promote platelet intercalation into the 
fibrin clot, which stabilizes the clot and further prevents hemorrhage (Kahn et al., 1998).  Additionally 
PAR-1 and PAR-4 have also been shown to be expressed by numerous cell types other than platelets such 
as liver stellate cells which may contribute to liver injury and fibrosis (Fiorucci et al., 2004; Rullier et al., 
2006).   
Several other components of the procoagulant pathway also have signaling functions outside of 
classical fibrin clot formation and platelet activation.  For example, TF can activate PAR-2 when bound to 
factor VIIa and factor X has been shown to activate both PAR-1 and PAR-2 under certain conditions 
(Borensztajn and Spek, 2011; Rothmeier and Ruf, 2012).  Furthermore, PAR-1, PAR-2, and PAR-4 have 
been shown to be expressed by several cell types within the liver and have been shown to participate in 
the pathogenesis of multiple liver injuries (Copple et al., 2003; Fiorucci et al., 2004; Martinelli et al., 
2008; Luyendyk et al., 2010).  The mechanism whereby PARs contribute to drug induced toxicities is 
most likely through the regulation of the local inflammatory response.  However, as with platelets, 
stimulation of PAR-1 on fibroblasts is thought to cause changes in the cytoskeleton that may activate 
certain cellular receptors such as the profibrotic αVb6 integrin which contributes to a model of drug-
induced pulmonary injury (Munger et al., 1999).  Additionally, stimulation of PAR-1 or PAR-4 causes 
stellate cell contraction and thrombin can induce endothelial cell contraction (Fiorucci et al., 2004; 
Kolozsvari et al., 2009).  Contraction of these two cell types is an essential determinant of portal pressure 
in the liver and may help limit or coordinate blood flow within the injured liver.  Furthermore, during 
chronic liver injury and fibrosis, excessive portal pressure may lead to esophageal varices (Bari and 
Garcia-Tsao, 2012).   However, the specific mechanisms whereby PARs contribute to the different phases 
of injury seem to be greatly diverse and model dependent.  
In addition to PAR signaling, alternative signaling functions for several coagulation proteins have 
also been described.  For example, TF can also interact with several integrins and can promote 
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angiogenesis in some cell types (Dorfleutner et al., 2004).  Similarly, alternative substrates for the 
protease plasmin have been found, such as the matrix metalloproteinases (MMP) MMP-2 and MMP-9 
and have been shown to play a role in several models of drug induced toxicity (Shanmukhappa et al., 
2006; Schaller and Gerber, 2011).  Additionally uPA can signal through ligation of its receptor uPAR, 
which can alter its enzymatic activity (Ngo et al., 2011).  Taken together, the blood coagulation cascade is 
a highly dynamic pathway that prevents hemorrhage and is kept in check by an anticoagulant and 
fibrinolytic pathway.  Several protein components of this pathway have multiple functions outside of 
classical coagulation cascade through interaction with cellular receptors.  These receptors contribute to 
disease pathology through regulating other non-hemostatic functions such as local inflammation, cellular 
signaling, and extracellular matrix remodeling.  Further studies are required to understand the specific cell 
types and mechanisms whereby effecter molecules affect different liver injuries in patients. 
1.5 Coagulation in liver injury and disease 
1.5.1 Background 
In addition to performing essential metabolic and detoxification processes, the liver is also the 
primary site for synthesis of new coagulation factors and the site for exchange of consumed coagulation 
factors (Mammen, 1992; Casarett et al., 2008).  Controlling appropriate plasma concentrations and 
synthesis of coagulation factors by the liver represents an essential primary regulatory mechanism to 
control coagulation.  A prime example of this hepatic regulatory feature has been exploited in the clinic 
by the use of the common anti-coagulant drug warfarin.  Warfarin works as a vitamin K epoxide 
reductase inhibitor, an essential enzyme in the maturation step of several procoagulant coagulation factors 
including factor II, VII, IX, and X (Ansell et al., 2008).  In the clinical application, a mild synthesis defect 
can lower systemic coagulation factor levels and has an anticoagulant effect which can be beneficial for 
some patients.  However, these patients must be carefully monitored as moderate failure of the liver to 
regulate the synthesis of these factors can lead to unbalanced hemostasis resulting in severe and 
potentially fatal hemorrhage (Zareh et al., 2011).  Insofar as warfarin therapy can cause life threatening 
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hemorrhage, several other hepatic diseases and drug-induced hepatotoxicities have been associated with 
reduced coagulation factor levels and decreased hemostatic function (Mammen, 1992; Segal et al., 1997; 
Copple et al., 2002b; Kerr et al., 2003; Ganey et al., 2007; Luyendyk et al., 2010).   
1.5.2 The role of coagulation on liver injury in zone 1 of the hepatic lobule 
 Acute zone 1 induced liver injury in rodents has identified several abnormalities in hemostasis.  
ANIT-induced hepatotoxicity is associated with TF-dependent coagulation cascade activation indicated 
by increased plasma TAT levels and hepatic fibrin deposition (Luyendyk et al., 2009).  Reduction in 
coagulation and hepatic fibrin deposition in TF-deficient mice is associated with reduced liver injury 48 
hours after ANIT administration, indicated by a decrease in serum ALT, ALP, and serum bile acid levels 
(Deng et al., 2009).  Similarly, in models of acute MDA hepatotoxicity and biliary obstruction fibrin 
deposition is evident in the injured liver (Santa Cruz et al., 2007; Wang et al., 2007c); however, the role 
of hepatic fibrin and coagulation on acute injury in these two models of zone 1 induced liver injury is not 
known. 
One mechanism whereby the coagulation cascade could contribute to acute ANIT-induced liver 
injury is through the activation of protease activated receptors on platelets as ample coagulation cascade 
activation and thrombin generation is present by this time.  Platelets have been shown to be involved in 
several models of liver injury (Kuroda and Shiohara, 1996; Hisakura et al., 2010).    Interestingly, liver 
injury was reduced 24 hours after ANIT administration in rats that were depleted of platelets (Bailie et al., 
1994).  Similarly, mice depleted of platelets had reduced liver injury 12 hours after BDL (Laschke et al., 
2008).  In that same study, administration of a neutralizing p-selectin antibody also reduced liver injury to 
a similar extent, suggesting that platelets are involved in the early injury after BDL (Laschke et al., 2008).  
In contrast to acute cholestasis, mice genetically deficient in platelets had increased fibrosis after bile duct 
ligation, suggesting that platelets may play a second role in liver injury outside of the initial insult phase 
and may contribute to the repair process in this model.  As decreased platelet counts have been observed 
in patients with PBC/PSC, this could suggest that platelet therapy might attenuate liver fibrosis during 
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chronic cholestasis (Pihusch et al., 2002; Kodama et al., 2010).  However, whether the coagulation system 
is responsible for the activation of platelets and the mechanisms whereby they contribute to cholestatic 
induced liver injury is not known.  
Another mechanism whereby coagulation may contribute to liver injury during cholestasis is 
through activation of PAR-1, which has been shown to contribute to several models of liver injury and is 
expressed by several cell types within the liver (Copple et al., 2003; Fiorucci et al., 2004; Jesmin et al., 
2006; Ganey et al., 2007; Luyendyk et al., 2010).  Rats given a PAR-1 antagonist had reduced liver injury 
and fibrosis 31 days after BDL (Fiorucci et al., 2004).  This reduction in liver injury could be due to a 
decreased inflammatory response as monocyte chemotactic protein 1 (MCP-1) was reduced in this model.  
Of importance, MCP-1 is influential in attracting circulating monocytes and lymphocytes, the latter are 
thought to be essential for injury progression in cholestasis-induced liver injury (Dahm et al., 1991; Roth 
and Dahm, 1997; Gujral et al., 2003; Seki et al., 2009).  As PAR-1 expressing fibroblasts contribute to 
liver injury in this zone, other cell types that express PAR-1 should also be evaluated in this model of 
liver injury. 
During chronic cholestasis, several components of the fibrinolytic pathway are altered such as 
increased PAI-1 levels and decreased levels of plasminogen and a2-antiplasmin (Segal et al., 1997).  
Additionally, components of the fibrinolytic pathway have been shown to contribute to liver injury after 
BDL.  For example, mice that are deficient in PAI-1, the main endogenous inhibitor of fibrinolysis, have 
reduced levels of liver injury after BDL and consequentially these mice also have reduced levels of 
fibrosis, suggesting that enhanced PA activity and potentially enhanced clearance of fibrin clots may be 
protective in this model (Bergheim et al., 2006).  In agreement with these results, deficiency in tPA led to 
increased liver injury after BDL (Wang et al., 2007c).  As expected, liver injury in these mice was also 
associated with an increase in hepatic fibrin deposition and increased neutrophil accumulation which 
promotes liver injury in BDL (Wang et al., 2007c).  As CD18 is a component of the fibrin binding MAC-
1 integrin and is essential for liver injury in BDL, these data might suggest that fibrin promotes liver 
injury in cholestatic-induced liver injury by promoting neutrophil accumulation in areas of fibrin 
16 
 
deposition (Gujral et al., 2003; Flick et al., 2004).  However, fibrinogen-deficiency was associated with 
both increased liver injury and hepatic neutrophil accumulation in ANIT-induced liver injury suggesting a 
different role for fibrin between these two models (Luyendyk et al., 2011a).  Additional studies are 
required to identify the mechanisms whereby fibrin and fibrinolysis contribute to cholestatic liver injury 
and fibrosis.  
1.5.3 The role of coagulation in liver injury in zone 3 of the hepatic lobule 
 APAP is a well known classical zone 3 hepatotoxicant and several alterations in coagulation 
parameters are evident in patients presenting with APAP-induced toxicity (Gazzard et al., 1975; Kerr et 
al., 2003; Ganey et al., 2007).  Patients that present with APAP-induced hepatotoxicity have increased 
plasma levels of TAT complexes suggesting that coagulation is activated in these patients.  Furthermore, 
increased TAT is also associated with decreased levels of coagulation factors II, V, VII, and X, while 
factors IX and XI are relatively normal in these patients (Gazzard et al., 1975; Kerr et al., 2003).  This 
suggests that the liver has the capacity to synthesize sufficient levels of these proteins and that these 
patients are potentially suffering from a consumptive coagulopathy (Gazzard et al., 1975; Kerr, 2003).  
Additionally, thrombocytopenia is also observed in human patients suffering from APAP-induced 
hepatotoxicity, and the severity of liver injury is inversely proportional to the patients’ platelet count 
(Skokan et al., 1973; Fischereder and Jaffe, 1994).  Interestingly, these same phenomena can be 
reproduced in mice given a single hepatotoxic dose of APAP, which is accompanied by a decrease in 
circulating plasma fibrinogen levels, increased hepatic fibrin deposition, and decreased platelet counts, 
suggesting that the mouse model of APAP-induced liver injury recapitulates some of the hemostatic 
defects seen in human patients (Ganey et al., 2007; Bougie et al., 2010).  The majority of coagulation in 
this model is TF-dependent as thrombin generation is dramatically reduced in TF-deficient mice given a 
hepatotoxic dose of APAP (Ganey et al., 2007).  Of importance, TF-deficient mice or wild type mice 
pretreated with the anticoagulant heparin have reduced liver injury and hepatic fibrin deposition 6 hours 
after APAP administration (Ganey et al., 2007).  Taken together this suggests that coagulation cascade 
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activation is present in both mice and patients suffering from APAP-hepatotoxicity and that coagulation 
contributes to the progression of APAP-induced liver injury. 
 Another classical zone 3 hepatotoxicant is carbon tetrachloride.  Carbon tetrachloride was once 
widely used as an industrial solvent, but has since been phased out due to its hepatotoxicity effects and its 
role in ozone depletion (Recknagel, 1967; Hutzinger, 1980).  Similar to APAP, carbon tetrachloride is 
also metabolized to a reactive intermediate by the cytochrome P450s (Raucy et al., 1993).  Early studies 
with this compound identified numerous effects on the blood coagulation cascade in rats given 
hepatotoxic doses of carbon tetrachloride including increased thrombin times, hepatic hemorrhage, and 
increased hepatic fibrinogen deposition (Scott and Howell, 1964; Rake et al., 1973).  Similar to APAP, 
thrombocytopenia is also observed in rats given a hepatotoxic dose of carbon tetrachloride (Yamashita et 
al., 2000).  This could suggest that in both of these models, coagulation cascade activation could 
contribute to thrombocytopenia by activating platelets and promoting their aggregation in the injured 
liver, however, whether coagulation activates platelets in these two models is not known.   
Another mechanism whereby coagulation activation could contribute to both APAP and carbon 
tetrachloride hepatotoxicity is through activation of PAR-1.  PAR-1-deficiency reduced early APAP-
induced liver injury, however, PAR-1 deficiency did not alter the extent of acute liver injury in carbon 
tetrachloride toxicity (Ganey et al., 2007; Rullier et al., 2008).  Although there was no difference in liver 
injury, PAR-1 promoted liver fibrosis in the chronic model of carbon tetrachloride induced liver injury 
(Rullier et al., 2008).  The decrease in hepatic fibrosis in PAR-1-deficient mice was associated with a 
decrease in a-smooth muscle actin, a marker for activated fibroblasts, the main collagen producing cell 
types within the liver (Friedman, 2008; Rullier et al., 2008).  Furthermore, FV Leiden mice, which carry a 
mutation in FV and are hypercoagulable, develop enhanced fibrosis, whereas mice treated with the 
anticoagulant warfarin develop less fibrosis after chronic tetrachloride induced liver injury (Anstee et al., 
2008).  PAR-1 signaling has been shown to affect several cell types within the liver including stimulating 
stellate cells to produce collagen (Fiorucci et al., 2004), which is probably the main cell type responsible 
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for liver fibrosis in the carbon tetrachloride model of liver fibrosis, however, the important hepatic 
cellular sources of contributing PAR-1 in acute APAP-induced liver injury is not known. 
 As thrombocytopenia is induced in both APAP and carbon tetrachloride-induced liver injury 
(Yamashita et al., 2000; Bougie et al., 2010), another mechanism whereby coagulation cascade activation 
could contribute to liver injury is through thrombin-dependent activation of platelets by PARs.  A recent 
study has suggested that mice given prostacyclin, an inhibitor of platelet activation, protects against 
APAP-induced liver injury (Cavar et al., 2009).  Similarly, several studies have identified prostacyclins 
and several prostacyclin derivatives to be protective after carbon tetrachloride induced liver injury 
(Divald et al., 1985).  Other studies have shown that inhibiting platelets by giving either aspirin or platelet 
activating factor receptor antagonists, reduced liver injury in rodent models of APAP-induced 
hepatotoxicity (Grypioti et al., 2006; Imaeda et al., 2009).  Furthermore, as there is abundant thrombin 
and hepatic fibrin generated after APAP-induced toxicity, this could stimulate platelets locally to promote 
their aggregation and release of granules in the liver.  However, another group showed that administration 
of low dose aspirin did not protect against APAP-induced liver injury (Williams et al., 2011).  Further, 
studies are required to identify whether platelets contribute to the progression of acute APAP and carbon 
tetrachloride-induced liver injury.  Additionally, platelets should be evaluated in the chronic model of 
carbon tetrachloride induced liver fibrosis, as platelets have been shown to contribute to liver fibrosis 
after BDL.  Furthermore, studies should be performed to identify whether the thrombocytopenia is 
dependent on coagulation cascade activation in these two models. 
  Similar to zone 1-induced liver injury, the fibrinolytic system also contributes to xenobiotic-
induced liver injury progression and resolution.  In contrast to BDL where enhanced fibrinolytic activity 
seems to have a protective effect in liver injury, PAI-1 deficiency in the mouse model of APAP-induced 
toxicity is associated with increased hepatocellular injury, sinusoidal hemorrhage, and mortality (Bajt et 
al., 2008).  PAI-1-deficiency was also associated with an increase in liver injury and an increase in liver 
fibrosis in mice treated with carbon tetrachloride (von Montfort et al., 2010).  However, tPA-deficient 
mice had increased liver fibrosis in this model (Hsiao et al., 2008).  Interestingly, in the acute carbon 
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tetrachloride model, uPA-deficiency did not protect against liver injury, but significantly delayed the 
repair and regeneration of liver injury (Shanmukhappa et al., 2006).  Interestingly, this result was 
completely independent of both its receptor uPAR or tPA activity.  These studies clearly identify a role 
for several components of the fibrinolytic pathway in both acute and chronic liver injury in this zone of 
the liver.  However, the role of both uPA and tPA should be explored in both the acute and resolution 
phases of APAP-induced liver injury.  Furthermore, as both PAI-1- and tPA-deficient mice had increased 
fibrosis, this suggests that these two proteins contribute to liver fibrosis through different mechanisms.  
Further studies are needed to understand the mechanisms whereby uPA, tPA, and PAI-1 contribute to 
both acute and chronic liver injury after carbon tetrachloride.   
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1.6 Figures 
Figure 1.1 
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Figure 1.1: A summary of the blood coagulation cascade 
The blood coagulation cascade is tightly controlled by both procoagulant (red) and anticoagulant (blue) 
proteins, which regulate the extent of coagulation cascade activation and subsequent fibrin clot formation.  
Fibrin clot dissolution is also regulated by enzymes in the fibrinolytic pathway (black).  Additionally, 
several coagulation factors such as thrombin and factor Xa have extracellular signaling functions by 
activating protease activated receptors (PARs; green), G-protein coupled receptors that can promote 
platelet aggregation and local inflammation. 
1.7 Summary and overview of dissertation    
 In summary, the liver plays an essential primary role in hemostasis by regulating the synthesis of 
coagulation factors.  The location and function of the liver also predisposes this organ to drug-induced 
liver injury by xenobiotics, which can cause altered hemostasis in patients through several mechanisms.  
Furthermore, multiple components of the blood coagulation system have been shown to contribute to 
drug-induced hepatotoxicity, however, these mechanisms seem to be various and model-dependent.  
Understanding how components of the blood coagulation system contribute to drug-induced liver injury 
could help identify novel targets for therapeutic intervention to limit injury and fibrosis in some patients.  
Additionally, as some components of the fibrinolytic pathway contribute to liver repair and regeneration, 
pharmacologically targeting this pathway might be beneficial to speed up recovery times in patients with 
acute liver injury.   
Inasmuch as coagulation is associated with liver injury, we utilized two model hepatotoxicants to 
evaluate the role of several components of the coagulation cascade in drug-induced liver injury 
originating from two different zones of the liver.  The first half of the dissertation describes how the 
coagulation cascade contributes to zone 1 related hepatotoxicity by the use of ANIT, a selective BDEC 
toxicant that causes cholestasis.  When looked at from a short term perspective, using a rodent model of 
ANIT toxicity can help identify mechanisms whereby the coagulation cascade can participate in direct 
hepatotoxicity in response to BDEC damage.  In addition, this model hepatotoxicant can be used to study 
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mechanisms associated with fibrosis during chronic injury to BDECs and we further explore the role of 
PAR-1 activation on the regulation of several profibrogenic genes in a cell culture model using BDECs.  
The second part of the dissertation describes the role of coagulation in APAP-induced hepatotoxicity, a 
classical zone 3 hepatotoxicant and a drug that commonly causes acute liver failure.   
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Protective and damaging effect of platelets in acute cholestatic liver injury revealed by depletion 
and inhibition strategies. 
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2.1 Abstract 
Alpha-naphthylisothiocyanate (ANIT) causes cholestatic hepatitis characterized by intrahepatic bile duct 
epithelial cell (BDEC) injury and periportal hepatocellular necrosis. The progression of ANIT-induced 
hepatocyte injury is reported to involve extrahepatic cells including platelets. We showed recently that the 
procoagulant protein tissue factor (TF) is essential for ANIT-induced coagulation and contributes to 
ANIT-induced liver necrosis. Platelets have been shown to express TF and can contribute to coagulation 
cascade activation. To this end, we tested the hypothesis that platelet-dependent coagulation contributes 
to ANIT-induced liver injury. In ANIT (60 mg/kg)-treated mice, activation of the coagulation cascade 
occurred prior to a decrease of platelets in the blood. Immunostaining for glycoprotein IIb (CD41) 
revealed platelet accumulation along the borders of necrotic foci in livers of ANIT-treated mice. 
Antibody-mediated platelet depletion did not affect coagulation, but markedly affected liver 
histopathology in ANIT-treated mice. Platelet depletion induced marked pooling of blood within necrotic 
lesions consistent with parenchymal-type peliosis as early as 24 hours after ANIT treatment. In contrast, 
treatment with the P2Y12 inhibitor clopidogrel significantly reduced ANIT-induced hepatocyte necrosis 
and serum ALT activity, but did not exaggerate bleeding into necrotic foci. Clopidogrel also reduced 
hepatic neutrophil accumulation but did not affect induction of ICAM-1 or KC/Gro  mRNA expression 
in liver. The data indicate that ANIT-induced coagulation is platelet-independent and that platelets 
contribute to ANIT-induced hepatocyte necrosis by promoting neutrophil accumulation. In contrast, 
severe thrombocytopenia induces parenchymal-type peliosis in the livers of ANIT-treated mice, a rare 
hepatic lesion associated with pooling of blood in the liver. 
2.2 Introduction 
 Acute intrahepatic cholestatic liver injury is modeled by administration of the xenobiotic alpha-
naphthylisothiocyanate (ANIT), which selectively injures intrahepatic bile duct epithelial cells (BDECs) 
after oral administration (Plaa and Priestly, 1976).  Damage to bile ducts causes the release of high 
concentrations of bile acids into the liver sinusoids. Although bile acids are cytotoxic to hepatocytes 
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(Perez and Briz, 2009), several studies suggest that the progression of acute cholestatic liver injury 
involves multiple mediators. For example, neutrophil depletion or deficiency in the 2 integrin CD18 
reduced liver necrosis induced by bile duct ligation (BDL) or ANIT treatment (Dahm et al., 1991; Gujral 
et al., 2003; Kodali et al., 2006). The coagulation cascade also contributes to BDL- and ANIT-induced 
liver injury (Abdel-Salam et al., 2005; Luyendyk et al., 2009). Platelets also appear to contribute to 
cholestatic liver injury (Bailie et al., 1994; Laschke et al., 2008). Taken together, these studies indicate an 
important role of elements of blood in cholestatic liver injury. 
 Previous studies using BDL as a model of obstructive cholestasis indicated that platelets 
contribute to cholestatic liver injury by promoting induction of chemotactic factors and the accumulation 
of neutrophils in the liver (Laschke et al., 2008). However, it is not clear whether this mechanism is 
shared in other models of cholestatic injury. It is possible that platelets contribute to cholestatic liver 
injury via other mechanisms. For example, we have shown that ANIT-induced liver injury is reduced in 
mice deficient in the procoagulant protein tissue factor (TF), suggesting that the coagulation cascade 
contributes to the pathogenesis (Luyendyk et al., 2009). Activated platelets possess a thrombogenic 
surface capable of propagating coagulation cascade activation (Ofosu, 2002). Platelets have been shown 
to express TF via a functional spliceosome (Schwertz et al., 2006). Accordingly, platelet activation and 
accumulation in the liver of ANIT-treated mice could contribute to liver injury by activating the 
coagulation cascade. However, the role of platelets in the procoagulant response induced by cholestatic 
liver injury has not been evaluated. 
 Interestingly, in addition to the potential for damaging effects of platelets during acute liver 
injury, they may also serve a protective function. Some studies implicate the release of serotonin by 
platelets as a mediator of liver regeneration and repair after partial hepatectomy (Lesurtel et al., 2006), 
although this is not necessarily true for other types of liver injury (Nocito et al., 2007; Lang et al., 2008). 
Other studies have suggested that mediators released by platelets, such as sphingosine-1-phosphate and 
serotonin, can affect sinusoidal endothelial cell (SEC) fenestration and inhibit SEC injury (Braet et al., 
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1995; Zheng et al., 2006)). It is also possible that platelets limit hemorrhage secondary to SEC damage 
during early cholestasis, although this possibility has not been investigated.  
 We sought to clarify the role of platelets in the procoagulant response and hepatocyte damage 
elicited by acute xenobiotic-induced cholestatic liver injury utilizing both platelet depletion (i.e., anti-
CD41 antibody) and inhibition (i.e., clopidogrel) strategies. Biomarkers of coagulation, liver injury, and 
inflammatory cell accumulation were assessed. The results indicate divergent effects of platelet depletion 
and platelet inhibition on the progression of acute cholestatic liver injury. 
2.3 Materials and Methods:  
2.3.1 Mice and treatment models: Male, wild type C57Bl/6J mice used for these studies were purchased 
from the Jackson Laboratory. Mice were maintained in an Association for Accreditation and Assessment 
of Laboratory Animal Care International (AAALAC)-accredited facility at the University of Kansas 
Medical Center. Mice were housed at an ambient temperature of 22°C with alternating 12-h light/dark 
cycles, and allowed water and rodent chow ad libitum (Teklad 8604; Harlan, Indianapolis, IN). All animal 
procedures were performed according to the guidelines of the American Association for Laboratory 
Animal Science and were approved by the KUMC Institutional Animal Care and Use Committee.  
After removal of food overnight, mice were given ANIT (Sigma-Aldrich, St. Louis, MO) (60 
mg/kg, po) in a volume of corn oil determined by the weight of the mouse (i.e., 10 ml/kg body weight) or 
an equivalent volume of corn oil (vehicle control). Various times after ANIT treatment the mice were 
anesthetized with isoflurane and blood collected from the caudal vena cava into citrate (for thrombin-
antithrombin (TAT) determination), EDTA (for platelet quantification) or an empty syringe for the 
collection of serum. Plasma and serum were collected by centrifugation. Sections of liver from the left 
lateral lobe were fixed in 10% neutral-buffered formalin for 48 hours. The right medial lobe was affixed 
to a cork with OCT and frozen for 3 minutes in liquid nitrogen-chilled isopentane. The remaining liver 
was snap frozen in liquid nitrogen. For platelet depletion studies, mice were given a single dose  of 
endotoxin- and azide free anti-CD41 antibody (clone, MWReg30) (1 mg/kg in sterile PBS) custom 
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prepared by BioLegend (La Jolla, CA) or 1mg/kg isotype control rat IgG (BioXCell, West Lebanon, NH) 
16 hours before ANIT administration. For platelet inhibition studies, clopidogrel (Axxora, San Diego, 
CA) dissolved in sterile PBS or sterile PBS was given 8 hours (30 mg/kg, ip) after ANIT treatment, 
followed by additional injections every 12 hours (30 mg/kg, ip) until completion of the experiment.  
2.3.2 Histopathological analysis and immunofluorescent staining: Formalin-fixed livers were 
processed routinely, embedded in paraffin, sectioned at 5 microns, and stained with hematoxylin and 
eosin. Slides were evaluated by light microscopy by a Board-certified pathologist (O.T.). Liver specimens 
were carefully evaluated for evidence of inflammation, steatosis, fibrosis, necrosis and peliosis.  Necrosis 
was scored as 0 to 4 based on extent of necrosis as described previously (Luyendyk et al., 2009).  Areas 
without necrosis were scored as 0 and areas with extensive necrosis are scored as 4.  Multiple cyst-like, 
blood-filled cavities of variable sizes, shapes and numbers within liver parenchyma characteristically 
known as "peliosis" were noted in several mice with different treatments as discussed below.  In none of 
the cases was "phlebectatic peliosis," characterized by histologic features of regular blood filled cavities 
lined by endothelial cells identified.  Instead, the only type of peliosis that was noted was of the 
"parenchymal-type", where various blood or fibrin filled irregular cystic parenchymal spaces were 
identified surrounded and intermixed with necrotic, degenerated hepatocytes.  The extent of this 
parenchymal peliosis was graded into rare (rare minute microscopic foci of peliosis), moderate (moderate-
sized, multiple areas of peliosis) or severe (multiple, large-sized, coalescent foci).  For platelet and fibrin 
staining, frozen sections cut at 8 microns were fixed in 4% neutral-buffered formalin for 10 minutes at 
room temperature, washed 3 times with PBS, and blocked with 10% goat serum in PBS (block buffer) for 
1 hour. Sections were incubated with the primary antibodies rabbit anti-human fibrinogen (1:5000; Dako, 
Carpinteria, CA) and/or rat anti-mouse CD41 (1:1000; Serotec, Raleigh, NC) diluted in block buffer for 2 
hours at room temperature. The slides were washed and incubated with Alexa 488- and Alexa 594-
conjugated secondary antibodies (Invitrogen, Carlsbad, CA) diluted in block buffer +2% mouse serum for 
2 hours.  The slides were then washed with PBS and fluorescent staining of the livers sections was 
visualized using an Olympus BX41 microscope (Olympus, Lake Success, NY). Images were captured 
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using an Olympus DP70 and merged using the Olympus DP Manager software. Quantification of CD41 
area was performed utilizing Scion Image as described previously (Yee et al., 2003).  
2.3.3 Clinical chemistry, platelet quantification in blood and thrombin-antithrombin measurement: 
The serum activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were determined 
using commercially available reagents (Pointe Scientific, Canton, MI). Thrombin-antithrombin levels in 
plasma were determined using a commercially available ELISA kit (Siemens Healthcare Diagnostics, 
Deerfield, IL). Quantification of platelets was performed on EDTA-anticoagulated whole blood utilizing a 
Beckman Coulter LH 780.  
2.3.4 RNA isolation, cDNA synthesis, and real-time PCR:  RNA was isolated from 75 mg of snap-
frozen liver using TRI reagent (Molecular Research Center, Inc., Cincinnati, OH) according to the 
manufacturer’s protocol. One microgram of RNA was utilized for the synthesis of cDNA using a High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) and MyCycler thermal 
cycler (Bio-Rad, Hercules, CA). Levels of Cxcl1 (KC), ICAM-1 and 18S mRNA were determined using 
TaqMan gene expression assays and TaqMan gene expression master mix (Applied Biosystems, Foster 
City, CA) on an StepOnePlus sequence detection system (Applied Biosystems, Foster City, CA). The 
expression of KC and ICAM-1 mRNA was normalized relative to 18S expression levels, and relative 
expression level determined using the comparative Ct method. 
2.3.5 Tissue myeloperoxidase (MPO) activity: Neutrophil accumulation in liver was estimated by 
measuring liver homogenate MPO activity. 100 mg of frozen liver was homogenized in a buffer 
containing 0.5% hexadecyl trimethyl ammonium bromide, 10 mM EDTA and 50 mM Na2PO4, pH 5.4 
and subjected to 3 freeze-thaw cycles followed by centrifugation at 12,000 x g for 15 minutes at 4 C. 
MPO activity in the supernatant was determined by addition of 50 mM Na2PO4 containing 0.167 mg/ml o-
dianisidine dihydrochloride (Sigma, St. Louis, MO) and 0.0005% hydrogen peroxide (Sigma, St. Louis, 
MO) in 50 mM phosphate buffer (pH 6.0). MPO activity was expressed as the change in absorbance 
measured at 460 nm per mg of protein in the liver homogenate. The concentration of protein in liver 
homogenate was determined using a BCA assay (Pierce). 
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2.3.6 Statistics: Comparison of two groups was performed using Student’s t-test. Comparison of 3 or 
more groups was performed using one-way analysis of variance and Student-Newman-Keul’s post-hoc 
test. Where data were not normally distributed comparisons were made by ANOVA on ranks and 
Student-Newman-Keul’s post-hoc test. The criterion for statistical significance was P<0.05. 
2.4 Results 
2.4.1 Time course of ANIT-induced hepatic platelet accumulation, coagulation, and liver injury. 
First, we determined the relative time course of thrombocytopenia, coagulation cascade activation and 
liver injury in mice treated with ANIT. Serum ALT and ALP activity were slightly elevated in ANIT-
treated mice at 24 hours and injury progressed further by 48 hours (Fig. 2.1A-B). In agreement with our 
previous study (Luyendyk et al., 2009), plasma TAT concentration increased dramatically at 24 hours and 
increased further by 48 hours (Fig. 2.1C). An increase in TAT in the plasma indicates generation of the 
coagulation protease thrombin. Interestingly, the increase in plasma TAT concentration preceded a 
decrease in platelets in the blood. A decrease in platelets in blood was observed at 48 hours after ANIT 
treatment (Fig. 2.1D). Of importance, the results indicate that coagulation precedes the decrease in 
platelets in blood of ANIT-treated mice. Scattered CD41-positive (i.e., platelet) staining consistent with 
localization to the sinusoids and larger vessels was observed in liver sections from vehicle-treated mice 
(Fig. 2.2A) and within larger vessels. In agreement with previous studies (Yee et al., 2003; Luyendyk et 
al., 2009), fibrin staining in livers from vehicle treated mice was restricted to the intima of larger vessels 
(Fig. 2.2B-C). The marked decrease in blood platelets in ANIT-treated mice at 48 hours was associated 
with increased platelet accumulation within areas of hepatic necrosis (i.e., bile infarcts) (Fig. 2.2D). Fibrin 
deposition also occurred within areas of necrosis in ANIT-treated mice (Fig. 2.2E-F).  
2.4.2 Effect of platelet depletion on ANIT-induced coagulation and liver injury. Platelet depletion 
was accomplished using an anti-CD41 antibody, clone MWReg30. Previous studies have utilized this 
antibody to specifically deplete platelets in mice (Lesurtel et al., 2006). Platelet depletion with the anti-
CD41 antibody alone did not cause liver injury (data not shown). Pretreatment with the anti-CD41 
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antibody dramatically reduced blood platelets in ANIT-treated mice at 24 hours and at 48 hours (Fig. 
2.3A). Interestingly, platelet depletion did not affect ANIT-induced coagulation, as indicated by increased 
plasma TAT concentration at 24 hours and 48 hours (normal levels <5 ng/mL) (Fig. 2.3B). This is in 
agreement with our finding that coagulation preceded a decrease in platelets in the blood in ANIT-treated 
mice. Platelet depletion did not affect serum ALP activity in ANIT-treated mice at either 24 hours or 48 
hours (Fig. 2.3C). Interestingly, serum ALT activity was substantially increased by platelet depletion in 
ANIT-treated mice at 24 hours (Fig. 2.3D). While serum ALT activity did not increase further in platelet-
depleted mice given ANIT, serum ALT activity increased further by 48 hours in ANIT-treated mice given 
control antibody (Fig. 2.3D).  
2.4.3 Effect of platelet depletion on liver histopathology in ANIT-treated mice. Liver necrosis 
induced by ANIT is characterized by areas of periportal necrosis containing bile and is associated with 
marked inflammatory cell accumulation (Becker and Plaa, 1965; Plaa and Priestly, 1976). We have 
described the liver histopathology associated with high dose ANIT administration previously (Luyendyk 
et al., 2009). Of importance, these so-called “bile infarcts” were evident in the livers of ANIT-treated 
mice given control IgG at 24 hours (Fig. 2.4A) and the size and frequency of necrotic lesions increased in 
these mice by 48 hours (Fig. 2.4D) (Table 2.1). Red blood cell infiltration of necrotic areas was evident in 
mice given ANIT and control IgG and this was somewhat increased at 48 hours (Table 2.1). Interestingly, 
platelet depletion increased the severity of necrotic lesions in ANIT-treated mice at 24 hours and this was 
associated with substantial pooling of blood within areas of necrosis, a lesion consistent with 
parenchymal-type peliosis (Tsokos and Erbersdobler, 2005). Peliosis was evident both in proximity to 
periportal necrosis (Fig. 2.4B) and in regions of the liver several hepatocytes separated from damaged bile 
ducts (Fig. 2.4C). Peliosis was also prominent in these mice at 48 hours (Fig. 2.4F), and in contrast to 
mice given control IgG, the severity of necrosis did not substantially increase between 24 and 48 hours 
(Table 2.1).   
2.4.4 Inhibition of platelet activation reduces ANIT-induced liver injury: evidence for platelet-
dependent neutrophil accumulation. As opposed to depleting all platelets, we next utilized the P2Y12 
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receptor antagonist clopidogrel to inhibit platelet activation. Administration of clopidogrel alone did not 
affect serum ALT activity (data not shown) or liver histopathology (Table 2.2). Clopidogrel 
administration did not affect serum ALT activity in ANIT-treated mice at 24 hours (902  204 U/L 
[ANIT+Veh] vs. 748  226 U/L [ANIT+clopidogrel]). In contrast, at 48 hours clopidogrel administration 
significantly reduced serum ALT activity in ANIT-treated mice (Fig. 2.5A) but did not affect increases in 
serum ALP activity (Fig. 2.5B). Clopidogrel treatment reduced hepatic platelet accumulation (Fig. 2.5C-
G) in ANIT-treated mice and reduced the severity of necrosis (Table 2.2), but did not increase red blood 
cell accumulation within necrotic lesions. Clopidogrel did not affect ICAM-1 or KC induction in the 
livers of ANIT-treated mice (Fig. 2.6A-B). In contrast, clopidogrel substantially reduced hepatic 
neutrophil accumulation, as indicated by reduced liver homogenate MPO activity (Fig. 2.6C).  
2.5 Discussion 
Platelets have been implicated in the pathogenesis of multiple types of liver damage including 
viral hepatitis (Lang et al., 2008), ischemia-reperfusion (Yadav et al., 1999), bile duct ligation (Laschke et 
al., 2008), and injury induced by xenobiotics including concanavalin (Miyazawa et al., 1998; Massaguer 
et al., 2002), and lipopolysaccharide (Pearson et al., 1995). Our data agree with a previous study showing 
that platelet depletion in rats (Bailie et al., 1994) reduces ANIT-induced liver necrosis. Both platelet 
depletion and inhibition strategies reduced the severity of liver necrosis in ANIT-treated mice. However, 
platelet depletion exacerbated a perhaps underappreciated lesion in ANIT-treated mice characterized by 
pooling of blood in areas of necrosis (i.e., peliosis). The data support the hypothesis that platelets have 
both protective and damaging effects in ANIT-induced liver injury.  
Our previous work indicated that ANIT-induced coagulation cascade activation is TF-dependent, 
and that TF contributes to the progression of ANIT-induced liver injury. Insofar as platelets can express 
TF and contribute to activation of the coagulation cascade (Ofosu, 2002; Schwertz et al., 2006), we 
examined their involvement in this capacity in ANIT-induced liver injury. The results presented herein 
indicate that blood platelets are reduced after coagulation cascade activation and platelet depletion did not 
32 
 
affect thrombin generation. This indicates that coagulation cascade activation is not dependent on 
platelets in ANIT-treated mice, and that another cell type expressing TF is important for coagulation in 
this model. Indeed, we have shown that BDECs express TF (Luyendyk et al., 2009), and the initial 
destruction of these cells by ANIT may cause TF-dependent coagulation. Moreover, TF expressed by 
other cells in the liver such as hepatocytes (Stephenne et al., 2007) could contribute to ANIT-induced 
coagulation.  
 Platelets appear to modify hepatocellular injury in ANIT-treated mice by impacting hepatic 
accumulation of inflammatory cells. Clopidogrel treatment reduced neutrophil accumulation in the livers 
of ANIT-treated mice. Of importance, platelet depletion did not significantly reduce liver homogenate 
MPO activity 48 hours after ANIT treatment (71  15 vs. 130  62), although direct comparison of these 
results is complex as leukocyte infiltration may be driven by additional mechanisms under conditions of 
peliosis induced by complete platelet deficiency. It has also been shown after BDL that platelet depletion 
reduced neutrophil accumulation in liver, as well as hepatic ICAM-1 and KC/Gro  mRNA levels 
(Laschke et al., 2008). In contrast, clopidogrel treatment did not affect hepatic expression of ICAM-1 or 
KC mRNAs in ANIT-treated mice. Adhesion molecules on the surface of activated platelets, including 
GPIIb/IIIa and P-selectin, interact directly with integrins and selectins on the surface of neutrophils 
(Zarbock et al., 2007). Of interest, a P-selectin antibody decreased the accumulation of neutrophils in 
liver after BDL (Laschke et al., 2008). Interactions between platelets, neutrophils and sinusoidal 
endothelial cells may be critical for promoting neutrophil accumulation in the livers of ANIT-treated 
mice. 
 The mechanisms by which platelets are recruited and activated in the livers of ANIT-treated mice 
have not been determined. While we sought to evaluate the role of platelets in activating the coagulation 
cascade, the time course of coagulation and of platelet activation suggests the possibility of the opposite 
relationship. That is, that the coagulation cascade is a mediator of platelet activation during cholestatic 
liver injury. Thrombin is a potent activator of platelets via protease activated receptors (PARs). Thrombin 
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activation of human platelets requires PAR-1 (Trejo et al., 1996), whereas in mice, PAR-3 and PAR-4 are 
required (Kahn et al., 1998). In addition to eliciting intracellular signaling in platelets, the interaction of 
these cells with cross-linked fibrin (Lupu et al., 2005) within areas of necrosis in ANIT-treated mice 
could be an important mechanism for platelet accumulation. Indeed, platelets colocalized with fibrin in 
areas of necrosis in livers of ANIT-treated mice. Additional studies clarifying the role of thrombin and 
fibrin in the platelet activation observed in ANIT-treated mice are required.  
  Previous studies have implicated platelets as mediators of liver damage during cholestasis (Bailie 
et al., 1994; Laschke et al., 2008). Depletion of platelets in rats limited the progression of ANIT-induced 
hepatocellular injury, but did not affect biomarkers of biliary injury (Bailie et al., 1994). The present 
results agree with those described previously, insofar as a pharmacologic inhibitor of platelet activation 
(i.e., clopidogrel) reduced hepatocyte necrosis in ANIT-treated mice, but did not impact serum ALP 
activity, an indicator of cholangiocyte damage. However, in striking contrast to platelet depletion in rats, 
platelet depletion in ANIT-treated mice exacerbated the pooling of blood within necrotic lesions, 
consistent with parenchymal type peliosis (Tsokos and Erbersdobler, 2005). This variant of peliosis is 
typified by pooling of blood within or adjacent to necrotic tissue, and the lesions are not necessarily 
bordered by endothelium or fibrotic material, the latter being a hallmark of another peliosis variant called 
phlebectatic peliosis (Tsokos and Erbersdobler, 2005). The basis for this lesion in our study but not in 
platelet-depleted ANIT-exposed rats is not clear, but could relate to multiple factors including differences 
in species, fasting, severity of liver injury, or use of whole antiserum vs. anti-CD41 antibody. Of 
importance, the anti-CD41 (GP11bIIIa) antibody commonly utilized to examine the role of platelets in 
tissue injury has systemic effects, including transient induction of hypothermia and lung injury 
(Nieswandt et al., 1999; Nieswandt et al., 2000). Moreover, complexes of this antibody and platelets 
accumulate in the liver after administration and may be cleared by Kupffer cells (Bagchus et al., 1989). 
This could impact normal hepatic homeostasis.  
Peliosis hepatis in patients is a relatively rare clinical finding associated with a variety of diseases 
and treatment with various drugs including 6-mercaptopurines and steroids (Tsokos and Erbersdobler, 
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2005). Peliosis in the liver has also been described in rodent models of exposure to xenobiotics including 
TCDD (Niittynen et al., 2003), cadmium (Habeebu et al., 1998; Tzirogiannis et al., 2006) , 
hexachlorobenzene (Carthew and Smith, 1994), and anabolic steroids (Stang-Voss and Appell, 1981; 
Tsirigotis et al., 2007). Interestingly, peliosis has been reported in the context of cholestatic liver injury in 
rodent models (Romagnuolo et al., 1998; Niittynen et al., 2003) and in patients (Hayward et al., 1991; 
Russmann et al., 2001). Moreover, in some patients, peliosis in liver and pancreas has been associated 
with exaggerated coagulation and thrombotic thrombocytopenic purpura (TTP) (Samyn et al., 2004; 
Belovejdov et al., 2008), a somewhat counterintuitive finding in the context of altered hemostasis in liver. 
Of importance, peliosis in ANIT-treated mice depleted of platelets occurred in the presence of marked 
coagulation, as indicated by increased plasma TAT concentration. However, a definitive mechanistic role 
of either the coagulation cascade or platelets in the pathogenesis of peliosis has not been described.  
It is curious in our study that a near complete depletion of platelets caused peliosis in ANIT-
treated mice at 24 hours, a time point at which ANIT alone had minimal effect on the number of platelets 
in the blood. It is possible that the accumulation of very few platelets is required to limit peliosis in the 
liver during cholestasis. Indeed, although we did not detect a difference in platelet numbers in blood, the 
number of platelets in the sinusoids increased 24 hours after ANIT treatment (Supplemental Figure 2.1). 
Indeed, the upregulation of adhesion molecules, such as P-selectin, on the surface of platelets may 
precede an observable decrease in blood platelets. Additional studies are required to determine the time 
course of P-selectin upregulation on platelets in this model. The pathogenesis of peliosis has been 
proposed to stem from perturbed sinusoidal endothelial cell function in the liver (Tsokos and 
Erbersdobler, 2005; DeLeve, 2007), including induction of cell death, and it is possible that initial platelet 
accumulation in the liver during cholestasis limits SEC dysfunction that leads to peliosis. Indeed, 
cholestatic liver injury is associated with SEC dysfunction, and bile acids can activate intracellular 
signaling pathways in SECs (Yoshidome et al., 2000; Keitel et al., 2007). Platelet release of sphingosine-
1-phosphate has been shown to be cytoprotective to endothelial cells (Zheng et al., 2006). Moreover, 
serotonin released from platelets promotes liver regeneration and has been shown to alter SEC 
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fenestration (Braet et al., 1995). Another possibility is that the accumulation of platelets at the expanding 
edge of necrotic lesions constitutes a cellular barrier to limit bleeding into necrotic areas. To this end, 
severe thrombocytopenia and concurrent cholestasis may be risk factors for developing peliosis. 
Additional studies are warranted to determine the mechanism whereby platelets can prevent peliosis 
during cholestasis. 
In summary, the results indicate that in ANIT-induced cholestatic liver injury, hepatic platelet 
accumulation promotes neutrophil accumulation and hepatocyte necrosis, but not coagulation cascade 
activation. Of importance, the finding of peliosis in livers of ANIT-treated mice after platelet depletion 
suggests that severe thrombocytopenia may render the liver susceptible to peliosis during cholestasis.   
2.6 Figures 
Figure 2.1 
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Figure 2.1: Time course of ANIT-induced liver injury, coagulation and blood platelets in mice.   
Mice were given ANIT (60 mg/kg, po) or vehicle (corn oil). (A) Serum ALT activity, (B) serum ALP 
activity, (C) plasma thrombin-antithrombin (TAT) levels, and (D) platelets in EDTA-anticoagulated 
whole blood were determined 24 and 48 hours after ANIT administration.  Levels of all biomarkers in 
mice given vehicle were not different between 24 and 48 hours. 48 hour data are shown. Data are 
expressed as mean ± SEM. n=5 mice per group. *Significantly different from Veh-treated mice. P<0.05. 
 
Figure 2.2 
 
Figure 2.2: Platelet accumulation and fibrin deposition in livers of ANIT-treated mice.   
Mice were given ANIT (60 mg/kg, po) or vehicle (corn oil) and livers removed 48 hours later. (A-B) 
Representative photomicrographs showing (A) CD41 (platelet, green) staining and (B) fibrin (red) 
staining in a liver section from a vehicle-treated mouse. The digital merge of these images is shown in 
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panel C. Asterisk indicates fibrin staining (red) outlining the border of a central vein. (D-E) 
Representative photomicrographs showing marked (D) CD41 (platelet, green) staining and (E) fibrin (red) 
staining in areas of necrosis in a liver section from a ANIT-treated mouse. The digital merge of these 
images is shown in panel F. Bar = 20 microns. Arrow indicates an area of hepatic necrosis containing 
fibrin and bordered by marked platelet accumulation.  
Figure 2.3 
 
Figure 2.3: Effect of platelet depletion on ANIT-induced coagulation and liver injury.   
Mice were given 1 mg/kg of anti-CD41 antibody (MWReg30) or isotype control antibody 16 hours prior 
to treatment with ANIT (60 mg/kg, po). (A) Platelets in EDTA-anticoagulated whole blood, (B) plasma 
thrombin-antithrombin (TAT) levels, (C) serum ALP activity, and (D) serum ALT activity were 
determined 24 and 48 hours later. Data are expressed as mean ± SEM. n=5 mice per group.*Significantly 
different from the same group of mice at 24 hours. #Significantly different from ANIT-treated mice 
pretreated with isotype control antibody. 
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Figure 2.4 
 
Figure 2.4:  Effect of platelet depletion on ANIT-induced liver histopathology.   
Mice were given 1 mg/kg of anti-CD41 antibody or isotype control antibody 16 hours prior to treatment 
with ANIT (60 mg/kg, po). Representative photomicrographs showing H&E-stained liver sections from 
isotype control antibody-pretreated mice (A) 24 hours and (D) 48 hours after ANIT-treatment, and in anti-
CD41 antibody-pretreated mice 24 hours after ANIT treatment (B and C) and 48 hours after ANIT-
treatment (E and F). Bar = 20 microns (A and B), 10 microns (C), 50 microns (D-F). Arrows indicate 
areas of periportal hepatocellular necrosis. Asterisks are near areas of parenchymal-type peliosis. 
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Figure 2.5 
 
Figure 2.5:  Effect of clopidogrel treatment on ANIT-induced liver injury.   
Mice were treated with ANIT (60 mg/kg, po), then subsequently with clopidogrel (30 mg/kg, ip) or sterile 
PBS 8, 20, and 32 hours later. Serum (A) ALT activity and (B) ALP activity were determined 48 hours 
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later. Representative photomicrographs showing H&E-stained (C and D, Bar=50 microns) and anti-CD41 
(platelet, red) stained (E and F, Bar= 20 microns) liver sections from ANIT-treated mice given vehicle (C 
and E) or clopidogrel (D and F). (G) Quantification of CD41-positive staining (platelets) in liver sections 
from each group of mice. Data are expressed as mean ± SEM. n=3-6 mice per group. *Significantly 
different from ANIT-treated mice given sterile PBS. P<0.05. Arrows indicate areas of periportal 
hepatocellular necrosis. 
Figure 2.6 
 
Figure 2.6: Effect of clopidogrel treatment on indicators of neutrophil accumulation.   
Mice were treated with ANIT (60 mg/kg, po), then subsequently with clopidogrel (30 mg/kg, ip) or sterile 
PBS 8, 20, and 32 hours later. Hepatic KC (A) and ICAM-1 (B) mRNA levels were determined 48 hours 
later. (C) Liver homogenate myeloperoxidase (MPO) activity was measured 48 hours after ANIT 
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treatment. Data are expressed as mean ± SEM. n=3-6 mice per group. *Significantly different from 
ANIT-treated mice given sterile PBS. P<0.05. 
2.7 Supplemental Figures 
 
Supplemental Figure 2.1: Hepatic accumulation of platelets 24 hours after ANIT treatment.   
Wild type mice were given ANIT (60 mg/kg, po) or vehicle (corn oil) and livers removed 24 hours later. 
Representative photomicrographs showing CD41 (platelet, red) staining in liver sections from a mouse 
treated with vehicle (A) for 24 hours or ANIT (B) for 24 hours. Sections were counterstained with DAPI. 
Bar= 20 microns 
2.8 Tables 
Table 2.1 
 ANIT 24 hours ANIT 48 hours 
 IgG MWReg30 IgG MWReg30 
Necrosis (score) 1.4 (0,1,2,2,2) 3 (3,3,3) 4 (4,4,4,4,4) 3.6 (3,3,4,4,4) 
Peliosis (grade) A (2), R (3)  M (1), P (2)  R (2), M (3) M (3), P (2)  
 
 
 
42 
 
Table 2.1:  Effect of platelet depletion on ANIT-induced liver necrosis and parenchymal-type 
peliosis.  
Mice were given 1 mg/kg of anti-CD41 antibody (MWReg30) or isotype control antibody 16 hours prior 
to treatment with ANIT (60 mg/kg, po) and livers were collected 24 or 48 hours later. The severity of 
necrosis in liver sections was assigned a score from 0-4, increasing in severity as described in Methods. 
Average necrosis scores and the score for each animal are shown. Parenchymal-type peliosis in liver 
sections was categorized as absent (A) rare, microscopic foci (R), multiple lesions moderate in size (M) or 
multiple large sized coalescent foci (P). 
Table 2.2 
  Vehicle Clopidogrel 
Vehicle 0 (0,0,0) 0 (0,0,0) 
ANIT 2.7 (3,3,3,3,2,2) 2.0 (1/2,2,2,2,2,3) 
 
Table 2.2:  Effect of platelet depletion on ANIT-induced liver necrosis.   
Mice were treated with ANIT (60 mg/kg, po), then subsequently with clopidogrel (30 mg/kg, ip) or sterile 
PBS 8, 20, and 32 hours later. Livers were collected 48 hours after ANIT treatment and the severity of 
necrosis in liver sections was assigned a score from 0-4, increasing in severity as described in Methods. 
Average necrosis scores and the score for each animal are shown. 
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3.1 Abstract 
Alpha-naphthylisothiocyanate (ANIT)-induced cholestatic liver injury causes tissue factor (TF)-
dependent coagulation in mice and TF-deficiency reduces ANIT-induced liver injury. However, the 
mechanism whereby TF contributes to hepatotoxicity in this model is not known. Utilizing pharmacologic 
and genetic strategies, we evaluated the contribution of fibrinogen and two distinct receptors for 
thrombin, protease activated receptor-1 (PAR-1) and PAR-4, in a model of acute ANIT hepatotoxicity. 
ANIT administration (60 mg/kg, po) caused a marked induction of the genes encoding the three 
fibrinogen chains (α, β, and γ) in liver, an increase in plasma fibrinogen, and concurrent deposition of 
thrombin-cleaved fibrin in liver. Partial depletion of circulating fibrinogen with ancrod did not impact 
ANIT hepatotoxicity. However, complete fibrin(ogen)-deficiency significantly reduced serum ALT 
activity and hepatocellular necrosis in ANIT-treated mice. ANIT-induced hepatocellular necrosis was 
similar in PAR-1
-/-
 mice compared to PAR-1
+/+
 mice. Interestingly, the progression of ANIT-induced 
hepatocellular necrosis was significantly reduced in PAR-4
-/-
 mice, and by administration of an inhibitory 
PAR-4 pepducin (P4Pal-10, 0.5 mg/kg, sc) to wild type mice 8 hours after ANIT treatment. Interestingly, 
a distinct lesion, parenchymal-type peliosis, was also observed in PAR-4
-/-
 mice treated with ANIT, and in 
mice that were given P4Pal-10 prior to ANIT administration. The results suggest that fibrin(ogen), but not 
PAR-1, contributes to the progression of ANIT hepatotoxicity in mice. Moreover, the data suggest a dual 
role for PAR-4 in ANIT hepatotoxicity, both mediating an early protection against peliosis, and 
contributing to the progression of hepatocellular necrosis. 
3.2 Introduction 
 Acute chemical-induced cholestatic liver injury can be modeled in rodents by administration of 
alpha-naphthylisothiocyanate (ANIT), which achieves micromolar levels in the bile of exposed animals 
(Jean et al., 1995). This results in bile duct injury and formation of “bile infarcts,” areas of periportal 
hepatocellular necrosis containing dead/dying hepatocytes, bile, and inflammatory cells, which have been 
described in detail previously (Plaa and Priestly, 1976). Deficiency in the transport of ANIT into the bile 
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prevents necrosis, suggesting that the cytotoxic disruption of intrahepatic bile ducts is critical for necrosis 
in this model (Dietrich et al., 2001). In addition, several studies have shown that extrahepatic factors 
including platelets and neutrophils, as well as tissue factor (TF), the primary activator of the extrinsic 
pathway of blood coagulation, contribute to necrosis progression (Bailie et al., 1994; Kodali et al., 2006; 
Luyendyk et al., 2009; Sullivan et al., 2010a). 
 Acute ANIT hepatotoxicity is associated with activation of the coagulation cascade, as indicated 
by thrombin generation and deposition of fibrin clots within areas of hepatocellular necrosis. Indeed, 
coagulation cascade activation occurs in numerous models of chemical-induced hepatotoxicity. TF-
deficiency reduced generation of the coagulation protease thrombin and the severity of hepatocellular 
necrosis in ANIT-treated mice (Luyendyk et al., 2009). However, the mechanism whereby the 
coagulation cascade contributes to the progression of liver necrosis in this model is not known. 
Investigation of the role of coagulation in hepatotoxicity is frequently limited to examining the effect of 
thrombin inhibition (i.e, with anticoagulants) on hepatotoxicity, with the exact mechanism whereby 
thrombin contributes to liver injury left unanswered. 
 Thrombin generated by activation of the coagulation cascade has multiple roles. Thrombin 
cleaves circulating fibrinogen to fibrin monomers, which are cross-linked to form insoluble fibrin clots. 
Moreover, thrombin can cleave and activate cell-surface G-protein coupled protease activated receptors 
(PARs) to elicit intracellular signaling (Coughlin, 1999). PAR-1 and PAR-4 are thrombin receptors 
expressed by nonparenchymal cells in the liver (Copple et al., 2003; Jesmin et al., 2006). Unlike humans, 
mouse platelets do not express PAR-1; rather, murine platelets are activated by thrombin via cleavage of 
PAR-4 (Sambrano et al., 2001). Of importance, the involvement of fibrin and PARs in acute ANIT 
hepatotoxicity has not been evaluated. 
 Although the role of PAR-1 in liver fibrosis induced by chronic liver injury has been investigated 
previously (Fiorucci et al., 2004; Rullier et al., 2008; Sullivan et al., 2010b), the role of this receptor in 
acute hepatotoxicity is less clear. PAR-1-deficient mice were protected from acute acetaminophen 
hepatotoxicity (Ganey et al., 2007). Activation of PAR-1 contributed to neutrophil activation in 
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lipopolysaccharide-primed livers (Copple et al., 2003). However, PAR-1-deficiency does not contribute 
to the acute hepatotoxic effects of other chemicals, such as carbon tetrachloride (Rullier et al., 2008). In 
comparison to PAR-1, few studies have examined the role of PAR-4 in hepatotoxicity.  
 Since we have shown previously that genetically reducing coagulation limits ANIT-induced liver 
injury, the present study tested the hypothesis that PAR-1 and PAR-4 signaling, as well as fibrin clots 
contribute to acute ANIT-induced hepatotoxicity.  
3.3 Materials and Methods 
3.3.1 Mice: Male and female mice between the ages of 8-16 weeks were used for these studies. Male wild 
type C57Bl/6J mice were purchased from The Jackson Laboratory for studies of ancrod and P4Pal-10 
administration. PAR-1
-/-
 mice (Connolly et al. 1997) and PAR-1
+/+
 mice on an identical genetic 
background (N8 C57Bl/6J) were maintained by homozygous breeding. Age-matched male PAR-1
+/+
 mice 
and PAR-1
-/-
 mice were used for experiments. Fbgα
-/- 
(Fbg
-/-
) mice (Suh et al., 1995) were kindly provided 
by Dr. Jay Degen (Cincinnati Children's Hospital Medical Center, Cincinnati, OH). Female Fbg
-/-
 mice 
and Fbg
+/- 
mice were used for 4 independent experiments with age-matched mice of each genotype. PAR-
4
-/-
 mice (Sambrano et al., 2001) and PAR-4
+/+
 mice were maintained by homozygous breeding. Age-
matched male PAR-4
+/+
 mice and PAR-4
-/-
 mice were used for experiments. Mice were maintained in an 
AAALAC-accredited facility at the University of Kansas Medical Center. Mice were housed at an 
ambient temperature of 22°C with alternating 12-h light/dark cycles, and allowed water and rodent chow 
ad libitum (Teklad 8604; Harlan, Indianapolis, IN). All animal procedures were performed according to 
the guidelines of the American Association for Laboratory Animal Science and were approved by the 
KUMC Institutional Animal Care and Use Committee. 
3.3.2 ANIT hepatotoxicity model and pharmacologic interventions: Fasted mice were treated with 
ANIT (Sigma-Aldrich, St. Louis, MO) dissolved in corn oil (60 mg/kg, p.o.) or corn oil alone (control 
[vehicle] treatment) at 10 ml/kg. Food was returned after treatment with ANIT or vehicle. For fibrinogen 
depletion studies, 1.75U ancrod/mouse (National Institute for Biological Standards and Control, 
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Hertfordshire, England) or its vehicle (sterile saline) was administered by intraperitoneal injection 2, 12, 
24 and 36 hours after ANIT administration. The PAR-4 pepducin P4pal-10 (palmitoyl-SGRRYGHALR-
NH2; Genscript, Piscataway, NJ), or its vehicle (PBS), was administered by subcutaneous injection at a 
dose of 0.5 mg/kg 8 and 24 hours after ANIT treatment. For select studies, an additional dose of P4pal-10 
was also given 2 hours prior to ANIT. The mice were then anesthetized using isoflurane 24 or 48 hours 
after ANIT treatment for the collection of blood and liver samples. Blood was collected from the caudal 
vena cava into a syringe containing sodium citrate (final concentration, 0.38%) and additional blood was 
collected into a syringe without anticoagulant. Plasma and serum were collected from this blood by 
centrifugation. Sections of liver from the left lateral lobe were fixed in 10% neutral-buffered formalin. 
The right medial lobe was cut into a cube and affixed to a cork using OCT and frozen for 3 minutes in 
liquid nitrogen-chilled isopentane. The remaining liver was snap frozen in liquid nitrogen.   
3.3.3 RNA isolation, cDNA synthesis, and real-time PCR:  RNA was isolated from approximately 100 
mg of snap-frozen liver using TRI reagent (Molecular Research Center, Inc., Cincinnati, OH). cDNA 
synthesis was performed using 1 microgram of RNA and a High Capacity cDNA Reverse Transcription 
kit (Applied Biosystems) and MyCycler thermal cycler (Bio-Rad). Levels of Fbgα, Fbgβ, Fbgγ, serum 
amyloid A1 (SAA1), and GAPDH mRNA were determined using TaqMan gene expression assays and 
TaqMan gene expression master mix (Applied Biosystems) and a StepOnePlus (Applied Biosystems). 
The expression of each mRNA was normalized relative to GAPDH expression levels, and relative 
expression level determined using the comparative Ct method. 
3.3.4 Clinical chemistry, plasma fibrinogen determination, and fibrin western blotting: The serum 
activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were determined using 
commercially available reagents (Thermo Scientific). The concentration of bile acids in serum was 
determined by using a commercial kit (Bio-quant, San Diego, CA). Plasma fibrinogen levels were 
determined using commercial reagents (Siemens Healthcare Diagnostics, Deerfield, IL) and a STart4 
coagulation analyzer (Diagnostica Stago). Levels of fibrin in liver extracts were determined by western 
blotting as described previously (Luyendyk et al., 2009).  
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3.3.5 Histopathology: Formalin-fixed livers were subjected to routine processing, sectioned at 5 microns, 
stained with hematoxylin and eosin, and evaluated by light microscopy for the presence of hepatocellular 
necrosis, the features of which we have described in detail previously (Luyendyk et al., 2009).  Three 
sections of liver from the left lateral lobe were evaluated from each animal.  Each section was evaluated 
in its entirety.  Low magnification (40X) images encompassing each section were captured in a masked 
fashion. Areas of hepatocellular necrosis in each image were outlined manually using Scion imaging 
software by J.P.L., and the area of liver occupied by necrotic areas (i.e,. bile infarcts) was measured and 
compared to the total area of liver in each image. The % necrotic area, number of lesions per 40X field, 
and average lesion size in square microns was determined.  
3.3.7 Statistics: Comparison of two groups was performed using Student’s t-test. Data resistant to 
transformation to achieve a normal distribution were compared utilizing the Mann-Whitney Rank Sum 
Test. Comparison of 3 or more groups was performed using one-way analysis of variance and Student-
Newman-Keul’s post-hoc test. The criterion for statistical significance was P<0.05. 
3.4 Results 
3.4.1 Induction of fibrinogen expression in ANIT-induced cholestatic liver injury. Compared to 
vehicle-treated mice, levels of mRNAs encoding the Fbgα, Fbgβ, and Fbgγ genes were significantly 
increased in livers of ANIT-treated mice (Fig. 3.1A-C). We have shown previously that ANIT treatment 
activates the coagulation cascade and causes marked deposition of fibrin in the liver (Luyendyk et al., 
2009). To this end, we anticipated that ANIT treatment would elicit consumption of circulating 
fibrinogen. In contrast, and in line with induction of fibrinogen expression in liver, ANIT treatment was 
associated with a significant increase in plasma fibrinogen concentration (Fig. 3.1D).  Interestingly, 
mRNA levels of SAA1 were dramatically increased in livers of mice treated with ANIT (Fig 3.1E).  
3.4.2 Effect of fibrin(ogen)-deficiency on ANIT-induced cholestatic liver injury. To deplete 
circulating fibrinogen in wild type mice, we utilized ancrod, which enzymatically cleaves fibrinogen. 
Ancrod partially reduced plasma fibrinogen levels (Fig. 3.2A) and hepatic fibrin deposition (Fig. 3.2B) in 
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ANIT-treated mice. However, depletion of fibrinogen with ancrod did not significantly affect the increase 
in serum ALT activity, ALP activity, serum bile acid levels or liver necrosis in ANIT-treated mice (Fig. 
3.2C-H). Of importance, in preliminary studies we found that ancrod treatment reduced fibrinogen levels 
in naïve mice to undetectable levels (data not shown). The induction of fibrinogen expression in ANIT-
treated mice prevented complete depletion of fibrinogen with ancrod, with fibrinogen levels in ANIT-
treated mice given ancrod resembling normal physiological fibrinogen levels (i.e., compare Fig. 3.2A vs. 
Fig. 3.1D). To this end, we utilized Fbgα
-/-
 mice (Fbg
-/- 
mice), which lack circulating fibrinogen (Suh et 
al., 1995). Serum ALT activity was reduced in ANIT-treated Fbg
-/- 
mice compared to ANIT-treated Fbg
+/- 
mice, although this difference did not achieve statistical significance at 48 hours (Fig. 3.3A).  However, 
fibrinogen deficiency did not significantly affect serum ALP activity or bile acid concentration in ANIT-
treated mice (Fig 3.3B-C).  Interestingly, both the number and average size of necrotic lesions tended to 
be lower in ANIT-treated Fbg
-/- 
mice compared to ANIT-treated Fbg
+/- 
mice, although these differences 
did not achieve statistical significance (Fig. 3.3D-E). Of importance, the overall area of necrosis induced 
by ANIT treatment was significantly reduced in ANIT-treated Fbg
-/- 
mice compared to ANIT-treated 
Fbg
+/- 
mice (Fig. 3.3F-H).  
3.4.3 Characterization of ANIT-induced cholestatic liver injury in PAR-1 deficient and PAR-4 
deficient mice. Thrombin can activate intracellular signaling via PAR-1 and PAR-4. To this end, we 
evaluated the role of these PARs in ANIT hepatotoxicity utilizing PAR-1
-/-
 mice and PAR-4
-/-
 mice. 
Serum ALT activity, ALP activity, and bile acid levels were similar in PAR-1
+/+ 
mice and PAR-1
-/- 
mice 
48 hours after ANIT treatment (Fig. 3.4A-C). In agreement, PAR-1-deficiency did not affect necrosis in 
ANIT-treated mice (Fig. 3.4D-F).  
Twenty-four hours after ANIT administration, serum ALT activity was significantly increased in 
PAR-4
-/-
 mice compared to PAR-4
+/+
 mice (Fig. 3.5A).  In contrast, serum ALP activity and bile acid 
levels were not different between  PAR-4
-/-
 mice and PAR-4
+/+
 mice at 24 or 48 hours (Fig. 3.5B-C). 
Interestingly, within 48 hours after ANIT treatment, serum ALT activity in PAR-4
+/+ 
mice achieved levels 
similar to PAR-4
-/-
 mice (Fig. 3.5A). Minimal necrosis was observed in ANIT-treated PAR-4
+/+
 mice at 24 
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hours (Fig. 3.5D-G). In striking contrast, significant liver injury occurred in the livers of ANIT-treated 
PAR-4
-/-
 mice 24 hours after ANIT treatment (Fig 3.5D-F, 3.5H). This injury was characterized by 
periportal necrosis associated with marked accumulation of red blood cells within the necrotic area, a 
unique lesion with features resembling parenchymal-type peliosis, which also occured in platelet-depleted 
mice challenged with ANIT (Sullivan et al., 2010a). Interestingly, in agreement with our previous studies 
(Luyendyk et al., 2009), ANIT-induced necrosis markedly increased in the livers of PAR-4
+/+
 mice by 48 
hours (Fig. 3.5D-F, 3.5I). In contrast, the severity of necrosis did not increase in PAR-4
-/-
 mice between 
24 and 48 hours (Fig. 3.5D-F, 3.5J), although the lesions observed at 24 hours appeared to persist at 48 
hours (Fig. 3.5J). The results are consistent with the hypothesis that PAR-4 both protects the liver from 
early necrosis/hemorrhage during the early phase of ANIT-induced cholestasis, but also contributes at 
later times to the progression of periportal hepatocellular necrosis. 
3.4.4 Effect of pharmacological inhibition of PAR-4 on ANIT-induced cholestatic liver injury. The 
whole-body PAR-4-deficient mice did not allow us to characterize the role of PAR-4 during different 
phases of ANIT-induced liver injury. To address the contribution of PAR-4 in both the initiation and 
progression of ANIT-induced cholestatic liver injury, we utilized a selective cell-permeable peptide 
inhibitor of PAR-4, P4Pal-10 (Covic et al., 2002). The dose selected for these studies has been shown 
previously to inhibit PAR-4-dependent activation of mouse platelets (Covic et al., 2002) and reduces 
inflammation in another murine model (Slofstra et al., 2007). The pepducin was administered by 
subcutaneous injection as this prolongs the half-life of the peptide in rodents (Covic et al., 2002).  
To test the hypothesis that PAR-4 contributes to the progression of ANIT hepatotoxicity, we 
administered P4Pal-10 by subcutaneous injection 8 hours after ANIT treatment. Compared to mice given 
vehicle, ANIT-induced liver injury was significantly reduced in mice given P4Pal-10, as indicated by a 
significant reduction in serum ALT activity and the area of hepatocellular necrosis (Fig. 3.6A, 3.6D-F). 
Interestingly, serum ALP activity tended to be lower in P4Pal-10-treated mice, although this change did 
not meet statistical significance. Serum bile acids were significantly reduced in P4Pal-10-treated mice 
given ANIT (Fig. 3.6B-C). Of importance, in mice given pepducin in this paradigm, there was no 
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evidence of excessive red blood cell accumulation within necrotic lesions compared to mice given vehicle 
and ANIT (not shown). This result is consistent with an early protective effect of PAR-4, left intact in this 
paradigm by delaying administration of the PAR-4 inhibitor. In contrast, and mirroring the effect of 
complete PAR-4-deficiency (Fig. 3.5), when P4Pal-10 was administered to mice 2 hours prior to ANIT, 
serum ALT activity was significantly increased at 24 hours (Fig. 3.7A). In 50% of the mice given P4Pal-
10 prior to ANIT, significant hemorrhage was evident within necrotic areas (Fig. 3.7E), resembling 
changes observed in PAR-4
-/- 
mice treated with ANIT (Fig. 3.5H).  Interestingly, similar to PAR-4
-/-
 mice, 
no changes in serum ALP activity or levels of bile acids were observed 24 hours after ANIT 
administration in mice pre-treated with P4Pal-10 (Fig 3.7B-C).  
3.5 Discussion 
 Anticoagulant administration reduced the hepatotoxicity of several xenobiotics in rodents, 
including lipopolysaccharide (LPS) (Pearson et al., 1996), monocrotaline (Copple et al., 2002b), 
dimethylnitrosamine (Fujiwara et al., 1988), and acetaminophen (Ganey et al., 2007), as well as the 
ability of LPS to enhance hepatotoxicity in xenobiotic co-exposure models (Deng et al., 2009). These 
studies strongly support the hypothesis that the coagulation cascade contributes to hepatotoxic responses, 
but the mechanism whereby thrombin promotes liver injury in these models has not been investigated in 
detail. Indeed, thrombin could contribute to hepatotoxic responses via fibrin clot formation as well as 
signaling through various PARs. ANIT-induced thrombin generation and liver injury were reduced in 
mice expressing very low levels of TF (Luyendyk et al., 2009). Elaborating on this result, we found that 
both fibrin(ogen) and PAR-4, but not PAR-1, contribute to acute ANIT-induced cholestatic liver injury in 
mice.   
 Circulating fibrinogen protein is comprised of three subunits encoded by different genes (i.e, 
α,β,γ), which are primarily expressed by the liver. In other models of hepatotoxicity, deposition of cross-
linked fibrin occurs in conjunction with consumption of circulating fibrinogen protein (Copple et al., 
2002a; Ganey et al., 2007). Of interest, in ANIT-treated mice, fibrinogen gene expression and circulating 
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fibrinogen concentration increased. This increase in fibrinogen availability could contribute to the marked 
fibrin deposition within necrotic lesions in ANIT-treated mice (Luyendyk et al., 2009). The dramatic 
induction of SAA1 suggests a basis for the induction of fibrinogen in ANIT-treated mice as a component 
of an acute phase response. However, the fibrinogen genes have also been shown to be targets of the 
nuclear receptor farnesoid X receptor (FXR), a bile acid receptor (Anisfeld et al., 2005). Insofar as bile 
acid levels increase substantially in the livers of ANIT-treated mice, this could be a plausible mechanism 
whereby fibrinogen expression increases in this model. Interestingly, FXR-deficiency did not affect basal 
fibrinogen gene expression in mice, nor did cholic-acid feeding affect Fbg gene induction in mice 
(Anisfeld et al., 2005). Additional studies are needed to clarify the mechanism of fibrinogen induction in 
the ANIT model, and comparison with other models of non-cholestatic liver injury may provide further 
insight into the regulation of the fibrinogen genes.  
 Fibrinogen depletion with ancrod did not affect ANIT-induced liver injury. However, ancrod 
administration did not completely deplete circulating fibrinogen or prevent fibrin deposition in ANIT-
treated mice, most likely due to parallel fibrinogen gene induction. Of interest, ANIT-induced liver 
necrosis was significantly reduced in mice lacking fibrinogen. This result is consistent with the hypothesis 
that fibrin deposition contributes to ANIT hepatotoxicity in mice. One mechanism whereby fibrin could 
contribute to the progression of liver injury in this model is by causing local hypoxia that promotes 
hepatocyte injury. Indeed, anticoagulant administration has been shown to reduce liver hypoxia in other 
models of xenobiotic hepatotoxicity (Luyendyk et al., 2004; Copple et al., 2006). Alternatively, fibrin 
could promote liver necrosis in ANIT-treated mice by enhancing the recruitment or activation of 
inflammatory cells. Through interactions with αIIbβ3 and Mac-1 integrins, fibrin(ogen) can direct the 
accumulation and activation of platelets and neutrophils, respectively (Williams et al., 1995; Flick et al., 
2004). Indeed, both of these cell types have been shown to contribute to liver injury in ANIT-treated 
rodents (Bailie et al., 1994; Kodali et al., 2006; Sullivan et al., 2010a). Of importance, a complete 
depletion of platelets caused parenchymal-type peliosis in ANIT-treated mice (Sullivan et al., 2010a), and 
there was no evidence of peliosis or severe hemorrhage in ANIT-treated Fbg
-/- 
mice.  
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 Distinct from its role in generating fibrin clots, thrombin activates intracellular signaling 
pathways via cleavage of various PARs (Kahn et al., 1998; Coughlin, 1999). Whereas PAR-1 expression 
was not identified on hepatocytes (Copple et al., 2003), hepatic non-parenchymal cells have been shown 
to express PAR-1 (Gaca et al., 2002; Copple et al., 2003; Gillibert-Duplantier et al., 2007). The cellular 
distribution of PAR-4 in liver has not been extensively evaluated, although immunohistochemical staining 
in one study suggested expression by Kupffer cells (Rullier et al., 2006). Of importance, the cellular 
distribution of these two receptors is different in mice and humans, with PAR-1 being the principal 
receptor for thrombin on human platelets, whereas thrombin signaling through PAR-4 is important for the 
activation of platelets in mice (Sambrano et al., 2001). 
 Thrombin activation of PAR-1 has been shown to elicit the expression of neutrophil chemokines 
(Uzonyi et al., 2006) and PAR-1 activation promotes neutrophil-dependent hepatotoxicity in LPS-primed 
livers (Copple et al., 2003), suggesting a potential avenue for cross-talk between PAR-1 signaling and 
neutrophil accumulation/activation in cholestatic liver injury. However, PAR-1
-/-
 mice were not protected 
from ANIT-induced liver injury. Interestingly, a previous study showed that a pharmacologic inhibitor of 
PAR-1 reduced serum ALT activity after bile duct ligation (Fiorucci et al., 2004), although the inhibitor 
also prevented fibrinogen consumption, suggesting inhibition of thrombin generation.  
 Previous work by our group and others has shown that platelets contribute to ANIT-induced liver 
injury (Bailie et al., 1994; Sullivan et al., 2010a). However, an important dichotomy exists for the role of 
platelets in this model. Depleting platelets prior to ANIT administration induced parenchymal-type 
peliosis in ANIT-treated mice. In contrast, delayed inhibition of platelets by treatment with the ADP 
receptor antagonist clopidogrel (i.e,. 8 hours post ANIT administration) reduced hepatic neutrophil 
accumulation and necrosis, but did not cause parenchymal-type peliosis (Sullivan et al., 2010a). The 
parallels between these observations and the current PAR-4 studies are intriguing. Complete PAR-4-
deficiency, like platelet-depletion, caused parenchymal type peliosis, but reduced the progression of 
ANIT-induced periportal necrosis, whereas delayed administration of PAR-4 pepducin significantly 
reduced the severity of necrosis. Taken together, these results suggest two roles for PAR-4 in the ANIT 
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model. Initial activation of PAR-4 protects the liver by limiting bleeding into areas of necrosis, 
resembling parenchymal-type peliosis. Late activation of PAR-4 contributes to the progression of ANIT-
induced periportal necrosis. Additional studies may reveal critical crosstalk between thrombin, platelets, 
and neutrophils required for both protective and damaging processes in the livers of ANIT-treated mice. 
Examples of potential lines of investigation include evaluating the role of PAR-4 in initiation of liver 
repair and regeneration and in the accumulation/activation of inflammatory cells, such as neutrophils, 
which contribute to ANIT hepatotoxicity. 
3.6 Figures 
Figure 3.1 
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Figure 3.1: Induction of fibrinogen and serum amyloid A1 expression in ANIT-treated mice.  
Wild type C57Bl/6J mice were treated with vehicle (corn oil) or ANIT (60 mg/kg, po). Hepatic (A) fbg , 
(B) fbg  and (C) fbgα mRNA levels, (D) plasma fibrinogen concentration, and (E) SAA1 mRNA 
expression were determined 24 and 48 hours later. Levels of all biomarkers in mice given vehicle were 
not different between 24 and 48 hours and were pooled. Data are expressed as mean ± SEM. n=5 mice per 
group. *Significantly different from vehicle-treated mice.  
Figure 3.2 
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Figure 3.2: Effect of fibrinogen depletion on ANIT-induced liver injury.  
ANIT-treated (60 mg/kg, po) wild type C57Bl/6J mice were given multiple injections of ancrod 
(1.75U/mouse, ip) or PBS as described in Methods. (A) Plasma fibrinogen levels and (B) hepatic fibrin 
deposition (representative western blot shown) were determined 48 hours after ANIT administration. (C) 
Serum ALT, and (D) ALP activity, (E) and bile acid levels were determined 24 and 48 hours after ANIT 
administration. For analysis of liver histopathology, the (F) average number of necrotic lesions per 40X 
field (G) average lesion size and (H) percentage of necrotic tissue were determined as described in 
Methods. Data are expressed as mean ± SEM. n=10 mice per group for circulating biomarkers in the 
blood and 5 mice per group for analysis of liver histopathology. *Significantly different from ANIT-
treated mice given PBS. 
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Figure 3.3 
 
Figure 3.3: Effect of complete fibrinogen deficiency on ANIT-induced liver injury.  
Fbg
+/-
 mice and Fbg
-/-
 mice were treated with ANIT (60 mg/kg, po) and (A) serum ALT, and (B) ALP 
activity, (C) and bile acid levels were determined 24 and 48 hours later. For analysis of liver 
histopathology, the (D) average number of necrotic lesions per 40X field (E) average lesion size and (F) 
percentage of necrotic tissue were determined as described in Methods. Data are expressed as mean ± 
SEM. n=7 Fbg
+/- 
mice and 5 Fbg
-/-
 mice per group at 24 hours, and 11 Fbg
+/-
 mice and 7 Fbg
-/-
 mice per 
group at 48 hours.  *Significantly different from ANIT-treated Fbg
+/-
 mice. Representative 
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photomicrographs showing H&E-stained liver sections from ANIT-treated (G) Fbg
+/-
 mice and (H) 
ANIT-treated Fbg
-/-
 mice. 
Figure 3.4 
 
Figure 3.4: Effect of PAR-1 deficiency on ANIT-induced liver injury.  
PAR-1
+/+
 mice and PAR-1
-/-
 mice were treated with ANIT (60 mg/kg, po) and (A) serum ALT, and (B) 
ALP activity, and (C) bile acid levels were determined 48 hours later. For analysis of liver 
histopathology, the (D) average number of necrotic lesions per 40X field (E) average lesion size and (F) 
percentage of necrotic tissue were determined as described in Methods. Data are expressed as mean ± 
SEM. n= 8 PAR-1
+/+
 mice and 7 PAR-1
-/-
 mice per group.  
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Figure 3.5 
 
Figure 3.5: Effect of PAR-4 deficiency on ANIT-induced liver injury.  
PAR-4
+/+
 mice and PAR-4
-/-
 mice were treated with ANIT (60 mg/kg, po) and (A) serum ALT, and (B) 
ALP activity, and (C) bile acid levels were determined 24 and 48 hours later. For analysis of liver 
histopathology, the (D) average number of necrotic lesions per 40X field, (E) average lesion size and (F) 
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percentage of necrotic tissue were determined as described in Methods. Representative photomicrographs 
of H&E-stained liver sections from ANIT-treated PAR-4
+/+ 
mice at (G) 24 hours and (I) 48 hours, and 
ANIT-treated PAR-4
-/-
 mice at (H) 24 hours and (J) 48 hours are shown. Bar = 10 microns.  Data are 
expressed as mean ± SEM. n=4 mice per group at 24 hours and 6 mice per group at 48 hours. 
*Significantly different from mice of the same genotype at 24 hours. #Significantly different from ANIT-
treated PAR-4
+/+ 
mice at that time. 
Figure 3.6 
 
Figure 3.6: Effect of delayed PAR-4 inhibitor treatment on ANIT-induced liver injury.  
ANIT-treated (60 mg/kg, po) wild type C57Bl/6J mice were treated with P4Pal-10 (0.5 mg/kg, sc) or PBS 
8 and 24 hours after ANIT, as described in Methods. (A) Serum ALT, and (B) ALP activity, and (C) bile 
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acid levels were determined 48 hours after ANIT administration. For analysis of liver histopathology, the 
(D) average number of necrotic lesions per 40X field (E) average lesion size and (F) percentage of 
necrotic tissue were determined as described in Methods. Representative photomicrographs of H&E-
stained liver sections from ANIT-treated mice given (G) PBS or (H) P4Pal-10 are shown. Data are 
expressed as mean ± SEM. n=10 mice treated with PBS and 10 mice treated with P4Pal-10. 
*Significantly different from ANIT-treated mice given PBS. 
Figure 3.7 
 
Figure 3.7: Effect of PAR-4 inhibitor pretreatment on ANIT-induced liver injury.  
ANIT-treated (60 mg/kg, po) wild type C57Bl/6J mice were given P4Pal-10 (0.5 mg/kg, sc) or PBS 2 
hours prior to and 8 hours after ANIT, as described in Methods.  (A) Serum ALT, and (B) ALP activity, 
and (C) bile acid levels were determined 24 hours later. Representative photomicrographs of H&E-stained 
liver sections from ANIT-treated mice given (D) PBS or (E) P4Pal-10 are shown. n=6 mice per group. 
*Significantly different from ANIT-treated mice given PBS. 
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4.1 Abstract 
Chronic injury to intrahepatic bile duct epithelial cells (BDECs) elicits expression of various 
mediators that promote liver fibrosis, including the V 6 integrin. We tested the hypothesis that tissue 
factor (TF)-dependent thrombin generation and protease activated receptor-1 (PAR-1) activation 
contribute to liver fibrosis induced by cholestasis via induction of V 6 expression. To test this 
hypothesis, mice deficient in either TF or PAR-1 were fed a diet containing 0.025% alpha-
naphthylisothiocyanate (ANIT), a BDEC selective toxicant. In genetically modified mice with a 50% 
reduction in liver TF activity fed an ANIT diet, coagulation cascade activation and liver fibrosis were 
reduced. Similarly, liver fibrosis was significantly reduced in PAR-1
-/-
 mice fed an ANIT diet. Hepatic 
integrin 6 mRNA induction, expression of V 6 protein by intrahepatic BDECs, and SMAD2 
phosphorylation were reduced by TF-deficiency and PAR-1-deficiency in mice fed the ANIT diet. 
Treatment with either an anti- V 6 blocking antibody or soluble TGF-  receptor type II reduced liver 
fibrosis in mice fed the ANIT diet. PAR-1 activation enhanced TGF- 1-induced integrin 6 mRNA 
expression in transformed human BDECs and in primary rat BDECs.  Interestingly, TF and PAR-1 
mRNA levels were increased in livers from patients with cholestatic liver disease. These results indicate 
that a TF-PAR-1 pathway contributes to liver fibrosis induced by chronic cholestasis by increasing 
expression of the V 6 integrin, an important regulator of TGF- 1 activation. 
4.2 Introduction 
Chronic injury to intrahepatic bile duct epithelial cells (BDECs) causes cholestatic liver disease 
characterized by an increase in toxic bile constituents in the hepatic parenchyma. This elicits 
inflammation and a profibrogenic response characterized by excessive deposition of extracellular matrix 
(e.g., collagens), which may lead to liver cirrhosis (Friedman, 2008). The cellular and molecular 
mechanisms of liver fibrosis caused by intrahepatic BDEC injury are not completely understood. Recent 
animal studies have clearly demonstrated that V 6 is critical for the development of liver fibrosis in two 
distinct models of cholestasis, and that it promotes fibrosis by activating the profibrogenic growth factor, 
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TGF- 1 (Wang et al., 2007a; Patsenker et al., 2008).  However, the mechanism of V 6 upregulation on 
BDECs during cholestasis is not known. 
Injury to intrahepatic BDECs can be modeled in rodents by administration of the xenobiotic 
alpha-naphthylisothiocyanate (ANIT) (Plaa and Priestly, 1976). Repetitive canilicular transport of an 
unstable ANIT-glutathione conjugate from hepatocytes into the bile exposes BDECs to toxic 
concentrations of ANIT (Roth and Dahm, 1997; Dietrich et al., 2001). In animals administered large 
doses of ANIT, hepatocellular necrosis manifests proximal to damaged bile ducts (Becker and Plaa, 1965) 
by mechanisms likely involving both high concentrations of hydrophobic bile acids released from 
damaged bile ducts (Perez and Briz, 2009) and infiltration of inflammatory cells (Kodali et al., 2006). In 
contrast, rodents fed a small dose of ANIT in their diet (e.g., 0.25-1 gram/kg diet) develop modest BDEC 
injury associated with BDEC proliferation, periportal inflammation, profibrogenic gene expression, and 
peribiliary collagen deposition (Tjandra et al., 2000; Lesage et al., 2001; Xu et al., 2004; Moritoki et al., 
2006). Consequently, ANIT-induced chronic BDEC injury provides an important model to evaluate the 
pathogenesis of liver fibrosis stemming from cytotoxic challenge to the intrahepatic BDECs.  
Tissue factor (TF) is a transmembrane protein and the principal activator of the extrinsic blood 
coagulation cascade. It is involved in both physiological hemostasis and the pathogenesis of various 
diseases (Mackman, 2009). In the liver, TF is expressed by various cells including BDECs (Luyendyk et 
al., 2009). Previous studies have shown that in rodents the coagulation cascade is activated by obstructive 
cholestasis and after acute toxic insult to the biliary epithelium (Abdel-Salam et al., 2005; Luyendyk et 
al., 2009). Similarly, generation of the coagulation protease thrombin is evident in patients with primary 
biliary cirrhosis (PBC) (Segal et al., 1997; Biagini et al., 2006). Pharmacologic anticoagulation and a 
protease activated receptor-1 (PAR-1) antagonist reduced hepatic collagen levels after bile duct ligation 
(Fiorucci et al., 2004; Abdel-Salam et al., 2005), suggesting that thrombin contributes to liver fibrosis 
during obstructive cholestasis. These experiments demonstrate a role for PAR-1 in fibrosis induced by 
cholestasis. However, the mechanism of coagulation cascade activation during cholestasis and 
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downstream consequences of PAR-1 activation that promote liver fibrosis during cholestasis are not 
known. 
 In the present studies, we tested the hypothesis that a TF-dependent procoagulant response 
accompanies intrahepatic BDEC injury and promotes liver fibrosis by a mechanism requiring thrombin-
dependent induction of the V 6 integrin by BDECs.  
4.3 Methods 
4.3.1 Mice:  All studies were carried out with mice of 8-16 weeks of age. Wild type C57Bl/6J mice were 
purchased from The Jackson Laboratory (Bar Harbor, MA). Mice heterozygous for murine (m) TF 
(mTF
+/-
hTF
+
 mice; hereafter referred to as TF
+/-
 mice) and control mice (mTF
+/+
hTF
+
 mice; hereafter 
referred to as TF
+/+ 
mice), each expressing a low level (approximately 1%) of human TF (hTF), were 
kindly provided by Dr. Nigel Mackman (University of North Carolina-Chapel Hill). Age-matched TF
+/-
 
mice and TF
+/+
 littermates were used for these studies. PAR-1
-/-
 mice and PAR-1
+/+
 mice on an identical 
genetic background (N8 C57Bl/6J) were maintained by homozygous breeding. Mice were maintained in 
an AAALAC-accredited facility at the University of Kansas Medical Center. Mice were housed at an 
ambient temperature of 22°C with alternating 12-h light/dark cycles, and provided water and rodent chow 
ad libitum (Teklad 8604; Harlan, Indianapolis, IN) prior to feeding custom diets. All animal procedures 
were performed according to the guidelines of the American Association for Laboratory Animal Science 
and were approved by the University of Kansas Medical Center Institutional Animal Care and Use 
Committee. 
4.3.2 Diets and sample collection: Diets were prepared by Dyets, Inc (Bethlehem, PA). The ANIT diet 
was an AIN-93M purified diet containing 0.025% ANIT (Sigma-Aldrich, St. Louis, MO). The control 
diet was AIN-93M, a purified diet formulated for maintenance of mature rodents. For antibody studies, 
wild type C57Bl/6J mice were administered once weekly intraperitoneal (ip) injections of isotype control 
antibody (clone 1E6, 10 mg/kg), recombinant murine TGF-β  receptor II-Fc fusion protein (mTGFβRII-
Fc, 5 mg/kg) (Wang et al., 2007a) or anti- V 6 antibody (Clone 6.3G9, 1 or 10 mg/kg) (Wang et al., 
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2007a), each diluted in sterile, endotoxin-free phosphate-buffered saline (PBS). Mice were fed the diets 
for 2 weeks, subsequently anesthetized with isoflurane, and blood was collected from the caudal vena 
cava into sodium citrate (final, 0.38%) or an empty syringe for the collection of plasma and serum, 
respectively. The liver was removed, washed in saline, and the intact gall bladder removed. The left 
medial lobe of the liver was affixed to a cork with OCT and frozen for 3 minutes in liquid nitrogen-
chilled isopentane. Sections of the left lateral lobe were fixed in neutral-buffered formalin for 48 hours 
prior to routine processing. The remaining liver was cut into 100 mg pieces and flash-frozen in liquid 
nitrogen.  
4.3.3. Biomarkers of injury and coagulation and MCP-1 determination: Serum ALT activity was 
determined using a commercial assay (ThermoFisher, Waltham, MA). Plasma thrombin-antithrombin 
(TAT) levels were determined using a commercial ELISA (Siemens Healthcare Diagnostics, Waltham, 
MA). Supernatant MCP-1 levels were determined using a commercial ELISA (eBioscience, San Diego, 
CA). 
4.3.4 Cell culture and treatments: Transformed human bile duct epithelial cells (MMNK-1 cells) 
(Maruyama et al., 2004) were kindly provided by Dr. Melissa Runge-Morris (Wayne State University, 
Detroit, MI), on behalf of Dr. Naoya Kobayashi (Okayama University, Okayama, Japan). The cells were 
maintained at 37
o
 C at 5% CO2 in DMEM supplemented with 10% fetal bovine serum (FBS), 10 U/ml 
Penicillin and 10 µg/ml Streptomycin (Sigma-Aldrich, St. Louis, MO), serum starved for 60 minutes, and 
then stimulated with recombinant human TGF- 1 (5 ng/ml, Peprotech, Rocky Hill, NJ) or its vehicle 
(endotoxin-free PBS containing 2 mg/ml BSA), and with human α-thrombin (10 U/ml, Enzyme Research 
Laboratories, South Bend, IN), 10 µM TFLLRN, 100 µM SFLLRN, 100 µM FSLLRN (AnaSpec, Inc., 
San Jose, CA) or associated vehicle (endotoxin-free  PBS, Sigma-Aldrich). Primary rat BDECs were 
kindly provided by Dr. Vasanthi Bhaskaran, Dr. Monica Otieno, and Dr. Lois Lehman-Mckeeman 
(Brisol-Myers Squibb, Princeton, NJ).  Rat BDECs were maintained in LYD medium (DMEM/F12 
supplemented with 1.2 mg/ml sodium bicarbonate, 5 mg/ml D-glucose, 3 µM forskolin, 1 µM 
dexamethasone, 5 nM triiodothyronine [Sigma], 10% Nuserum IV, 20 ng/ml epidermal growth factor, 
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12.5 µg/ ml bovine pituitary extract, 1% ITS premix [BD Biosciences, San Jose CA] and 50 µg/ml 
Gentamicin [Invitrogen, Carlsbad CA] pH 7.35). The rat BDECs were co-stimulated with TGF- 1 and 
thrombin as described above.  
4.3.5 RNA isolation, cDNA synthesis and real-time PCR: Total RNA was isolated from 100 mg of 
snap-frozen liver or adherent cells utilizing TRI Reagent (Molecular Research Center, Cincinnati, OH), 
from which 1 µg of cDNA was synthesized utilizing a high capacity cDNA synthesis kit (Applied 
Biosystems, Foster City, CA). Subsequent real-time PCR analysis was performed utilizing a StepOnePlus 
instrument (Applied Biosystems, Foster City, CA) and 2X Taqman Master Mix and Taqman gene 
expression assays (Applied Biosystems, Foster City, CA). The levels of each gene were adjusted to the 
levels of 18S RNA for in vivo studies and GAPDH for in vitro studies and the relative levels of each gene 
evaluated utilizing the Ct method. 
4.3.6 Detection of phosphorylated SMAD2 in liver homogenate: Approximately 100 mg of liver was 
homogenized in 1.5 ml of a buffer containing 10 mM HEPES, 10 mM KCl, 300 mM sucrose, 1.5 mM 
MgCl2, 0.5 mM DTT, 1 mM PMSF, and a protease/phosphatase inhibitor cocktail (Pierce), and subjected 
to centrifugation at 3600 x g for 10 min at 4 C. The resulting pellet was lysed in 0.2 mL of a buffer 
containing 20 mM HEPES, 100 mM KCl, 100 mM NaCl, 20% glycerol, 1 mM PMSF, and a 
protease/phosphatase inhibitor cocktail (Pierce), incubated on ice for 30 minutes, then subjected to 
centrifugation at 20,800 x g for 15 minutes at 4 C. The supernatant (i.e., nuclear fraction) was collected 
and protein levels determined using a Bio-rad Dc kit (Bio-Rad). 100 µg of this protein extract was utilized 
for the detection of phosphorylated SMAD2 (Ser465/467) using a commercially available PathScan 
ELISA (Cell Signaling Technology).  
4.3.7 Immunofluorescent staining and confocal microscopy: For all immunofluorescent staining, 5 
micron frozen sections obtained from the isopentane-fixed livers were used. For each staining, the 
sections were fixed with 4% neutral buffered formalin for 10 minutes. For Type 1 collagen staining, 
sections were blocked with 10% goat serum in PBS for 1 hour at room temperature and then incubated 
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with primary antibody (rabbit anti-mouse Type 1 collagen, AB765 Millipore [Temecula, CA]) diluted to 
0.5 µg/ml in block buffer overnight at 4 C. The sections were washed with PBS and then incubated with 
an anti-rabbit Alexa 594-conjugated secondary antibody (Invitrogen, Carlsbad, CA) for 2 hours at room 
temperature. For V 6 staining, sections were blocked with 10% goat serum in PBS for 1 hour at room 
temperature and then incubated with primary antibody (human/mouse chimeric anti- V 6, ch2A1 ) (Van 
Aarsen et al., 2008) diluted 1:200 in block buffer overnight at 4 C. The sections were then washed and 
incubated with a rat anti-mouse CK19 antibody diluted 1:2000 in block buffer for 2 hours at room 
temperature (clone TROMA-3, Developmental Studies Hybridoma Bank, Iowa City, IA). The TROMA-3 
antibody developed by R. Kemler was obtained from the Developmental Studies Hybridoma Bank 
developed under the auspices of the NICHD and maintained by The University of Iowa, Department of 
Biology, Iowa City, IA. The sections were then incubated with cross-adsorbed secondary antibodies: 
Alexa 488-conjugated goat anti-rat IgG and Alexa 594-conjugated goat anti-human IgG (Invitrogen, 
Carlsbad, CA), each diluted 1:500 in block buffer.  Slides were then washed with PBS after secondary 
antibody addition and fluorescent staining in the livers sections was visualized using an Olympus BX41 
microscope (Olympus, Lake Success, NY). Staining protocols for confocal microscopy were similar with 
substitution of goat anti-human IgG Alexa 546-conjugated antibody. Slides were visualized using a Nikon 
TE2000-U Motorized Inverted Scope (Nikon Instruments Inc., Melville, NY) outfitted with a 3-laser 
confocal system. Images were captured using Nikon-EZC1 3.8 confocal imaging software.  
Quantification of Type 1 Collagen staining in 10 randomly selected 100X fields per tissue was 
performed using Scion Image (Scion Corporation, Frederick, MD) as described previously (Kim et al., 
2006). Quantification of V 6 staining was performed using Scion Image as follows: 1) 10 randomly 
selected 400X fields containing periportal regions (positive for CK19 staining) were captured per tissue, 
2) For each identical field the red fluorescence (positive red V 6 staining) was also captured. For each 
image the area of CK19 staining (positive pixels) and accompanying V 6 staining intensity (integrated 
density) was determined and V 6 staining intensity expressed as a ratio of the CK19 area. For 
69 
 
representative photomicrographs, red and green images were merged using the Olympus DP Manager 
software. 
4.3.8 Trichrome staining: Formalin-fixed sections were stained utilizing a Chromaview Gomori 
Trichrome staining kit (Thermo-Fisher, Waltham, MA) as described by the manufacturer’s protocol. 
4.3.9 Flow Cytometry: MMNK-1 cells were collected by trypsinization and pelleted by centrifugation at 
700 x g for 2 minutes. The cells were then adjusted to a density of 1x10
6 
cells/ml in block buffer (10% 
goat serum in PBS) and incubated for 20 minutes at 4
o
C.  Cells were then incubated for 1 hour at 4
o
C with 
anti-mouse PAR-1 antibody (ATAP2, Santa Cruz Biotechnology, Santa Cruz, CA) or IgG2a isotype 
control (BioLegend, San Diego, CA) at a concentration of 1 µg/10
6 
cells.  Cells were pelleted by 
centrifugation at 700 x g and washed 5 times with 2% FBS in PBS.  Cells were then incubated with Alexa 
Fluor 647-conjugated goat anti-mouse secondary antibody at a concentration of 1 µg/10
6 
cells for 1 hour 
at 4
o
C.  Cells were washed 5 times with 2% FBS in PBS and then fixed in 4% paraformaldehyde 
(BioLegend) for 20 minutes.  Cells were then resuspended in 2% FBS in PBS and 20,000 events were 
measured on a FACSCalibur (BD Biosciences, San Jose, CA). 
4.3.10 Human liver samples: Research involving human livers was reviewed by the University of 
Kansas Medical Center Human Research Protection Program and the use of de-identified human liver 
samples was approved. The specimens used in this study were collected by Erik Schadde, M.D, Richard 
Gilroy, M.D., Bashar Abdulkarim, M.D., Ph.D, Jameson Forster,M.D, Mojtaba Olyaee, M.D., and Atta M 
Nawabi, M.D., and provided by the KU Liver Center Tissue Bank. The project “Determination of gene 
expression related to coagulation signaling in liver disease” is sponsored by the Liver Center at The 
University of Kansas Medical Center. Diseased liver tissue utilized was from patients with primary biliary 
cirrhosis (4 Females, age 59, 56, 60, 61; 1 Male, age 47) and patients with primary sclerosing cholangitis 
(3 Males, age 44, 45, 57). Donor liver samples without histological evidence of cholestasis, fibrosis or 
severe inflammation were selected as control tissues (5 Females, age 41, 48, 56, 52, 66; 5 Males, age 57, 
45, 57, 58, 48). 
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4.3.11 Statistics: Comparison of two groups was performed using Student’s t-test. Comparison of 3 or 
more groups was performed using one- or two-way analysis of variance, as appropriate, and the Student-
Newman-Keuls post-hoc test. The criterion for statistical significance was P<0.05. 
4.4 Results   
4.4.1 TF-deficiency reduces coagulation and attenuates liver fibrosis in mice fed the ANIT diet. 
Heterozygous TF-deficiency (TF
+/-
), which reduces liver TF activity by 50% (Luyendyk et al., 2009), did 
not affect plasma thrombin-antithrombin (TAT) levels in mice fed the control diet (Table 4.1). Plasma 
TAT levels increased significantly in TF
+/+
 mice fed the ANIT diet compared to mice fed control diet 
(Table 4.1), and this increase was largely prevented in TF
+/- 
mice (Table 4.1, P=0.070 for the comparison 
of TF
+/-
 mice fed ANIT diet with TF
+/-
 mice fed control diet.). TF-deficiency did not affect the modest 
increase in serum ALT activity in mice fed the ANIT diet (Table 4.1). The induction of alpha-1 type I 
collagen (Col1a1) mRNA in liver was significantly reduced in TF
+/-
 mice fed the ANIT diet compared to 
TF
+/+
 mice fed the ANIT diet (Fig. 4.1A). Increased periportal deposition of type 1 collagen was evident 
in the livers of TF
+/+
 mice fed the ANIT diet compared to mice fed the control diet (Fig. 4.1C and G). 
Similarly, trichrome staining revealed marked periportal collagen deposition in livers of TF
+/+
 mice fed 
the ANIT diet (Fig. 4.1H). In agreement with the reduction in Col1a1 mRNA levels, collagen deposition 
was significantly reduced in the livers of TF
+/-
 mice fed the ANIT diet (Fig. 4.1B and G-J).  
4.4.2 Role of protease activated receptor-1 in liver fibrosis in mice fed the ANIT diet. One 
mechanism whereby TF-dependent thrombin generation could contribute to liver fibrosis in mice fed the 
ANIT diet is by activation of PAR-1. To determine the role of PAR-1 in hepatic injury and fibrosis 
induced by the ANIT diet we utilized PAR-1
-/- 
mice. Serum ALT activity increased similarly in PAR-1
+/+
 
mice and PAR-1
-/-
 mice fed the ANIT diet (data not shown). Reflecting the effect of TF-deficiency on 
liver fibrosis in mice fed the ANIT diet, Col1a1 mRNA and collagen deposition were significantly 
reduced in the livers of PAR-1
-/-
 mice compared to PAR-1
+/+ 
mice fed the ANIT diet (Fig. 4.2A-J).  
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4.4.3 Effect of TF- or PAR-1-deficiency on induction of fibrogenic genes in the livers of mice fed the 
ANIT diet.  Insofar as both TF-deficiency and PAR-1-deficiency reduced liver fibrosis in mice fed the 
ANIT diet, we examined similarities in the induction of profibrogenic genes in liver as a prelude to 
identify the mechanism(s) whereby coagulation protease signaling contributes to liver fibrosis. Both TF-
deficiency and PAR-1-deficiency attenuated induction of tissue inhibitor of metalloproteinase-1 (TIMP-1) 
mRNA in livers of mice fed the ANIT diet (Fig. 4.3A-B). Interestingly, levels of transforming growth 
factor- 1 (TGF- 1) mRNA in livers of mice fed the ANIT diet were not significantly affected by either 
TF- or PAR-1-deficiency (Fig. 4.3C-D). However, induction of integrin 6 mRNA was significantly 
reduced by TF-deficiency and PAR-1-deficiency (Fig. 4.3E-F). 
4.4.4 TF and PAR-1 contribute to the V 6 integrin expression by bile duct epithelial cells (BDECs) 
and SMAD2 phosphorylation in livers of mice fed the ANIT diet. The V 6 integrin is highly 
expressed in BDECs in mice subjected to common bile duct ligation (BDL) and in livers of patients with 
cholestatic liver disease (Wang et al., 2007a). Indeed, we found that integrin β6 mRNA levels increased 
in the livers of patients with PBC and PSC compared to control livers (data not shown). Recent studies 
utilizing pharmacologic and genetic strategies indicated a critical role for this integrin in the activation of 
TGF-  and liver fibrosis induced by chronic cholestasis (Wang et al., 2007a; Patsenker et al., 2008). Of 
importance, the mechanism whereby V 6 integrin expression increases during chronic cholestasis is not 
known. To determine whether the effect of TF- and PAR-1-deficiency on integrin β6 mRNA levels (Fig. 
4.3E-F) was mirrored by changes in the biliary levels of the 6 protein, we utilized immunofluorescent 
staining. Liver sections from mice fed either control diet or ANIT diet were co-stained for the 6 integrin 
and cytokeratin 19 (CK19), the latter a biomarker of BDECs in the adult mouse liver. Minimal V 6 
integrin staining was observed in livers of TF
+/+
 mice and TF
+/-
 mice fed the control diet (Fig. 4.4A and 
D). An increase in BDEC number, as indicated by an increase in CK19-positive staining, was evident in 
the livers of TF
+/+
 mice and TF
+/- 
mice fed the ANIT diet (Fig. 4.4H and K). V 6 integrin expression 
increased substantially in TF
+/+
 mice fed the ANIT diet and the staining colocalized with CK19, 
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indicating V 6 expression by BDECs (Fig. 4.4G-I). Visualization of V 6/CK19 co-staining by 
confocal microscopy indicated colocalization of these proteins within the same plane of cells 
(Supplemental Fig. 4.1). Compared to TF
+/+
 mice fed the ANIT diet, the intensity of V 6 staining was 
significantly reduced in TF
+/-
 mice fed the ANIT diet (Fig. 4.4J and M). Moreover, an analogous pattern 
of CK19 and V 6 staining was observed in liver sections from PAR-1
+/+ 
mice and PAR-1
-/-
 mice fed the 
ANIT diet (Fig. 4.5A-M). 
 To determine whether V 6 expression correlated with activation of TGF-β signaling, we 
evaluated levels of phosphorylated SMAD-2 in liver. TGF-β signaling culminates in SMAD2 
phosphorylation, and this readout has been used previously as an indicator of TGF-β activation (Wang et 
al., 2007a; Horan et al., 2008). Both TF-deficiency (p=0.058) and PAR-1-deficiency reduced the levels of 
phospho-SMAD2 in livers of mice fed the ANIT diet, consistent with the reduced V 6 protein 
expression in TF-deficient and PAR-1-deficient mice (Fig. 4.4N and 4.5N).  
4.4.5 The V 6 integrin and TGF-  contribute to liver fibrosis in mice fed the ANIT diet. The role 
of V 6 and TGF- 1 in the liver fibrosis induced by the ANIT diet has not been described previously. To 
this end, we evaluated whether TF- and PAR-1-dependent upregulation of V 6 could contribute to liver 
fibrosis in this model. Compared to wild type mice administered an isotype control antibody (1E6), wild 
type mice administered a function blocking anti- V 6 antibody (clone 6.3G9) (Weinreb et al., 2004) and 
fed the ANIT diet demonstrated a dose-dependent inhibition of TIMP-1 and Col1a1 gene expression (Fig. 
4.6A and B) and Type 1 collagen deposition (Fig. 4.6C, E-J) in the liver. Of importance, administration of 
the anti- V 6 antibody significantly reduced SMAD2 phosphorylation in the livers of mice fed the ANIT 
diet, indicating inhibition of TGF-  activation (Fig. 4.6D).  Since V 6 led to activation of the TGF-  
cytokine (Munger et al., 1999), we evaluated the contribution of TGF-  to liver fibrosis in this model 
using a recombinant murine TGF-  receptor type II-Fc fusion protein (mTGF RII-Fc) (2). 
Administration of mTGF RII-Fc blocked SMAD2 phosphorylation in liver (Fig. 4.6D) and also 
significantly reduced TIMP-1 and Col1a1 gene expression (Fig. 4.6A and B) and Type 1 collagen 
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deposition (Fig. 4.6C, E-F, and K-L) in the livers of wild type mice fed the ANIT diet. These results 
indicate that V 6 contributes to TGF-  activation and liver fibrosis in mice fed the ANIT diet, and are 
consistent with the hypothesis that a TF-PAR-1-dependent pathway contributes to liver fibrosis by 
upregulating V 6 expression. 
4.4.6 Expression of PAR-1 by transformed human bile duct epithelial cells. One possible mechanism 
whereby PAR-1 could contribute to expression of integrin β6 mRNA is by direct stimulation of BDECs. 
Although other epithelial cells have been shown to express PAR-1 (Shimizu et al., 2000; Rondeau et al., 
2001), the expression of PAR-1 by BDECs has not been described. To address this question we selected 
MMNK-1 cells, a transformed human bile duct epithelial cell line shown to express low levels of integrin 
β6 mRNA (Patsenker et al., 2008), analogous to normal BDECs in vivo. Of importance, MMNK-1 cells 
expressed PAR-1 mRNA (data not shown) and PAR-1 protein on the cell surface (Fig. 4.7A). Stimulation 
of MMNK-1 cells with human -thrombin or the specific PAR-1 agonist peptide TFLLRN (Blackhart et 
al., 1996) induced MCP-1 mRNA expression (Fig. 4.7B and data not shown), a positive control for PAR-
1 activation. Thrombin stimulation also increased MCP-1 levels in the culture supernatant (Fig. 4.7C). 
Interestingly, hepatic MCP-1 mRNA induction was reduced by TF-deficiency and PAR-1-deficiency in 
mice fed the ANIT diet (Fig. 4.7D-E). The results suggest a PAR-1-dependent pathway of MCP-1 
expression during chronic cholestatic liver injury. Furthermore, these data demonstrate that activation of 
PAR-1 on BDECs activates signaling pathways that lead to gene expression changes. 
4.4.7 PAR-1 activation enhances TGF- 1 induction of integrin β6 mRNA expression. In contrast to 
thrombin stimulation of MMNK-1 cells in vitro, thrombin generated during cholestasis likely promotes 
fibrosis in synergy with other mediators. Accordingly, thrombin could modify the response of BDECs to 
other profibrogenic mediators that induce integrin β6 mRNA expression. Interestingly, we found that 
mice fed the ANIT diet and treated with mTGF RII-Fc showed a significant inhibition of hepatic integrin 
β6 expression as compared to isotype control-treated mice (Fig. 4.8A). Consistent with this result, 
stimulation of MMNK-1 cells and primary rat BDECs with TGF- 1 increased integrin β6 mRNA levels 
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(Fig. 4.8B-C). Stimulation of MMNK-1 cells and primary rat BDECs with thrombin alone did not affect 
integrin β6 mRNA levels. In contrast, thrombin enhanced TGF- 1-mediated induction of integrin β6 
mRNA expression in MMNK-1 cells and primary rat BDECs (Fig. 4.8B-C). We also evaluated the role of 
PAR-1 in this cell system by utilizing pharmacologic agonists of this receptor. The PAR-1 agonist 
peptides SFLLRN and TFLLRN, which are based on the N-terminal tethered-ligand sequence of PAR-1 
(Blackhart et al., 1996), also enhanced TGF- 1-induced integrin β6 mRNA expression in MMNK-1 cells 
(Fig. 4.8D-E). In contrast, the peptide FSLLRN, which does not activate PAR-1, did not enhance TGF-
1-induced integrin β6 mRNA expression in MMNK-1 cells (Fig. 4.8F).The data indicate that activation 
of PAR-1 on BDECs enhances TGF- 1 induction of integrin β6 mRNA expression. 
4.4.8 TF and PAR-1 mRNAs are increased in livers of mice fed the ANIT diet and in patients with 
primary biliary cirrhosis and sclerosing cholangitis. It is unlikely that patients with cholestatic liver 
disease are uniformly procoagulant to an extent considered pathologic (i.e., thrombosis), especially 
insofar as prothrombin time can be prolonged in these patients. However, a few studies have shown 
modest thrombin generation and increased circulating tissue factor levels in patients with PBC (Segal et 
al., 1997; Biagini et al., 2006). Although such changes may be insufficient to dramatically affect systemic 
hemostasis, low levels of hepatic thrombin generation could be sufficient to trigger intracellular signaling 
in the liver. Of importance, we found that similar to mice fed the ANIT diet (Fig. 4.9A-B), levels of both 
TF mRNA and PAR-1 mRNA were increased in liver samples from patients with fibrosis associated with 
chronic cholestatic liver disease (PBC [n=5] and PSC [n=3]) compared to control liver samples without 
evidence of inflammation or fibrosis (Fig. 4.9C-D).  
4.5 Discussion 
It is increasingly clear that BDECs are not simply passive targets of injury in models of 
cholestatic liver disease. Rather, these cells actively participate in liver fibrosis by producing a wide array 
of mediators (Glaser et al., 2009). One of these is the heterodimeric integrin V 6, which has diverse 
functions including activation of latent-TGF-  to its mature, active form (Munger et al., 1999).  Elegant 
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studies using pharmacologic and genetic interventions demonstrated a critical role for the V 6 integrin 
in liver fibrosis induced by MDR2-deficiency or BDL in rodents (Wang et al., 2007a; Patsenker et al., 
2008). We found that administration of a function blocking anti- V 6 integrin antibody also reduced 
liver fibrosis in the ANIT diet model of cholestasis, indicating the effectiveness of V 6 blockade across 
multiple models of cholestasis, and further supporting the case for taking therapeutics forward. Moreover, 
administration of a murine recombinant TGF-  receptor type II-Fc fusion protein significantly reduced 
liver fibrosis in mice fed the ANIT diet. Taken together, the results implicate the V 6 integrin and TGF-
 in the pathogenesis of liver fibrosis induced by the ANIT diet.  
The TGF-  isoforms are expressed as part of an inactive complex by both normal and diseased 
tissues (Nishimura, 2009). In liver, TGF-  is expressed by several cell types including myofibroblasts, 
hepatocytes, and Kupffer cells (Gressner and Weiskirchen, 2006). Our findings in the ANIT diet model 
and previous studies (Wang et al., 2007a; Patsenker et al., 2008) indicate that the V 6 integrin is 
required for activation of TGF-  to its profibrogenic form during cholestasis, and that the V 6 integrin 
expression is primarily localized to the BDEC. One potential cellular source of latent TGF-  complex 
relevant to cholestatic liver disease is the periportal myofibroblast (Dranoff and Wells, 2010). Liver 
myofibroblasts have been shown to express the latent TGF-  complex (Mangasser-Stephan et al., 2001), 
and the proximity of these cells to BDECs may deliver latent TGF-  to V 6 integrin on BDECs for 
activation. Another intriguing possibility is that BDECs themselves express the requisite latent TGF- . 
Increased expression of TGF- 1 by BDECs after BDL has been described previously, although BDEC 
expression levels were low compared to the adjacent fibroblasts (Sedlaczek et al., 2001). Of importance, 
the expression of V 6 integrin appears to be the critical, rate-limiting step for the activation of latent 
TGF-  during cholestasis. 
Expression of the V 6 integrin is negligible in normal liver (Wang et al., 2007a). However, 
after biliary injury, hepatic integrin 6 mRNA levels increase and expression of the V 6 integrin 
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increases on BDECs (Wang et al., 2007a; Patsenker et al., 2008). Similar to extrahepatic, obstructive 
cholestasis (e.g., BDL), we found that chronic xenobiotic-induced intrahepatic BDEC injury markedly 
increased integrin 6 mRNA levels in liver and expression of the integrin 6 protein selectively on 
BDECs. Of importance, the mechanism whereby V 6 integrin expression increases during cholestatic 
liver injury has not been identified. Potential inducers of V 6 include direct cellular injury and a number 
of profibrogenic mediators produced in response to chronic cholestatic liver injury. Analogous to previous 
studies in other extrahepatic cell types (Copple et al., 2003; Levy and Hill, 2005), we found that TGF- 1 
stimulation of BDECs induced integrin 6 mRNA expression, suggesting the presence of a feed-forward 
pathway whereby TGF- 1 amplifies activation of additional latent-TGF-  via induction of integrin 6 
mRNA (Fig. 4.10). In agreement with our findings in vitro, administration of a soluble TGF-  receptor 
type II attenuated the induction of integrin 6 mRNA expression in livers of mice fed the ANIT diet. 
Interestingly, administration of the anti- V 6 integrin antibody did not impact induction of integrin 6 
mRNA in mice fed the ANIT diet, suggesting that the V 6 integrin is not the only activator of TGF-  in 
this model, or that low levels of V 6 are sufficient for localized activation of TGF-  and subsequent 
integrin 6 mRNA induction. Overall, the data indicate that TGF-  contributes to integrin 6 mRNA 
induction during cholestasis. However, TGF-  stimulates various cell types concurrently with other 
pathways activated by liver damage and interaction between these pathways may increase profibrogenic 
stimuli. 
One pathway activated by chronic liver damage is the coagulation cascade. Pharmacologic 
inhibition of thrombin or its receptor PAR-1 reduced hepatic collagen deposition after bile duct ligation 
(BDL) (Fiorucci et al., 2004; Abdel-Salam et al., 2005). Despite this and other evidence supporting a role 
for thrombin and PAR-1 in liver fibrosis, the mechanism of coagulation activation and the distal 
mechanism whereby PAR-1 activation contributes to liver fibrosis has not been identified. Our results 
indicate that pathologic coagulation cascade activation during chronic cholestasis in mice fed the ANIT 
diet is TF-dependent, and that the thrombin generated contributes to liver fibrosis by activating PAR-1. 
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Of interest, TF-deficiency and PAR-1-deficiency attenuated V 6 integrin expression and TGF-  
activation in livers of mice fed the ANIT diet. These results reveal a novel mechanism whereby 
coagulation protease signaling contributes to liver fibrosis during cholestasis (Fig. 4.10). Of importance, 
the mechanism whereby thrombin contributes to liver fibrosis may be model dependent.  
Previous studies suggested that the expression of PAR-1 in the liver is restricted to non-
parenchymal cells (Copple et al., 2003). We found that PAR-1 is expressed on the surface of transformed 
human BDECs (i.e., MMNK-1 cells) and that these cells respond to thrombin and PAR-1 agonist peptide 
stimulation by producing MCP-1. Of importance, PAR-1-deficiency also reduced MCP-1 expression in 
mice fed the ANIT diet. Insofar as MCP-1 contributes to liver fibrosis after BDL (Seki et al., 2009), this 
suggests another mechanism whereby PAR-1 could contribute to liver fibrosis in this model. Although 
treatment of MMNK-1 cells or primary rat BDECs with thrombin had no effect on integrin 6 mRNA 
levels in vitro, thrombin enhanced TGF- 1-induced integrin 6 mRNA expression in both cell types. 
Similar experiments using agonist peptides mimicking the PAR-1 N-terminal tethered-ligand support the 
hypothesis that this effect is PAR-1-dependent. These experiments reveal a novel mechanism whereby 
thrombin and TGF-  synergistically promote profibrogenic gene expression and provide an important in 
vitro correlate for our observation that both PAR-1 and TGF-  contribute to V 6 expression in vivo. 
Interestingly, another study showed that stimulation of pulmonary epithelial cells with thrombin or PAR-
1 agonist peptide increased V 6 integrin-dependent activation of latent TGF-  (Jenkins et al., 2006). In 
the latter study, de novo synthesis of integrin 6 mRNA was not required. Taken together, the results 
suggest that the coagulation cascade fine tunes, via PAR-1, the TGF- -dependent induction of integrin 6 
expression and the fibrogenic activity of V 6 in models of fibrosis (Fig. 4.10). 
Despite prolonged prothrombin time in patients with liver disease (Segal et al., 1997), moderate 
thrombin generation occurs, as indicated by elevated plasma TAT levels (Segal et al., 1997; Biagini et al., 
2006). This low level of thrombin generation could be sufficient to elicit signaling through PAR-1 that 
contributes to disease progression. We found that TF and PAR-1 mRNA levels, as well as integrin 6 
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mRNA levels (not shown) were increased in patients with cholestatic liver disease. Another study also 
found elevated PAR-1 expression in patients with PBC (Shackel et al., 2001). Moreover, we have shown 
previously that normal murine BDECs express TF in vitro and in vivo (Luyendyk et al., 2009).  The 
intricate association and apparent cellular co-localization of TF, PAR-1 and V 6 in liver is intriguing, as 
it suggests a paradigm where critical profibrogenic processes can respond rapidly to BDEC injury. That 
is, BDEC injury could result in membrane disruption that exposes TF or TF-positive microparticles to the 
blood, generating locally high thrombin concentrations. Subsequent activation of PAR-1 on BDECs could 
promote V 6 expression and peribiliary fibrosis.  
In summary, the results indicate that TF and PAR-1 contribute to liver fibrosis in a model of 
chronic xenobiotic-induced cholestatic liver injury by enhancing TGF- -dependent V 6 expression by 
BDECs. Continued investigation of the mechanism whereby coagulation protease signaling contributes to 
liver fibrosis may lead to novel approaches to limit TGF-  activation and fibrosis in patients. 
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4.6 Figures 
Figure 4.1 
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Figure 4.1: Reduced liver fibrosis in livers of TF-deficient mice fed the ANIT diet.  
Mice wild type for TF (TF
+/+
) and mice heterozygous for TF (TF
+/-
) were fed either control diet (CD) or 
identical diet containing 0.025% ANIT (AD) for 14 days. (A) Levels of Col1a1 mRNA were determined 
in liver. (B) Quantification of Type 1 collagen staining (see below) as described in Methods. n=4-8 mice 
per group. Data are expressed as mean ± SEM. *Significantly different from the same mice fed control 
diet. 
#
Significantly different from TF
+/+
 mice fed the ANIT diet. (C-J) Representative photomicrographs 
showing immunofluorescent Type 1 collagen staining and Trichrome staining (bar = 20 microns) of liver 
sections from TF
+/+ 
mice (C-D, G-H) or TF
+/- 
mice (E-F, I-J) fed control diet (C-F) or ANIT diet (G-J). 
For Type 1 collagen staining, the images were converted to grayscale and inverted such that positive 
staining is dark.  
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Figure 4.2 
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Figure 4.2: Reduced liver fibrosis in livers of PAR-1
-/- 
mice fed the ANIT diet.  
PAR-1
+/+
 mice and PAR-1
-/-
 mice were fed either control diet (CD) or identical diet containing 0.025% 
ANIT (AD) for 14 days. (A) Levels of Col1a1 mRNA were determined in liver. (B) Quantification of 
Type 1 collagen staining (see below) as described in Methods. n=4-12 mice per group. Data are expressed 
as mean ± SEM. *Significantly different from the same mice fed control diet. 
#
Significantly different 
from PAR-1
+/+
 mice fed the ANIT diet. (C-J) Representative photomicrographs showing 
immunofluorescent Type 1 collagen staining and Trichrome staining (bar = 20 microns) of liver sections 
from PAR-1
+/+ 
mice (C-D, G-H) or PAR-1
-/- 
mice (E-F, I-J) fed control diet (C-F) or ANIT diet (G-J). For 
Type 1 collagen staining, the images were converted to grayscale and inverted such that positive staining 
is dark. 
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Figure 4.3  
 
Figure 4.3: Effect of TF-deficiency and PAR-1-deficiency on the expression of fibrogenic genes in 
livers of mice fed the ANIT diet.  
Mice wild type for TF (TF
+/+
) and mice heterozygous for TF (TF
+/-
), and PAR-1
+/+
 mice and PAR-1
-/-
 
mice were fed either control diet or identical diet containing 0.025% ANIT for 14 days. Levels of (A,B) 
TIMP-1, (C,D) TGF- , and (E,F) integrin 6 (Itgb6) mRNA in liver were determined as described in 
Methods. n=4-12 mice per group. Data are expressed as mean ± SEM. *Significantly different from the 
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same mice fed control diet. 
#
Significantly different from control mice (TF
+/+
 mice or PAR-1
+/+
 mice) fed 
the ANIT diet. 
85 
 
Figure 4.4 
 
86 
 
Figure 4.4: Effect of TF-deficiency on V 6 integrin expression by BDECs in mice fed the ANIT 
diet. 
Mice wild type for TF (TF
+/+
) (A-C, G-I) and mice heterozygous for TF (TF
+/-
) (D-F, J-L) were fed either 
control diet (CD) (A-F) or identical diet containing 0.025% ANIT (AD) (G-L) for 14 days. Representative 
photomicrographs showing immunofluorescent staining for V 6 integrin (red), cytokeratin 19 (CK19, 
green) and the digital merge (yellow) were captured from liver sections. Bar = 10 microns. (M) V 6 
integrin staining intensity adjusted for CK19 area was determined as described in Methods. n=3-6 mice 
per group. (N) Levels of phosphorylated (Ser465/467) SMAD2 were determined in liver homogenate by 
ELISA as described in Methods. Data are expressed as mean ± SEM. *Significantly different from the 
same mice fed control diet. 
#
Significantly different from TF
+/+
 mice fed the ANIT diet. 
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Figure 4.5 
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Figure 4.5: Effect of PAR-1-deficiency on V 6 integrin expression by BDECs in mice fed the 
ANIT diet.  
PAR-1
+/+
 mice (A-C, G-I) and PAR-1
-/-
 mice (D-F, J-L) were fed either control diet (CD) or identical diet 
containing 0.025% ANIT (AD) for 14 days. Representative photomicrographs showing 
immunofluorescent staining for V 6 integrin (red), cytokeratin 19 (CK19, green) and the digital merge 
(yellow) were captured from liver sections. Bar = 10 microns.  (M) V 6 integrin staining intensity 
adjusted for CK19 area was determined as described in Methods. n=3-7 mice per group. (N) Levels of 
phosphorylated (Ser465/467) SMAD2 were determined in liver homogenate by ELISA as described in 
Methods. n=4-7 mice per group. Data are expressed as mean ± SEM. *Significantly different from the 
same mice fed control diet. 
#
Significantly different from PAR-1
+/+
 mice fed the ANIT diet. 
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Figure 4.6 
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Figure 4.6: Effect of inhibitory anti- V 6 integrin antibody and soluble TGF-  receptor treatment 
on liver fibrosis in mice fed the ANIT diet.  
Wild type C57Bl/6J mice were fed either control diet or identical diet containing 0.025% ANIT for 14 
days. Mice were given intraperitoneal injections of isotype control antibody (1E6, 10 mg/kg), 
recombinant TGF-  receptor type II-Fc fusion protein (TGFBRII-Fc, 5 mg/kg), or inhibitory anti- V 6 
antibody (6.3G9, 1 or 10 mg/kg) on experiment days 1 and 7. Levels of (A) TIMP-1 and (B) Col1a1 
mRNA in liver were determined as described in Methods. n=10 mice per group. (C) Quantification of 
Type 1 collagen staining (see panel E-L) as described in Methods. n=5 mice per group (D) Levels of 
phosphorylated (Ser465/467) SMAD2 were determined in liver homogenate by ELISA as described in 
Methods. n=10 mice per group. Data are expressed as mean ± SEM. *Significantly different from the 
same mice fed control diet. 
#
Significantly different from isotype control-treated mice fed the ANIT diet. 
(E-L) Representative photomicrographs showing immunofluorescent Type 1 collagen staining of liver 
sections. (bar = 20 microns) . The images were converted to grayscale and inverted such that positive 
staining is dark. 
Figure 4.7 
 
91 
 
Figure 4.7: Thrombin stimulation of transformed human BDECs.  
(A) Flow cytometric detection of PAR-1 expression on the surface of MMNK-1 cells (isotype control, 
gray; white, anti-PAR-1).  For B-C, MMNK-1 cells were stimulated with human -thrombin (10 U/ml) 
for 4 hours and (B) MCP-1 mRNA and (C) supernatant MCP-1 levels were determined. Data are 
expressed as mean ± SEM from at least 3 independent experiments. *Significantly different from vehicle-
treated cells. For D-E, mice wild type for TF (TF
+/+
) and mice heterozygous for TF (TF
+/-
), and PAR-1
+/+
 
mice and PAR-1
-/-
 mice were fed either control diet or identical diet containing 0.025% ANIT for 14 days. 
Levels of MCP-1 mRNA in liver were determined as described in Methods. n=4-12 mice per group. Data 
are expressed as mean ± SEM. *Significantly different from the same mice fed control diet. 
#
Significantly 
different from control mice (TF
+/+
 mice or PAR-1
+/+
 mice) fed the ANIT diet. 
Figure 4.8 
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Figure 4.8: PAR-1 activation enhances TGF- -induced integrin 6 mRNA expression.  
(A) Wild type C57Bl/6J mice were fed either control diet or identical diet containing 0.025% ANIT for 14 
days. Mice were given intraperitoneal injections of isotype control antibody (1E6, 10 mg/kg), 
recombinant TGF-  receptor type II-Fc fusion protein (TGFBRII-Fc, 5 mg/kg), or inhibitory anti- V 6 
antibody (3G9, 1 or 10 mg/kg) on experiment days 1 and 7. Levels of integrin 6 (Itgb6) mRNA in liver 
were determined as described in Methods. n=10 mice per group. Data are expressed as mean ± SEM. 
*Significantly different from the same mice fed control diet. 
#
Significantly different from isotype control-
treated mice fed the ANIT diet. (B) MMNK-1 cells or (C) primary rat BDECs were stimulated with TGF-
1 (5 ng/ml) or vehicle in the presence or absence of human -thrombin (10 U/ml), for 4 hours and Itgb6 
mRNA levels determined. For D-F, MMNK-1 cells were stimulated with TGF- 1 (5 ng/ml) or vehicle in 
the presence or absence of (D) 100 µM SFLLRN,  (E) 10 µM TFLLRN, or (F) 100 µM FSLLRN.  Data 
are expressed as mean ± SEM from at least 4 independent experiments. *Significantly different from 
respective treatment group in the absence of TGF- 1. 
#
Significantly different from cells treated with 
TGF- 1 alone.  
Figure 4.9  
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Figure 4.9: Increased expression of TF and PAR-1 mRNA in mice fed the ANIT diet and in patients 
with cholestatic liver disease.  
(A-B) TF and PAR-1 mRNA levels were determined in livers from wild type C57Bl/6J mice fed either 
control diet or identical diet containing 0.025% ANIT for 14 days. Data are expressed as mean ± SEM. 
n=5-13 mice per group. *Significantly different from mice fed the control diet. (C-D) TF and PAR-1 
mRNA levels were determined in livers from patients with PBC (n=5) and PSC (n=3) and from control 
livers (n=10) as described in methods. Data are expressed as mean ± SEM. *Significantly different from 
the control livers.  
Figure 4.10 
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Figure 4.10: Proposed mechanism of amplified β6 integrin expression by thrombin and TGF-β1 in 
bile duct epithelial cells.  
TGF-β1 generated during chronic cholestasis induces β6 integrin expression in bile duct epithelial cells 
(BDECs), which is expressed on the cell surface as an αVβ6 integrin heterodimer. The αVβ6 integrin 
contributes to activation of additional TGF-β1 that stimulates peribiliary fibroblasts to produce collagen, 
leading to peribiliary fibrosis. In a feed-forward amplification loop, TGF-β1 also stimulates additional β6 
integrin expression by BDECs. Chronic cellular injury elicits tissue factor-dependent coagulation cascade 
activation and thrombin generation. Thrombin activation of PAR-1 on BDECs contributes to peribiliary 
fibrosis by enhancing TGF-β1-induced β6 integrin expression. 
4.7 Supplemental Figures 
Supplemental Figure 4.1 
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Supplemental Figure 4.1: Assessment of V 6 and CK19 co-staining in liver sections from mice fed 
the ANIT diet by confocal microscopy.  
Wild type C57Bl/6J mice were fed either control diet or identical diet containing 0.025% ANIT for 14 
days. Shown in A-F are representative photomicrographs obtained using confocal microscopy (see 
Methods) showing immunofluorescent staining for V 6 integrin (red), cytokeratin 19 (CK19, green) and 
the digital merge (yellow) in liver sections from mice fed control diet (A-C) or ANIT diet (D-F). Images 
were captured at 400X using an oil immersion objective. 
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Chapter 5 
Regulation of TGF-β1-dependent integrin β6 expression by p38 MAPK in bile duct epithelial cells. 
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5.1 Abstract 
Bile duct epithelial cells (BDECs) contribute to liver fibrosis by expressing Vβ6 integrin, a 
critical activator of latent transforming growth factor β (TGF-β). β6 integrin (Itgβ6) mRNA induction and 
Vβ6 integrin expression in BDECs are partially TGF-β-dependent.  However, the signaling pathways 
required for TGF-β-dependent Itgβ6 mRNA induction in BDECs are not known.  We tested the 
hypothesis that the p38 MAPK signaling pathway contributes to TGF- 1 induction of Itgβ6 mRNA by 
activating SMAD and AP-1 transcription factors. Pretreatment of transformed human BDECs (MMNK-1 
cells) with two different p38 MAPK inhibitors, but not a control compound, inhibited TGF-β1 induction 
of Itgβ6 mRNA. Inhibition of p38 also reduced TGF-β1 activation of a SMAD-dependent reporter 
construct.  Expression of a dominant negative SMAD3 (SMAD3 C) significantly reduced TGF-β1-
induced Itgβ6 mRNA expression. Expression of JunB mRNA, but not other AP-1 proteins, increased in 
TGF-β1-treated MMNK-1 cells and induction of JunB expression was p38-dependent. Consistent with a 
requirement for de novo induction of JunB protein, cycloheximide pretreatment inhibited TGF-β1 
induction of Itgβ6 mRNA. Expression of a dominant negative AP-1 mutant (TAM67) also inhibited TGF-
β1 induction of Itgβ6 mRNA. Overall, the results suggest that p38 contributes to TGF-β1-induced Itgβ6 
mRNA expression in MMNK-1 cells by regulating activation of both SMAD and AP-1 transcription 
factors. 
5.2 Introduction 
Bile duct epithelial cells (BDECs) are injured chronically in cholestatic liver diseases such as 
primary sclerosing cholangitis and primary biliary cirrhosis. In addition to being targets of disease 
processes, it is increasingly clear that BDECs actively participate in the pathogenesis of cholestatic liver 
disease by producing proinflammatory and profibrogenic mediators such as transforming growth factor 
beta 1 (TGF-β1) and the V 6 integrin (Sedlaczek et al., 2001; Hahm et al., 2007; Sullivan et al., 2010b).  
These mediators stimulate other cell types including portal fibroblasts to produce collagen, leading to 
liver fibrosis (Bataller and Brenner, 2005).  
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The V 6 integrin is selectively expressed by epithelial cells in multiple tissues and plays a role 
in physiological processes such as fetal development and wound healing (Breuss et al., 1995), as well as 
pathological processes including tumor cell invasion and fibrosis (Marsh et al., 2008; Patsenker et al., 
2008).  Most notably, the V 6 integrin binds to and facilitates the activation of latent transforming 
growth factor beta 1 (TGF- 1) (Munger et al., 1999), a cytokine and important profibrogenic mediator 
(Bataller and Brenner, 2005).  Several recent studies utilizing mice deficient in the 6 integrin subunit 
have demonstrated a crucial role for this integrin in the activation of TGF- 1 during fibrosis induced by 
chronic tissue injury. For example, in rodent models of lung and liver fibrosis, integrin 6 (Itg 6) 
deficiency reduced the deposition of extracellular matrix in these tissues (Jenkins et al., 2006; Hahm et 
al., 2007). 
The Itg 6 gene, which encodes the limiting subunit of the V 6 integrin, is expressed at low 
levels in normal liver.  However, in rodent models of cholestasis, both hepatic Itg 6 mRNA and V 6 
protein are increased (Hahm et al., 2007; Patsenker et al., 2008; Popov et al., 2008; Sullivan et al., 
2010b), and V 6 protein expression co-localizes with BDECs (Hahm et al., 2007; Patsenker et al., 2008; 
Sullivan et al., 2010b). Various genetic and pharmacologic interventions targeting the V 6 integrin have 
been shown to reduce the activation of TGF- 1 and fibrosis in mice and rats during cholestasis (Jenkins et 
al., 2006; Patsenker et al., 2008; Sullivan et al., 2010b). Taken together, these studies suggest that the 
induction of Itg 6 expression is a critical step in the fibrogenic response associated with chronic 
cholestasis. However, the mechanism of Itg 6 mRNA induction in BDECs is not known. 
We have shown previously that neutralizing TGF-β reduces Itg 6 mRNA expression during 
cholestasis (Sullivan et al., 2010), suggesting the presence of a feed-forward amplification loop of TGF-β 
activation. Of importance, the mechanism whereby TGF-β regulates Itg 6 in bile duct epithelial cells is 
not completely understood. Mature TGF- 1 binds its type II receptor, which is expressed by BDECs (Lu 
et al., 2003).  This binding event initiates downstream canonical signaling involving activation of TGF-  
type I receptor, C-terminal phosphorylation of the regulatory (R-)SMAD transcription factors (SMAD 2 
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and SMAD3), the heterodimerization of these proteins with SMAD4, and translocation to the nucleus 
where this complex regulates transcription (Derynck and Zhang, 2003).  The importance of SMAD-
dependent transcription in fibrosis has been demonstrated previously (Schnabl et al., 2001; Zhao et al., 
2002).  Of importance, TGF- -induced Itg 6 mRNA in keratinocytes is SMAD4-dependent (Levy and 
Hill, 2005).  TGF- 1 also activates non-canonical signaling pathways such as the p38 mitogen activated 
protein kinase (MAPK), which can regulate gene expression through activation of downstream 
transcription factors such as activator protein 1 (AP-1).   Non-canonical signaling pathways have been 
shown to be involved in profibrogenic gene induction (Shaulian and Karin, 2001; Derynck and Zhang, 
2003; Javelaud and Mauviel, 2005).  However, the involvement of the p38 MAPK pathway in the 
regulation of Itg 6 gene induction has not been determined.  
This study aimed to investigate the signaling mechanisms of TGF- 1-dependent expression of the 
profibrogenic 6 integrin in BDECs.  We utilized transformed human BDECs (MMNK-1 cells) to test the 
hypothesis that TGF- 1 activation of the SMAD and p38 MAPK signaling pathways coordinate the 
induction of the 6 integrin mRNA.   
5.3 Materials and Methods 
5.3.1 Antibodies and Reagents:  TGF- 1 (Peprotech, Rocky Hill, NJ), SB203580 (LC Laboratories, 
Woburn, MA), SB202190 and SB202474 (EMD Chemicals, Gibbstown, NJ), cycloheximide (Sigma-
Aldrich, Saint Louis, MO) and dimethyl sulfoxide (DMSO; Research Organics, Cleveland, OH) were 
used to treat cultured cells.  SMAD (SBE4, SABiosciences, Fredrick, MD) and AP-1 (pAP-1-Luc, 
Stratagene, Santa Clara, CA)  responsive luciferase reporter constructs mixed 40:1 with renilla 
transfection control vector (pRL-CMV, Promega, Madison, WI), Fugene 6 transfection reagent (Roche, 
Indianapolis, IN), and Dual-glo luciferase assay kit (Promega) were used for luciferase activity 
experiments.  Dominant negative SMAD2 (SMAD2∆C) and SMAD3 (SMAD3∆C) mutant as well as a 
control (pRK7) plasmid were obtained from addgene (Cambridge, MA), donated by Dr. Rik Derynck 
(Zhang et al., 1996).  A dominant negative AP-1 (TAM67) mutant and control (pCMV) plasmids were a 
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gift from Dr. Michael J. Soares (University of Kansas Medical Center, Kansas City, KS) (Brown et al., 
1993).  A TriFecta RNAi kit (IDT, Coralville, IA) containing ATF-2 siRNA, control siRNA, and 
triFECTin
TM
 transfection reagent were used for siRNA knockdown of ATF-2.  TRI reagent (Molecular 
Research Center, Inc., Cincinnati, OH), High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Foster City, CA) and a MyCycler thermal cycler (Bio-Rad, Hercules, CA) were used for the 
isolation of RNA and synthesis of cDNA.  TaqMan gene expression assays, TaqMan master mix and a 
StepOnePlus sequence detection analyzer (Applied Biosystems) were used for quantitative PCR.  Primary 
antibodies including rabbit anti-human p38, phospho-p38 (Thr180/Tyr182) (12F8) Rabbit mAb), 
SMAD2, and phospho-SMAD2 (Ser465/Ser467), SMAD3, phospho-SMAD3 (Ser423/425), ATF-2, 
phospho-ATF2 (Thr71), JunB, and Histone H3 (Cell Signaling Technology, Inc., Danvers, MA) were 
used for western blotting and immunoprecipitation.  HRP conjugated anti-rabbit secondary (Pierce, 
Rockford, IL) antibody was used for western blotting and ChIP-grade protein G conjugated magnetic 
beads were used for immunoprecipitation (Cell Signaling Technology).   
5.3.2 Cell Culture and treatments: MMNK-1 cells were kindly provided by Dr. Melissa Runge-Morris 
(Wayne State University, Detroit, MI), on behalf of Dr. Naoya Kobayashi (Okayama University, 
Okayama, Japan).  MMNK-1 cells were maintained at 37
o
 C at 5% CO2 in DMEM (Sigma) supplemented 
with 10% fetal bovine serum (FBS [Sigma]), 10 U/ml Penicillin and 10 µg/ml Streptomycin (Sigma) in 
75 cm
2 
flasks (ISC BioExpress, Kaysville, UT) and were routinely passaged with 0.5% trypsin (Sigma) 
after cells reached 95% confluency.  Prior to treatment, MMNK-1 cells were grown to 70% confluency 
and were serum-starved for 1 hour prior to stimulation with 5 ng/ml TGF- 1 or its vehicle (0.1% BSA 
[Fisher] in endotoxin free PBS [Sigma]).  For inhibitor studies, MMNK-1 cells were serum starved for 30 
minutes, and then pre-treated with, 10 µM SB203580, SB202190, SB202474 (LC Laboratories), 10 µg/ml 
cycloheximide (Sigma), or DMSO vehicle (final concentration, 0.1%) for an additional 30 minutes prior 
to treatment with 5 ng/ml TGF- 1 or vehicle.  For dominant negative mutant studies, cells were grown to 
50% confluency and transfected with 1 µg of plasmid using Fugene6 transfection reagent and allowed to 
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incubate for 24 hours to reach 70% confluency and were treated as described above.  For ATF-2 siRNA 
studies, cells were grown to 30% confluency, transfected with 10 nM control siRNA or ATF-2 siRNA 
(IDT) using triFECTin
TM
 transfection reagent (IDT) according to the manufacturer’s protocol, and 
allowed to incubate for 48 hours to reach 70% confluency prior to treatment.     
5.3.3 RNA isolation, cDNA synthesis, and real-time PCR:  RNA was isolated from adherent cells using 
TRI Reagent according to the manufacturer’s protocol. One microgram of total RNA was utilized for the 
synthesis of cDNA using a High Capacity cDNA Reverse Transcription kit on a MyCycler thermal cycler.  
Levels of Itg 6, GAPDH, ATF-2, and JunB mRNAs were determined using TaqMan gene expression 
assays and TaqMan gene expression master mix on a StepOnePlus sequence detection system.  The 
relative expression levels of Itg 6, ATF-2, and JunB mRNAs were determined using the comparative Ct 
method utilizing GAPDH mRNA as the endogenous control. 
5.3.4 Cytosolic and nuclear sample preparation, immunoprecipitation, western blotting and 
densitometry:  Cells were harvested by scraping into ice cold PBS and pelleted by centrifugation at 
3,500g at 4
o
C for 5 minutes.  The cell pellet was then resuspended in lysis buffer (10 mM HEPES, 10 mM 
KCl, 300 mM sucrose, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM PMSF, 0.1% NP40) containing protease 
and phosphatase inhibitors (Roche) and incubated for 10 minutes on ice.  Nuclei were pelleted from lysate 
by centrifugation at 3,500g for 10 minutes at 4
o
 C, and supernatant saved as the cytosolic fraction.  Nuclei 
were then resuspended in nuclear lysis buffer (20 mM HEPES, 100 mM KCl, 100 mM NaCl, 0.5 mM 
DTT, 0.5 mM PMSF in 20% glycerol) for 30 minutes on ice.  Nuclear debris was cleared by 
centrifugation at 20,000g for 2 minutes and supernatant saved as the nuclear fraction.  Protein 
concentration was determined using a commercially available kit (DC protein assay, Bio-Rad) according 
to manufacturer’s protocol.  For immunoprecipitation, 100 µg of total nuclear protein was incubated with 
SMAD3 antibody 1:100 (Cell Signaling) overnight with mild rotation at 4
o
C.  5 µg of protein was diluted 
into 2X NuPage LDS buffer containing 2.5% 2-Mercaptoethanol (2X LDS, Invitrogen), and saved as the 
input fraction.  Magnetic protein G conjugated beads were then added to the remaining sample and 
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incubated at 4
o
C for 2 hours. The magnetic beads were separated and immobilized using a magnetic tube 
rack, and the samples were then washed 5X in 1ml of nuclear lysis buffer.  The magnetic beads were 
separated and resuspended into 2X LDS and samples were eluted at 95
o 
C for 5 minutes prior to western 
blotting.  All western blotting samples were denatured and reduced in 2X LDS for 5 minutes at 95
o
 C, 
separated by SDS-PAGE using Criterion XT pre-cast 4-12% Bis-Tris gels and XT MOPS running buffer 
(Bio-Rad), and transferred onto PVDF membranes (Millipore, Billerica, MA).  Membranes were blocked 
for 60 minutes with 3% BSA in TBST (50 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.4).  
Membranes were then incubated overnight with primary antibodies diluted 1:1000 for p38, phospho-p38 
(Thr183/Tyr185), phospho-SMAD2 (Ser465/Ser467), SMAD2, phospho-SMAD3 (Ser423/425), SMAD3, 
ATF-2, phospho-ATF2 (Thr71), JunB, or Histone H3 (Cell Signaling Technology) in 1% BSA in TBST 
at 4
o
 C.  Membranes were washed 6 times in TBST for 5 minutes and then incubated with HRP 
conjugated goat anti-rabbit secondary antibody diluted 1:1000 in 1% BSA in TBST for 1 hour at room 
temperature.  Membranes were washed 6 additional times, then incubated with Super Signal West Pico 
Chemiluminescence Substrate Solution (Pierce) and exposed to blue autoradiography film (ISC 
BioExpress).  Developed films were scanned using an Epson Expression 1680 scanner and images were 
analyzed using Gel-Pro Analyzer 32 (Media Cybernetics, Inc, Bethesda, MD).  For densitometry, a ratio 
of phosphorylated p38 or ATF-2 to the respective band(s) indicating total p38 or ATF-2 protein was 
generated.  
5.3.5 Luciferase assays: MMNK-1 cells grown to 50% confluency were transfected overnight using 
Fugene 6 transfection reagent with 1 µg of SMAD-responsive (SBE4) or AP-1-responsive (pAP-1-Luc) 
luciferase reporter constructs, each mixed 40:1 with control renilla construct.  After 16 hours of 
transfection, cells were treated with 5 ng/ml TGF- 1 as described above.  Luciferase and renilla activities 
were determined using a Dual-Glo luciferase kit (Promega) per manufacturer’s protocol and read by an 
Infinite M200 plate reader (Tecan, Durham, NC).  For each sample, luciferase relative light units (RLU) 
were adjusted based on renilla activity as an estimation of transfection efficiency.   
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5.3.6 Statistics: Comparison of the effect of interventions with dominant negative proteins on TGF-β-
induced Itgb6 mRNA and luciferase reporter expression was made using a paired t-test.  For these 
experiments, at least 3 independent experiments were performed. Each individual experiment utilized a 
separate passage (i.e,. split) of MMNK-1 cells. For each experimental replicate, MMNK-1 cells derived 
from the same flask (i.e., a single split) were distributed identically into wells of 6-well culture plates and 
‘control’ and ‘experimental’ treatments were performed in parallel from a single cell passage. By design, 
comparing ‘control’ and ‘experimental’ groups using the paired t-test is appropriate (Motulsky, 1995). 
Comparison of 3 or more groups was performed using an analysis of variance and Student-Neuman-Keuls 
post-hoc test.  The criterion for statistical significance was P<0.05.   
5.4 Results  
5.4.1 TGF-β1 induction of Itgβ6 mRNA in MMNK-1 cells is SMAD-dependent.  TGF-β1 increased 
Itgβ6 mRNA in human transformed bile duct epithelial cells (MMNK-1) (Fig. 5.1A).  The cellular 
response to TGF-β is elicited in part through the canonical signaling pathway via the R-SMAD 
transcription factors, SMAD2 and SMAD3 (Derynck and Zhang, 2003).  Stimulation of MMNK-1 cells 
with TGF-β1 also increased nuclear levels of C-terminal phosphorylated SMAD2 and SMAD3 (Fig. 
5.1B).  TGF-β1 treatment of MMNK-1 cells increased activation of a SMAD-dependent reporter 
construct (Fig. 5.1C).  To test the hypothesis that TGF-β1-dependent Itgβ6 mRNA induction is SMAD-
dependent, we utilized dominant negative SMAD2 (SMAD2∆C) and SMAD3 (SMAD3∆C) mutants 
(Zhang et al., 1996).  MMNK-1 cells transfected with SMAD3∆C significantly reduced (~25%) TGF-β1-
dependent induction of Itgβ6 mRNA (Fig. 5.1D).  However, the inhibition (~15%) of TGF-β1-induced 
Itgβ6 mRNA by expression of SMAD2∆C did not achieve statistical significance (Fig. 5.1E, P=0.108).  
The data suggest SMAD3 is involved in TGF-β-induced Itgβ6 mRNA expression in MMNK-1 cells. 
5.4.2 Activation of p38 MAPK contributes to TGF-β1-dependent induction of Itgβ6 mRNA in 
MMNK-1 cells.  TGF-β can also signal through SMAD-independent, non-canonical signaling pathways 
leading to activation of the p38 MAPK (Derynck and Zhang, 2003).  Treatment of MMNK-1 cells with 
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TGF-β1 increased levels of phosphorylated p38 MAPK (Fig. 5.2A- B), an indicator of p38 MAPK 
activation.  To determine the role of p38 MAPK signaling pathway in TGF-β1-dependent induction of 
Itgβ6 mRNA, we utilized two selective pharmacologic inhibitors of p38 (SB203580 and SB202190).  
Pretreatment of MMNK-1 cells with SB203580 significantly reduced Itgβ6 mRNA expression in 
MMNK-1 cells treated with TGF-β1 by 40% (Fig. 5.2C).  Similarly, pretreatment with a more potent p38 
MAPK inhibitor, SB202190, significantly reduced Itgβ6 mRNA expression in MMNK-1 cells treated 
with TGF-β1 by 70% (Fig. 5.2D). In contrast, pretreatment with a structurally related negative control 
compound for these two inhibitors (SB202474) had no effect (Fig. 5.2E). The results indicate that p38 is 
involved in TGF-β1-dependent induction of Itgβ6 mRNA in MMNK-1 cells.  
5.4.3 Activation of AP-1 contributes to TGF-β1 induction of Itgβ6 mRNA in MMNK-1 cells.  
Activation of p38 MAPK directs transcriptional regulation in part through activation of AP-1 
transcription factor family members, including FosB, ATF-2, JunB, and c-Jun (Kumar et al., 1997; 
Shaulian and Karin, 2001; Humar et al., 2007).  Indeed, in MMNK-1 cells stimulated with TGF-β1, AP-
1-dependent luciferase activity was increased (Fig. 5.3A).  Of importance, MMNK-1 cells expressing a 
dominant negative AP-1 mutant (TAM67), which inhibits all AP-1 family members (Brown et al., 1994), 
attenuated (~20%) the TGF-β1-dependent induction of Itgβ6 mRNA (Fig. 5.3B).  The data indicate that 
AP-1 contributes to Itgβ6 mRNA induction in MMNK-1 cells. 
5.4.4 ATF-2 does not contribute to TGF-β1-induction of Itgβ6 mRNA in MMNK-1 cells.  ATF-2 is 
an AP-1 family member subject to phosphorylation and activation by p38 MAPK.  TGF-β-dependent 
activation of p38 MAPK and subsequent phosphorylation of ATF-2 is reduced after treatment with 
SB203580 (Edlund et al., 2003).  Interestingly, ATF-2 has been shown to bind SMAD3 and increase 
SMAD-dependent transcriptional activity (Kumar et al., 1997; Yamamura et al., 2000; Ionescu et al., 
2003).  TGF-β1 treatment increased the levels of phosphorylated ATF-2 in MMNK-1 cells (Fig. 5.4A-B), 
but did not increase ATF-2 mRNA levels (Fig. 5.4E).   Pretreatment with SB203580 reduced the levels of 
phosphorylated ATF-2 in two independent experiments (data not shown).  Co-immunoprecipitation 
experiments revealed an increased association of SMAD3 and ATF-2 in the nucleus of MMNK-1 cells 
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treated with TGF-β1 (Fig. 5.4C).  Interestingly, SB203580 pretreatment reduced TGF-β1-dependent 
SMAD luciferase activity by approximately 40% (Fig. 5.4D).  To determine whether ATF-2 contributes 
to Itgβ6 mRNA induction, an siRNA approach was used.  ATF-2 mRNA (Fig. 5.4E) and protein (Fig. 
5.4F) levels were reduced in MMNK-1 cells transfected with ATF-2 siRNA compared to a length-
matched control siRNA that has no complimentary human sequence.  Of importance, ATF-2 knockdown 
did not affect TGF-β1-dependent induction of Itgβ6 mRNA in MMNK-1 cells (Fig. 5.4G).  Although 
ATF-2 interacts with SMAD3 after TGF-β1 treatment, the data suggest that ATF-2 is not required for 
TGF-β1-induced Itgβ6 mRNA expression in MMNK-1 cells. 
5.4.5 TGF-β1 increases JunB expression in MMNK-1 cells in a p38-dependent manner.  In a 
transcription factor binding ELISA screen (TransAM, Active Motif, Carlsbad, CA) to identify other AP-1 
family members that could contribute to TGF-β-induced Itgβ6 mRNA expression, we found that TGF-β1 
treatment increased the nuclear levels of JunB, but not FosB, c-Fos, Fra-1, c-Jun-P(S73), or JunD (data 
not shown).  Validating this result, we found that JunB mRNA and protein increased in TGF-β1-treated 
MMNK-1 cells at 30 minutes (Fig. 5.5A) and 120 minutes, respectively (Fig. 5.5B).  Of importance, 
pretreatment of MMNK-1 cells with SB203580 prevented the induction of JunB mRNA (Fig. 5.5C) and 
the accumulation of nuclear JunB protein (Fig. 5.5D).  These results suggest that p38-dependent JunB 
induction could be a mechanism whereby TGF-β1 contributes to Itgβ6 mRNA expression.  Interestingly, 
pretreatment with the protein synthesis inhibitor cycloheximide (CHX) reduced the TGF-β1-dependent 
induction of Itgβ6 mRNA in MMNK-1 cells by approximately 30% (Fig. 5.5E).  The data suggest that 
p38 MAPK contributes to TGF-β1-induced JunB mRNA and increased nuclear protein levels.  
Furthermore, full TGF-β1-dependent Itgβ6 mRNA induction requires de novo protein synthesis in 
MMNK-1 cells. 
5.5 Discussion 
The V 6 integrin has been shown to facilitate activation of latent TGF- 1 (Munger et al., 1999), 
which contributes to fibrosis in multiple models (Hahm et al., 2007; Popov et al., 2008; Sullivan et al., 
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2010b). Cholestatic liver injury is associated with increased expression of Itg 6 mRNA in liver and 
expression of V 6 by bile duct epithelial cells (BDECs).  Induction of mRNA encoding the 6 subunit 
is likely a critical limiting factor for the surface expression of the V 6 integrin (Breuss et al., 1995). To 
this end, identifying the mediators and pathways required for the expression of this gene in BDECs could 
reveal novel targets for the treatment of liver fibrosis.  
In agreement with our previous study (Sullivan et al., 2010b), we found that treatment of 
MMNK-1 cells with TGF- 1 increased Itg 6 mRNA expression. It is initially counterintuitive to consider 
active TGF- 1 as a key player in the induction of a gene essential for activation of its own latent form. 
However, it should be noted that there are multiple mechanisms whereby TGF- 1 can become activated.  
For instance, other factors such as thrombospondin-1 may play a role in the initial activation of latent-
TGF- 1 (Crawford et al., 1998). Moreover, there may be low basal levels of surface V 6 integrin 
expression in normal liver. Finally, it is highly likely that more than one mediator contributes to Itg 6 
mRNA expression during cholestasis. Of importance, the induction of the limiting 6 subunit mRNA by 
active TGF- 1 may form the basis of an amplification loop whereby TGF- 1 drives the further activation 
of latent TGF- 1 and ultimately liver fibrosis.  Supporting this hypothesis are data from a previous study 
suggesting that inhibition of TGF-  signaling in vivo reduces Itg 6 mRNA and V 6 expression in 
BDECs (Sullivan et al., 2010b).  Also, pharmacologic inhibition of V 6 integrin reduces fibrosis in 
several rodent models of cholestasis (Wang et al., 2007a; Patsenker et al., 2008; Sullivan et al., 2010b).  
These studies further suggest that V 6 integrin is a key player in the development of fibrosis and 
enhance the argument for developing therapies targeting the V 6 integrin for the treatment of 
cholestasis-induced liver fibrosis.  
TGF- 1-induced intracellular signaling elicits SMAD-dependent gene induction in multiple cell 
types (Derynck and Zhang, 2003), including BDECs (Luo et al., 2005). Of importance, the pathogenesis 
of liver fibrosis in rodent models has been shown to involve SMAD-dependent induction of various 
profibrogenic genes including PAI-I and CTGF (Holmes et al., 2001; Schnabl et al., 2001; Levy and Hill, 
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2005; Wang et al., 2007b).  A recent study demonstrated that SMAD4 deficiency reduced TGF- 1-
dependent induction of Itg 6 expression in keratinocytes (Levy and Hill, 2005).  Similarly, we found that 
inhibition of SMAD3 reduced the TGF- 1-dependent mRNA induction of Itg 6.   Interestingly, various 
genes have shown differential dependency on SMAD2 and SMAD3 for their induction.  For example, 
TGF- -dependent induction of MMP-2 has been shown to be SMAD2-dependent, while CTGF is 
SMAD3-dependent, and -SMA relies on both SMAD2 and SMAD3 for induction (Holmes et al., 2001; 
Phanish et al., 2006).  Although the use of a dominant negative SMAD2 showed the same inhibitory trend 
on TGF- 1-dependent Itg 6 mRNA induction, this did not meet the level of significance.  Further studies 
are needed to clarify the individual roles of SMAD2 and SMAD3 in the induction of Itg 6 by TGF- 1 in 
 
It is increasingly clear that in addition to activation of the SMAD transcription factors, TGF- 1 
activates other signaling pathways, including p38 MAPK (Derynck and Zhang, 2003; Ohshima and 
Shimotohno, 2003). Indeed, TGF- 1 stimulation of MMNK-1 cells activated the p38 MAPK signaling 
pathway, and pretreatment of MMNK-1 cells with inhibitors of the p38 MAPK significantly reduced both 
TGF- 1-dependent Itg 6 mRNA expression and SMAD-luciferase reporter activation. The finding that 
two independent pharmacologic inhibitors of p38, but not a structurally related negative control 
compound, reduced TGF- 1-dependent Itg 6 mRNA expression constitutes strong evidence of p38 
involvement in Itg 6 induction in MMNK-1 cells. However, we cannot exclude the possibility that “off 
target” effects of these inhibitors (Bain et al., 2007; Shanware et al., 2009) contributes to their activity in 
MMNK-1 cells.  
  Of importance, TGF- 1 activation of the p38 MAPK has been shown to modify gene expression 
changes via cooperative enhancement of SMAD activity through multiple mechanisms. For example, 
TGF- 1-dependent p38 MAPK activation stimulates sumoylation of SMAD4, promoting SMAD4 
stabilization and sustained transcriptional activity (Ohshima and Shimotohno, 2003). Alternatively, p38 
can regulate AP-1 transcription factor components such as ATF-2, which have been shown to modify 
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SMAD transcriptional activity by directly binding SMAD3 and SMAD4 (Kumar et al., 1997; Yamamura 
et al., 2000; Ionescu et al., 2003).  Although we observed an association of ATF-2 with SMAD3 in TGF-
1-treated MMNK-1 cells, knockdown of ATF-2 did not affect TGF- 1-dependent Itg 6 mRNA 
induction.   
Other AP-1 family members such as Fos and Jun can alter transcriptional activation of TGF-  
target genes (Liboi et al., 1988; Laiho et al., 1991).  Of importance, inhibition of AP-1 by the expression 
of a dominant negative AP-1 mutant (TAM67), which inhibits all AP-1 family members, reduced TGF-
1-dependent Itg 6 mRNA expression. The relatively modest inhibition of Itg 6 mRNA expression by 
the dominant negative AP-1 suggests that AP-1 activation by p38 is one of several pathways that 
contribute to Itg 6 mRNA induction. Indeed, p38 activation of the SMAD3 transcription factor may be a 
parallel pathway regulating Itg 6 mRNA induction, as the dominant negative SMAD3 protein also 
reduced Itg 6 mRNA induction.  
In a screen to identify AP-1 family members that could be TGF- 1 sensitive, only nuclear levels 
of JunB were increased in TGF- 1 treated MMNK-1 cells.  Interestingly, JunB has been shown to be 
induced in response to TGF- 1 stimulation (Coussens et al., 1994; Shaulian and Karin, 2001) JunB can 
also bind to SMAD3, and its expression is essential for TGF- -dependent induction of select genes 
(Verrecchia et al., 2001; Selvamurugan et al., 2004).  Indeed, TGF- 1 stimulation of MMNK-1 cells 
increased JunB mRNA and nuclear protein levels in a p38 dependent manner.  It is important to note that 
the induction of JunB mRNA and nuclear protein accumulation occurred prior to the induction of Itg 6 
mRNA, suggesting a requirement for JunB induction.  Similarly, inhibition of protein synthesis reduced 
Itg 6 mRNA expression, further suggesting that a key step in Itg 6 mRNA induction is the de novo 
synthesis of this key regulatory protein.  However, further studies are required to elucidate the mechanism 
whereby individual AP-1 family members participate in TGF- 1-induced Itg 6 mRNA expression.  
In summary, TGF- 1 increased the expression of Itg 6 mRNAs in transformed human BDECs.  
Itg 6 induction required activation of the p38 MAPK signaling pathway and was also dependent upon 
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AP-1 and SMAD3 transcription factors. Overall, the data suggest that both the SMAD and p38 MAPK 
pathways contribute to Itgβ6 mRNA expression in BDECs.  
5.6 Figures 
Figure 5.1 
 
Figure 5.1: Role of SMAD 3 in TGF-β1-induced Itgβ6 mRNA expression in MMNK-1 cells. 
(A) MMNK-1 cells were stimulated with 5 ng/ml TGF-β1 or vehicle (0.1% BSA in PBS) for 4 hours.  
Itgβ6 mRNA levels were determined by qPCR.  (B) MMNK-1 cells were treated with 5 ng/ml TGF-β1 or 
vehicle for various times.  Levels of C-terminally phosphorylated SMAD2 and SMAD3, total SMAD2, 
and total SMAD3 levels were determined in nuclear extracts by western blotting.  A representative 
western blot is shown.  (C) MMNK-1 cells transiently transfected with a SMAD-responsive luciferase 
reporter construct (SBE4) were stimulated with 5 ng/ml TGF-β1 or vehicle for 4 hours, lysed, and 
luciferase activity was determined.  Data are expressed as fold change + SEM compared to vehicle treated 
MMNK-1 cells.  MMNK-1 cells transiently transfected with (D) SMAD3∆C or (E) SMAD2∆C mutants 
were treated with 5 ng/ml TGF-β1 or vehicle for 4 hours and Itgβ6 mRNA levels were determined by 
qPCR.  Data are expressed as mean + SEM relative to vehicle-treated cells transfected with an empty 
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control plasmid (pRK7) from at least three independent experiments.  *Significantly different from 0.1% 
BSA vehicle-treated group P<0.05.  
#
Significantly different from cells transfected with control plasmid 
P<0.05.   
Figure 5.2 
 
Figure 5.2: Role of p38 MAPK in TGF-β1-induced Itgβ6 mRNA expression in MMNK-1 cells. 
MMNK-1 cells were treated with 5 ng/ml TGF-β1 or vehicle for 10, 30 or 60 minutes.  (A) 
Representative western blot showing phosphorylated p38 and total p38 levels.  (B) Densitometry was 
performed on western blots from 3 independent experiments. Data is expressed as a ratio of 
phosphorylated p38 to total p38 relative to vehicle treated cells at 10 minutes.  For panels C-E, MMNK-1 
cells were pre-treated with (C) 10 µM SB203580, (D) 10 µM SB202190, (E) 10 µM SB202474 or (C-E) 
DMSO vehicle (0.1% final concentration) for 30 minutes and then treated with 5 ng/ml TGF-β1 or 
vehicle for 4 hours.  Itgβ6 mRNA levels were determined by qPCR.  *Significantly different from 0.1% 
BSA vehicle-treated cells P<0.05.  
#
Significantly different from cells pretreated with DMSO P<0.05. Data 
are expressed as mean + SEM from at least 3 independent experiments. 
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Figure 5.3 
 
Figure 5.3: Role of AP-1 in TGF-β1-dependent Itgβ6 mRNA induction in MMNK-1 cells. 
(A) MMNK-1 cells transfected with an AP-1 luciferase reporter construct (pAP-1-Luc) were treated with 
5 ng/ml TGF-β1 or vehicle for 4 hours, lysed, and luciferase activity was determined.  (B) MMNK-1 cells 
were transfected with a plasmid containing a dominant negative AP-1 (TAM67) mutant for 24 hours and 
then treated with 5 ng/ml TGF-β1 or vehicle for 4 hours.  Itgβ6 mRNA levels were determined by qPCR.   
*Significantly different from 0.1% BSA vehicle-treated cells P<0.05.  
#
Significantly different from cells 
transfected with a control plasmid (pCMV4) P<0.05. Data are expressed as mean + SEM relative to 
vehicle-treated cells from 3 independent experiments. 
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Figure 5.4 
 
Figure 5.4: Role of activating transcription factor 2 in TGF-β1-dependent Itgβ6 mRNA induction in 
MMNK-1 cells. 
(A) MMNK-1 cells were treated with 5 ng/ml TGF-β1 or vehicle (0.1% BSA in PBS) for 10 or 20 
minutes.  A representative western blot indicating levels of phosphorylated ATF-2 and total ATF-2 is 
shown.  (B)  Densitometry was performed on western blots from 3 independent experiments.  Data is 
expressed as a ratio of phosphorylated ATF-2 to total ATF-2 relative to vehicle treated cells. 
*Significantly different from 0.1% BSA vehicle treated cells P<0.05.    (C) MMNK-1 cells were treated 
with 5 ng/ml TGF-β1 or vehicle for 30 minutes and nuclear proteins were collected.  SMAD3 
immunoprecipitation was performed and levels of co-immunoprecipitated ATF-2 were determined by 
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western blot.  A representative western blot is shown.  (D) MMNK-1 cells transfected with a SMAD-
dependent reporter construct were pretreated with 10 µM SB203580 or vehicle (0.1% DMSO vehicle) for 
30 minutes prior to treatment with 5 ng/ml TGF-β1 for 4 hours, lysed, and luciferase activity was 
determined.   Data are expressed as fold change + SEM compared to DMSO treated cells.  *Significantly 
different from DMSO treated cells P<0.05.  (E-G) MMNK-1 cells were transfected with an ATF-2 siRNA 
or control siRNA for 48 hours prior to treatment with 5 ng/ml TGF-β1 or vehicle for 4 hours.  (E) ATF-2 
mRNA, (F) ATF-2 protein, and (G) Itgβ6 mRNA levels were determined.   Representative western blots 
are shown.  Data are expressed as mean + SEM relative to vehicle-treated cells from 3 independent 
experiments.  For E, *Significantly different from the same group treated with control siRNA P<0.05.  
For G, *Significantly different from the same group treated with 0.1% BSA vehicle P<0.05.   
Figure 5.5 
 
Figure 5: TGF-β1-dependent Itgβ6 mRNA induction requires protein synthesis in MMNK-1 cells. 
MMNK-1 cells were treated with 5 ng/ml TGF- β 1 or vehicle for various times.  (A) JunB mRNA and 
(B) nuclear protein levels were determined.   (C-D) MMNK-1 cells were pretreated with 10 µM 
SB203580 or vehicle (0.1% DMSO) for 30 minutes prior to treatment with 5 ng/ml TGF-β1 for (C) 30 
minutes or (D) 2 hours and (C) mRNA and (D) nuclear protein levels were determined.  (E) MMNK-1 
114 
 
cells were pretreated with 10 µg/ml cycloheximide (CHX) or vehicle (0.1% DMSO) for 30 minutes prior 
to treatment with 5 ng/ml TGF-β1 or vehicle for 4 hours and Itgβ6 mRNA levels were determined by 
qPCR.  Data are expressed as mean + SEM from 3 independent experiments.  *Significantly different 
from 0.1% BSA vehicle-treated cells P<0.05.  
#
Significantly different from cells pretreated with DMSO 
P<0.05.  
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6.1 Abstract 
Hepatic fibrin(ogen) (Fbg) deposition has been noted to occur following acetaminophen (APAP)-
induced liver injury in mice. Deficiency in plasminogen activator inhibitor-1 (PAI-1), the endogenous 
inhibitor of fibrinolysis (i.e., fibrin breakdown), has been shown to increase APAP-induced liver injury in 
mice. However, the role of Fbg and fibrinolysis in APAP-induced liver injury is not known. We tested the 
hypothesis that hepatic Fbg deposition reduces severity of APAP-induced liver injury. APAP (300 
mg/kg)-induced liver injury in mice was accompanied by thrombin generation, consumption of plasma 
Fbg, and deposition of hepatic fibrin.  Neither Fbg depletion with ancrod nor complete Fbg deficiency 
(Fbg
-/-
) affected APAP-induced liver injury. PAI-1 deficiency (PAI-1
-/-
) increased APAP-induced liver 
injury and hepatic fibrin deposition 6 hours after APAP administration, which was followed by marked 
hemorrhage at 24 hours. Mirroring PAI-1
-/-
 mice, administration of recombinant tissue plasminogen 
activator (tenecteplase, 5 mg/kg) worsened APAP-induced liver injury and hemorrhage in wild type mice. 
In contrast, APAP-induced liver injury was reduced in both plasminogen-deficient mice and in wild type 
mice treated with tranexamic acid, an inhibitor of plasminogen activation. Of interest, activation of matrix 
metalloproteinase 9 (MMP-9) paralleled injury, but MMP-9 deficiency did not affect APAP-induced liver 
injury. The results indicate that Fbg does not contribute to development of APAP-induced liver injury. 
Rather, the results suggest that plasminogen activation contributes to APAP-induced liver injury.  
6.2 Introduction 
 Acetaminophen (APAP) overdose is a leading cause of drug-induced liver failure in the United 
States (Chun et al., 2009).  APAP bioactivation by hepatocytes to the highly reactive N-acetyl-p-
benzoquinone imine (NAPQI) metabolite results in intracellular macromolecule modification and 
mitochondrial dysfunction, key initiating events of the subsequent hepatocellular necrosis (Chun et al., 
2009). The progression of APAP-induced liver injury is associated with numerous events, including 
activation of the blood coagulation cascade.  Thrombin generation is evident in patients suffering from 
acute APAP overdose and in mouse models of acute APAP-induced liver injury (Gazzard et al., 1975; 
Ganey et al., 2007). In mice given a hepatotoxic dose of APAP, tissue factor-dependent thrombin 
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generation is associated with consumption of circulating fibrinogen and deposition of insoluble fibrin 
clots in the liver (Ganey et al., 2007).  However, the role of fibrin(ogen) in APAP-induced liver injury is 
not known. 
  Fibrin deposition is determined by a balance of procoagulant (i.e., thrombin) and fibrinolytic 
pathways. Tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) convert 
plasminogen to the fibrinolytic enzyme plasmin, which degrades fibrin clots (Mackman, 2005).  The 
primary physiological inhibitor of uPA and tPA is plasminogen activator inhibitor-1 (PAI-1) (Schaller 
and Gerber, 2011). Hepatic PAI-1 mRNA expression and plasma PAI-1 protein levels increase 
dramatically after APAP administration (Reilly et al., 2001; Ganey et al., 2007; Bajt et al., 2008).  
Interestingly, a recent study reported that APAP-induced liver injury is increased in PAI-1-deficient mice, 
suggesting a protective role of PAI-1 in APAP hepatotoxicity (Bajt et al., 2008).  Bajt et al. proposed the 
intriguing hypothesis that accelerated fibrin degradation in livers of PAI-1
-/-
 mice precipitates APAP-
induced hemorrhage and increased parenchymal cell injury (Bajt et al., 2008), although the effect of PAI-
1 deficiency on hepatic fibrin deposition is not known. Moreover, the exact role of fibrin and fibrinolytic 
enzymes has not been determined in APAP-induced liver injury. 
Although exaggerated fibrinolysis and a reduction in hepatic fibrin composition is one 
mechanism whereby PAI-1 deficiency could increase APAP-induced liver injury, fibrin-independent 
mechanisms cannot be excluded.  For example, plasmin can directly activate pro-matrix 
metalloproteinase-2 (MMP-2) and pro-MMP-9. (Mazzieri et al., 1997; Legrand et al., 2001; Monea et al., 
2002; Takano et al., 2005; Gong et al., 2008). Interestingly, expression and activity of MMP-2 and MMP-
9 were shown to be increased in livers of mice treated with APAP, and an inhibitor of these gelatinases 
significantly reduced APAP-induced liver injury (Ito et al., 2005). Accordingly, one potential fibrin-
independent mechanism whereby increased plasmin could contribute to APAP-induced liver injury is by 
activation of the MMPs.  However, it is not currently known if the fibrinolytic system contributes to 
MMP activation after APAP overdose in mice.   
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 In this study, we characterized the time course of coagulation and hepatic fibrin deposition in a 
mouse model of APAP overdose, and utilized two strategies to determine the role of fibrin(ogen) in 
APAP-induced liver injury.  Moreover, using a combination of gene-targeted mice and specific 
pharmacological tools, we explored the role of plasminogen activation on MMP activity and on the 
progression of APAP hepatotoxicity by using pharmacologic and genetic approaches to modulate the 
plasminogen activators.    
6.3 Methods 
6.3.1 Mice:  All studies were carried out with male mice of 8 to 16 weeks of age. Wild-type C57Bl/6J 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME). PAI-1
-/-
 mice (B6.129S2-
Serpine1tm1Mlg/J mice), MMP-9
-/-
 mice (B6.FVB(Cg)-Mmp9tm1Tvu/J) and age-matched wild type 
C57Bl/6J mice were purchased from The Jackson Laboratory.  Fbg -deficient mice (Fbg
−/−
) and 
heterozygous control mice (Fbg
+/−
) mice back-crossed six generations onto a C57Bl/6J background 
[kindly provided by Dr. Jay Degen (Cincinnati Children's Hospital Medical Center, Cincinnati, OH)] 
were maintained in an Association for Assessment and Accreditation of Laboratory Animal Care 
International–accredited facility at the University of Kansas Medical Center.  Mice were housed at an 
ambient temperature of 22°C with alternating 14/10-hour light/dark cycles and provided water and rodent 
chow ad libitum (Teklad 8604; Harlan, Indianapolis, IN). Plg-deficient mice (Plg
-/-
) or wild type control 
mice (Plg
+/+
) backcrossed 8 generations on a C57Bl/6J background were maintained at Cincinnati 
Children’s Hospital Medical Center.  All animal procedures were approved by the University of Kansas 
Medical Center or Cincinnati Children’s Hospital Medical Center Institutional Animal Care and Use 
Committee(s). 
6.3.2 APAP model and pharmacological interventions:  Mice fasted for approximately 15 hours were 
given 300 mg/kg APAP (at 30 µl/gram body weight) or vehicle (sterile saline) via intraperitoneal (i.p.) 
injection and food was returned.  To deplete fibrinogen, mice were given 1.5 U ancrod (The National 
Institute for Biological Standards and Control, Hertfordshire, U.K.) or its vehicle (300 µl phosphate-
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buffered saline) i.p. 2 hours prior to APAP treatment.  Tenecteplase (TNK; 5 mg/kg at 10 µl/gram body 
weight), a kind gift from Genentech (San Francisco, CA) or its vehicle (sterile saline) was given 2 hours 
after APAP administration by retrorbital injection under isoflurane anesthesia.  Tranexamic acid (TA; 600 
mg/kg at 30 µl/gram body weight, Spectrum, New Brunswick, NJ) or its vehicle (sterile saline) was given 
i.p. 2 hours after APAP treatment.  Various times after APAP administration, mice were anesthetized 
using isoflurane, and blood was collected from the caudal vena cava into sodium citrate (final, 0.38%) or 
an empty syringe for the collection of plasma and serum, respectively.  The liver was removed, washed in 
saline, and the intact gall bladder removed. The left medial lobe of the liver was affixed to a cork with 
O.C.T. and frozen for 3 minutes in liquid nitrogen-chilled isopentane.  Sections of the left lateral lobe 
were fixed in neutral-buffered formalin for 48 hours before routine processing.  The remaining liver was 
cut into 100-mg pieces and frozen in liquid nitrogen. 
6.3.3 Histopathology and fibrin staining: Formalin-fixed livers were sectioned at 5 μm, stained with 
hematoxylin and eosin (H&E), and evaluated by light microscopy.  Three sections of liver from the left 
lateral lobe were evaluated from each animal.  The area of hepatocellular necrosis in several low 
magnification (40X) images encompassing the total area of the three sections was determined by J.P.L as 
described previously using Scion Image software (Luyendyk et al., 2011b) and was performed in a 
masked fashion.  To determine percent necrotic area, the area of liver occupied by necrosis was compared 
with the total area of liver in each image.  Immunofluorescent staining for insoluble hepatic fibrin(ogen) 
was performed as described previously (Luyendyk et al., 2009) using a rabbit anti-human fibrinogen 
antibody (Dako, Carpinteria, CA, A0080). The primary antibody was detected by the addition of goat 
anti-rabbit IgG conjugated to Alexa 488 (Invitrogen, Carlsbad, CA, A11008) and evaluated by fluorescent 
microscopy. 
6.3.4 Clinical chemistry: The serum activity of alanine aminotransferase (ALT) was determined using a 
commercially available reagent (Thermo Fisher, Waltham, MA).   Plasma thrombin-antithrombin (TAT) 
levels were determined using a commercial enzyme-linked immunosorbent assay kit (Siemens Health 
120 
 
care Diagnostics, Deerfield, IL). For each assay, data was acquired utilizing an Infinite M200 plate reader 
(Tecan, Durham, NC).   
6.3.5 Zymography: Gelatinase (MMP-2 and MMP-9) activity was determined using gelatin zymography.  
Approximately 100 mg frozen liver tissue was homogenized in ice cold 50 mM Tris-HCl buffer (pH 7.4) 
containing 150 mM NaCl, 5 mM CaCl2, and 1% Triton X-100. The homogenate was subjected to 
centrifugation at 9000 × g for 30 min at 4°C, supernatant was collected, and protein concentration 
determined using a commercial BCA protein assay kit (Dc, Bio-rad Laboratories, Hercules, CA).  
Supernatant containing 50 µg total protein was mixed with an equal volume of 2X Laemmli sample 
buffer lacking β-mercaptoethanol (Bio-rad) and subjected to electrophoresis in Ready Gel Zymogram 
Gels with gelatin (Bio-rad).  After electrophoresis, SDS was removed from the gels by three 20 minute 
washes with zymogram renaturation buffer (2.5% Triton X-100; Bio-rad).  The gels were then incubated 
in zymogram development buffer (50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM CaCl2; Bio-rad) at 
37°C without shaking for 48 hours. Gels were stained with Coomassie stain (Invitrogen) and MMPs were 
identified by their ability to digest gelatin (clear bands) and by their apparent molecular weights.  Gel 
images were captured by a VersaDoc imaging system (Bio-rad) and converted to grayscale.  
Densitometry was performed using Quantity One Software (Bio-rad).  
6.3.6 Statistics: Comparison of two groups was performed using Student's t-test. Comparison of 3 or 
more groups was performed using one- or two-way analysis of variance, as appropriate, and the Student-
Newman-Keuls post hoc test.  Data not conforming to a normal distribution were Log10 transformed prior 
to statistical evaluation. Statistical outliers identified by Grubb’s Test outliers (p<0.05) were excluded 
from further statistical analysis. The criterion for statistical significance was p<0.05. 
6.4 Results 
6.4.1 Time course of coagulation cascade activation and hepatotoxicity in APAP-treated mice.  
Administration of APAP (300 mg/kg) caused liver injury evident by increased serum ALT activity, with 
peak activity evident after 24 hours (Fig. 6.1A). Increased serum ALT activity was accompanied by 
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centrilobular hepatocellular necrosis (not shown). Plasma TAT levels, an indicator of thrombin 
generation, increased dramatically after APAP administration, indicating marked and rapid activation of 
the coagulation cascade (Fig. 6.1B).  In agreement with a previous study (Ganey et al., 2007), increased 
TAT levels were accompanied by a decrease in plasma fibrinogen levels (Fig. 6.1C) and an increase in 
hepatic fibrin deposition within areas of hepatocellular necrosis as early as 2 hours (Fig. 6.1D-H). Taken 
together, the results indicate that APAP hepatotoxicity in mice is associated with coagulation cascade 
activation, fibrinogen consumption, and hepatic fibrin deposition.  
6.4.2 Fibrin(ogen) does not contribute to acute APAP-induced liver injury.  To determine the role of 
fibrin(ogen) in APAP-induced liver injury, we utilized two independent approaches. First, circulating 
fibrinogen was depleted prior to APAP treatment by administering ancrod, a component of snake venom 
that enzymatically cleaves circulating fibrinogen (Ewart et al., 1969).  Compared to vehicle (PBS)-
pretreated mice, pretreatment of mice with ancrod reduced hepatic fibrin deposition after APAP 
administration at 24 hours (Fig. 6.2B-C). However, ancrod pretreatment had no effect on serum ALT 
activity at this time in APAP-treated mice (Fig. 6.2A).  Next, we utilized mice lacking the Fbgα gene 
(Fbg
-/- 
mice), which completely lack circulating fibrinogen (Suh et al., 1995). As expected, hepatic fibrin 
deposition was not detected in Fbg
-/- 
mice after APAP administration (Fig. 6.2E-F), confirming the 
absence of fibrinogen protein and the specificity of the immunofluorescent staining. In agreement with 
our fibrinogen depletion studies, complete fibrinogen deficiency did not affect APAP-induced liver 
injury, as indicated by serum ALT activity (Fig. 6.2D).  Overall, these studies suggest that fibrin(ogen) is 
not a critical mediator of APAP-induced liver injury in mice. 
6.4.3 PAI-1 deficiency enhances liver injury, hemorrhage and fibrin deposition in APAP-treated 
mice.  A previous study found that APAP-induced liver injury was increased in PAI-1-deficient (PAI-1
-/-
) 
mice (Bajt et al., 2008). In agreement, we found that APAP-induced liver injury, as indicated by increased 
serum ALT activity and centrilobular necrosis, was significantly increased at 6 hours after APAP 
administration in PAI-1
-/-
 mice (Fig. 6.3A and not shown).  In association with increased necrosis, hepatic 
fibrin deposition was increased in PAI-1
-/-
 mice at this time (Fig. 6.3B-C). Serum ALT activity also 
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trended higher in APAP-treated PAI-1
-/-
 mice relative to wild type control mice at 24 hours (Fig. 6.3D).  
In agreement with previous studies, marked hemorrhage was evident in livers of PAI-1
-/-
 mice by 24 
hours (see Supplemental Fig. 6.1).  Interestingly, fibrin was evident in areas of necrosis in both wild-type 
and PAI-1
-/-
 mice at 24 hours (Fig. 6.3E-F).  The results indicate that increased liver injury in APAP-
treated PAI-1
-/- 
mice is not a consequence of reduced hepatic fibrin deposition.  
6.4.4 Recombinant human tPA (tenecteplase) administration enhances APAP-induced liver injury 
in mice.  Enhanced APAP-induced liver injury in PAI-1
-/-
 mice suggests that increased plasminogen 
activator activity could worsen APAP-induced liver injury.  To test this hypothesis, we utilized 
tenecteplase (TNK), a recombinant human tPA (Verstraete, 2000).  Administration of TNK (5 mg/kg) 
alone to wild type mice had no effect on serum ALT levels (Fig. 6.4A) or liver histopathology (not 
shown). To minimize potential effects of TNK on metabolism of APAP, we administered TNK 2 hours 
after APAP injection.  TNK administration did not affect serum ALT activity 6 hours after APAP 
administration (Fig. 6.4A). However, increased hemorrhage was evident in areas of necrosis at 6 hours in 
APAP-treated mice given TNK (Fig. 6.4B-C).  Serum ALT activity was significantly increased at 24 
hours in mice treated with APAP and TNK compared to mice treated with APAP alone (Fig. 6.4A).  The 
increase in serum ALT activity at 24 hours in TNK-treated mice was accompanied by a dramatic increase 
in hemorrhage (Fig. 6.4D-E), which closely resembled livers of PAI-1-deficient mice treated with APAP 
for 24 hours (Supplemental Fig. 6.1 and (Bajt et al., 2008)). The data suggest that exaggerated activation 
of the plasminogen activators increases APAP-induced liver injury and hemorrhage.  
6.4.5 Pharmacologic inhibition of plasminogen activation and genetic plasminogen deficiency 
reduces APAP-induced liver injury.  One mechanism whereby the PAs could contribute to APAP-
induced liver injury is through conversion of plasminogen to plasmin (Legrand et al., 2001; Gong et al., 
2008). To identify whether plasmin participates in APAP-induced liver injury, we utilized tranexamic 
acid (TA), which binds plasminogen and inhibits its activation by the PAs (Iwamoto, 1975).  
Administration of TA alone did not alter serum ALT levels or liver histopathology (Fig. 6.5A-B). To 
minimize potential effects of TA on metabolism of APAP, TA was administered 2 hours after APAP 
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injection. Compared with vehicle (saline)-treated mice, TA administration reduced serum ALT activity at 
6 and 24 hours after APAP administration (Fig. 6.5A), although this difference did not achieve statistical 
significance at 6 hours (p=0.058).  Of importance, TA treatment significantly reduced the area of 
centrilobular necrosis in APAP-treated mice at 24 hours (Fig. 6.5B-D).  Similar to pharmacologic 
inhibition of plasminogen activation by TA, complete plasminogen deficiency significantly reduced 
APAP-dependent liver injury at 24 hours, as indicated by a reduction in serum ALT activity (Fig. 6.5E) 
and area of centrilobular necrosis (Fig. 6.5F-H).  The results suggest that plasminogen contributes to 
APAP-induced liver injury.   
6.4.6 Role of the plasminogen activators in MMP-9 activation in APAP-treated mice. One 
mechanism whereby plasmin could contribute to APAP-induced liver injury is by activating pro-MMP-2 
and pro-MMP-9, enzymes implicated previously in the progression of APAP-induced liver injury 
(Legrand et al., 2001; Ito et al., 2005; Gong et al., 2008).  Accordingly, we determined the time course of 
gelatinase (MMP-2/9) activation in APAP-treated mice and the effect of genetic and pharmacologic 
modulation of the PAs on MMP-2/9 activity. As indicated by gelatin zymography, MMP-9 activity was 
increased in livers of APAP-treated mice as early as 6 hours and remained elevated at 48 hours (Fig. 
6.6A-B). However, we found no detectable increase in MMP-2 activity in mice treated with APAP (not 
shown). Of interest, MMP-9 activity in livers of APAP-treated mice at 6 hours was increased by PAI-1 
deficiency (Fig. 6.6C-D) and by TNK treatment (Fig. 6.6E-F), suggesting that enhanced activation of the 
PAs increases MMP-9 activation in APAP-treated mice. TA administration significantly reduced hepatic 
MMP-9 activity in APAP-treated mice at 6 hours (Fig. 6.6G-H).  The data indicate that MMP-9 is 
activated after APAP-induced liver injury.   
6.4.7 MMP-9 deficiency does not protect against APAP-induced liver injury.  A previous study 
showed that APAP-induced liver injury was reduced in mice given a MMP-2/9 inhibitor (2-[(4-
biphenylsulfonyl)amino]-3-phenyl-propionic acid) (Ito et al., 2005). Insofar as we identified an increase 
in MMP-9 activity in livers of APAP-treated mice, we further evaluated whether MMP-9 could contribute 
to APAP-induced liver injury. Hepatic MMP-9 activity was not detectable by gelatin zymography in 
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MMP-9
-/-
 mice, confirming specificity of this assay (Fig. 6.7A).   Of interest, APAP-induced liver injury 
was similar in MMP-9
-/- 
mice compared to wild type control mice, as indicated by serum ALT activity 
(Fig. 6.7B). The results indicate that MMP-9 does not contribute to APAP-induced liver injury.   
6.5 Discussion 
The role of PAI-1 in liver injury is model dependent. For example, whereas PAI-1 deficiency 
reduces liver injury after bile duct ligation (Wang et al., 2007b), PAI-1
-/-
 mice are more susceptible to 
carbon tetrachloride-induced liver injury (von Montfort et al., 2010). The expression of PAI-1 mRNA is 
increased rapidly in liver after APAP overdose in mice (Reilly et al., 2001; Bajt et al., 2008) and PAI-1 
protein levels increase markedly in the plasma (Ganey et al., 2007). In support of work by Bajt et al. (Bajt 
et al., 2008), we found that APAP-induced liver injury was increased in PAI-1
-/- 
mice, suggesting that 
PAI-1 is a protective factor in APAP hepatotoxicity. Of importance, generation of the toxic metabolite 
NAPQI was unaffected by PAI-1 deficiency (Bajt et al., 2008), indicating this genotype does not affect 
APAP metabolism. It was suggested previously that the presence of marked hemorrhage in livers of 
APAP-treated PAI-1
-/-
 mice could occur as a consequence of reduced hepatic fibrin deposition and a 
failure to maintain normal hemostasis. Of importance, we found that hepatic fibrin levels actually 
increased in association with increased hepatocellular injury in PAI-1
-/-
 mice at 6 hours, and fibrin 
remained present in livers of APAP-treated PAI-1
-/-
 mice at 24 hours. This suggests that increased APAP 
hepatotoxicity in PAI-1
-/-
 mice is not a consequence of reduced fibrin levels in liver.  
 Hepatic fibrin deposition occurs in numerous models of xenobiotic-induced liver injury (Fujiwara 
et al., 1988; Bailie et al., 1993; Neubauer et al., 1995; Copple et al., 2002a; Ganey et al., 2007; Luyendyk 
et al., 2009), but the mechanistic contribution of fibrin(ogen) has not been determined in most models. In 
this study, we used two independent approaches to evaluate the role of fibrin(ogen) in APAP 
hepatotoxicity: 1) depletion of fibrinogen with ancrod and 2)  Fbg
-/-
 mice, which completely lack 
circulating fibrinogen protein (Suh et al., 1995).  We found that neither fibrinogen depletion nor complete 
fibrinogen deficiency affected APAP-induced liver injury at 24 hours, suggesting that fibrin(ogen) does 
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not contribute to acute APAP hepatotoxicity. This is in contrast to other models where fibrin(ogen) has 
been shown to be either damaging or hepatoprotective (Luyendyk et al., 2011a; Luyendyk et al., 2011b). 
Of importance, the finding that fibrinogen is not required for acute APAP hepatotoxicity supports the 
hypothesis that a change in hepatic fibrin clearance is not the primary mechanism of increased APAP 
hepatotoxicity in PAI-1-deficient mice. 
 To further delineate the effect of enhanced plasminogen activation on APAP-induced liver injury, 
we utilized a recombinant human tPA (i.e., TNK). We selected to administer TNK two hours after APAP 
treatment to avoid the possibility of interfering with APAP metabolism, NAPQI generation, and 
glutathione depletion, the vast majority of which occurs within 60 minutes of APAP administration 
(Knight et al., 2001; Jaeschke et al., 2011).  Mirroring changes in livers of APAP-treated PAI-1
-/-
 mice, 
hepatocellular injury and hemorrhage were increased by TNK administration, consistent with the 
hypothesis that APAP-induced liver injury is increased by exaggeration of PA activity.  However, it 
cannot be concluded from these studies that endogenous tPA is the critical PA participating in APAP-
induced liver injury. Both uPA and tPA can convert plasminogen to plasmin, but each PA generally 
serves different biological functions.  tPA is an important regulator of fibrin degradation and vascular 
hemostasis, whereas uPA generally participates in tissue repair and extracellular matrix remodeling 
(Schaller and Gerber, 2011). Interestingly, tPA directly binds fibrin polymers and this enhances its 
enzymatic activity by several hundred-fold (Schaller and Gerber, 2011). Insofar as fibrin deficiency did 
not affect APAP-induced liver injury, this could suggest that uPA rather than tPA is the critical 
endogenous PA during APAP-induced liver injury.  However, additional studies are required to determine 
the relative contribution of uPA and tPA in APAP-induced liver injury. 
Studies in PAI-1-deficient mice indicate that PAI-1 limits APAP-induced liver injury, and our 
studies with TNK administration support the hypothesis that exaggerated plasminogen activation worsens 
APAP-induced liver injury. To determine whether administration of an inhibitor of plasminogen 
activation could confer additional protection against APAP-induced liver injury under conditions where 
PAI-1 was present, we utilized tranexamic acid, an antifibrinolytic drug that prevents the conversion of 
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plasminogen to plasmin (Iwamoto, 1975). Like our studies with TNK, tranexamic acid was given 2 hours 
after APAP to avoid any potential effect on APAP metabolism. Our results suggest that the activation of 
plasmin, even in wild type mice with sufficient levels of PAI-1, contributes to the progression of liver 
injury in APAP-treated mice. Of importance, we found that complete genetic plasminogen deficiency also 
reduced APAP-induced liver injury.  However, these results do not identify the PA (tPA and/or uPA) that 
is responsible for activating plasminogen during APAP-induced liver injury.  Additionally, these studies 
do not test the possibility that either tPA and/or uPA also contribute to the progression of APAP-induced 
liver injury in a plasminogen-independent manner.  These studies are the subject of ongoing investigation 
in our laboratory. 
Our studies indicate that fibrin(ogen) is not involved in the development of APAP-induced liver 
injury. However, the results suggest that plasmin, the primary endogenous fibrinolytic enzyme, 
contributes to APAP-induced liver injury.  One fibrin-independent mechanism whereby plasmin might 
contribute to APAP toxicity is through activation of pro-MMP-2/9. Plasmin has been shown previously to 
contribute to activation of both pro-MMP-2 and pro-MMP-9 to their active forms (Mazzieri et al., 1997; 
Legrand et al., 2001; Monea et al., 2002; Takano et al., 2005; Gong et al., 2008).  A previous study 
showed that hepatic MMP-2 and MMP-9 expression and activity are increased in livers of mice after 
APAP overdose (Ito et al., 2005).  In agreement with that study, we found that MMP-9 activity increased 
in liver as early as 6 hours after APAP administration. In contrast, we were not able to detect an increase 
in MMP-2 activity after APAP administration (not shown).  To this end, we focused on the possibility 
that plasmin-dependent MMP-9 activation could contribute to APAP hepatotoxicity. In contrast to a 
previous study demonstrating that a pharmacologic inhibitor of MMP-2/9 reduced APAP hepatotoxicity
 
10
, MMP-9 deficiency did not affect APAP induced liver injury. Notable differences between our study 
utilizing MMP-9-deficient mice and a previous study utilizing a pharmacologic inhibitor of MMP-9 
include the use of DMSO as the solvent for the MMP inhibitor, a compound which is known to affect 
APAP metabolism and glutathione depletion (Jaeschke et al., 2011). The fast prior to APAP 
administration was also extensive (24 hours), and the dose/route of APAP administration differed 
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between the two studies. Our studies with MMP-9
-/-
 mice strongly suggest that the protection observed 
previously cannot be attributed to inhibition of MMP-9. 
 In the clinic, patients that present with APAP overdose arrive with varying degrees of liver injury 
and at various stages of injury progression.  Our data suggest that a PA-plasmin pathway participates in 
the early progression of APAP-induced liver injury in a mouse model.  Inhibition of this pathway could 
provide a therapeutic benefit to patients during the early progression phase of APAP-toxicity. However, 
the fibrinolytic system and MMPs have also been shown to participate in tissue regeneration and wound 
healing processes.  Deficiency in plasminogen has been shown to derange the wound healing process, 
including chronic liver injury (Pohl et al., 2001).  A previous study showed that impaired liver 
regeneration in plasminogen-deficient mice was not affected by a combined deficiency of fibrinogen, 
suggesting that plasminogen contributes to liver repair in a fibrinolysis-independent mechanism in that 
model (Bezerra et al., 1999). Although we found that fibrinogen deficiency does not affect acute APAP 
hepatotoxicity development, we cannot exclude a role for fibrinogen in the resolution of APAP-induced 
liver injury.  Similarly, this raises questions about the potential for differential roles of PAs and MMPs 
during the development and recovery phases of APAP-induced liver injury.  Accelerated injury resolution 
has been described in PAI-1
-/-
 mice in a dermal injury model (Chan et al., 2001). Of importance, uPA is 
known to activate hepatocyte growth factor, a critical cytokine that promotes liver regeneration (Shimizu 
et al., 2001).  Interestingly, a previous study showed that increased liver injury 24 hours after APAP 
administration in PAI-1
-/-
 mice was accompanied by a decrease in hepatic PCNA protein expression, 
suggesting that these mice have delayed liver regeneration (Bajt et al., 2008).  However, in that same 
study PAI-1
-/- 
mice with dramatically increased liver injury recovered alongside wild type mice by 48 
hours, suggesting those mice had enhanced liver regeneration in the recovery phase of APAP (Bajt et al., 
2008). Further experiments are needed to determine the role(s) of fibrin(ogen) and fibrinolytic enzymes in 
the resolution and repair of APAP-induced liver injury.  
In summary, we have shown through genetic and pharmacologic interventions that fibrinogen and 
fibrin are not involved in the development of APAP hepatotoxicity in mice.  Furthermore, we found that 
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both genetic (PAI-1
-/-
) and pharmacologic (TNK) interventions that increase PA activity also increase 
APAP-induced liver injury and hemorrhage.  Of importance, inhibition of plasminogen activation with 
tranexamic acid and complete plasminogen deficiency reduced liver injury in APAP-treated mice. Taken 
together, our studies indicate that the plasminogen activators and plasmin contribute to APAP-induced 
liver injury development in a fibrin(ogen)-independent manner.  Inhibition of the PA-Plasmin pathway 
may serve as a potential therapeutic target to limit acute liver injury development in patients presenting 
with APAP-overdose.  
6.6 Figures  
Figure 6.1 
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Figure 6.1: Time course of coagulation cascade activation and hepatotoxicity in APAP-treated mice. 
Fasted wild type mice were given a toxic dose of APAP (300 mg/kg, i.p.) or vehicle (sterile saline, time 
0) and samples were collected 2, 6, 24, and 48 hours later.  Levels of (A) serum ALT activity, (B) plasma 
thrombin anti-thrombin (TAT), and (C) plasma fibrinogen levels were determined.  Data are expressed as 
mean + SEM.  *Significantly different from saline-treated control mice (p<0.05).   (D-H) Representative 
photomicrographs of hepatic fibrin (dark) staining at (D) 0, (E) 2, (F) 6, (G) 24, and (H) 48 hours after 
APAP treatment.  n=5 mice per group.   
Figure 6.2 
 
Figure 6.2: Fibrin(ogen) does not contribute to acute APAP-induced liver injury.   
(A-C) Fasted wild type mice were treated with 1.5 U ancrod or vehicle (300 µl sterile PBS) two hours 
prior to treatment with APAP (300mg/kg) and then samples were collected 24 hours later.  (D-F) Fasted 
Fbg
+/-
 control mice and Fbg
-/- 
were treated with APAP (300 mg/kg) for 24 hours.  (A, D) Serum ALT 
activity was determined.  Data is expressed as mean + SEM.  (B-C, E-F) Representative 
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photomicrographs of fibrin (dark) staining after APAP treatment in livers of wild type mice treated with 
(B) PBS or (C) ancrod and in (E) Fbg
+/- 
or (F) Fbg
-/-
 mice.  n=7-12 mice per group. 
Figure 6.3 
 
Figure 6.3: PAI-1-deficiency enhances liver injury and fibrin deposition in APAP-treated mice.   
Fasted wild type or PAI-1
-/-
 mice were treated with APAP (300 mg/kg) and samples were collected (A-C) 
6 or (D-F) 24 hours later.  (A, D) Levels of serum ALT activity were determined.  Data is expressed as 
mean + SEM.  *Significantly different from wild type mice (p<0.05).  (B-C, E-F) Representative 
photomicrographs of fibrin (dark) stained livers from APAP-treated (B, E) wild type and (C, F) PAI-1
-/-
 
mice.   n=3-4 mice per group.   
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Figure 6.4 
 
Figure 6.4: Recombinant human tPA (tenecteplase) administration enhances APAP-induced liver 
injury in mice.   
Fasted wild type mice were treated with APAP (300 mg/kg) or vehicle (sterile saline) and 2 hours later 
mice were given tenecteplase (5 mg/kg, TNK, r.o.).  (A) Serum levels of ALT activity were determined 
after 6 and 24 hours of APAP treatment.  Data is expressed as mean + SEM.  *Significantly different 
from APAP-treated mice given saline vehicle at that time (p<0.05).  (B-E) Representative 
photomicrographs of hematoxylin and eosin stained liver sections from mice given (B, D) vehicle or (C, 
E) TNK and treated with APAP for (B-C) 6 or (D-E) 24 hours.  n=3-8 mice per group.   
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Figure 6.5 
 
Figure 6.5: Inhibition of plasminogen activation and complete plasminogen deficiency reduces 
APAP-induced liver injury.   
(A-D) Fasted wild type mice were treated with APAP (300 mg/kg) or vehicle (sterile saline).  Two hours 
later mice were treated with tranexamic acid (600 mg/kg, TA, i.p.) or vehicle (sterile saline).  (A) Serum 
ALT activity was determined 6 and 24 hours after APAP treatment and (B) area of necrosis (see methods) 
was determined 24 hours after APAP treatment.  Data are expressed as mean + SEM. *Significantly 
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different from APAP treated mice given saline vehicle at that time (p<0.05).  (C-D) Representative 
photomicrographs of hematoxylin and eosin stained liver sections from mice treated with APAP for 24 
hours and treated with (C) vehicle (saline) or (D) TA.  (E-H) Fasted wild type (Plg
+/+
) or plasminogen 
deficient (Plg
-/-
) mice were treated with APAP (300 mg/kg) or vehicle (sterile saline) and samples were 
collected 24 hours later.  (E) Serum ALT activity and (F) area of necrosis (see methods) were determined.  
Data are expressed as mean +SEM. *Significantly different from APAP treated Plg
+/+ 
mice (p<0.05).  (G-
H) Representative photomicrographs of hematoxylin and eosin stained liver sections from APAP-treated 
(G) Plg
+/+
 or (H) Plg
-/-
 mice 24 hours after APAP treatment.  n=3-10 mice per group. 
Figure 6.6 
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Figure 6.6: Role of the plasminogen activators in MMP-9 activation in APAP-treated mice. 
(A, C, E, G) Represenative zymogram images (~95 kDa) and (B, D, F, H) respective zymogram 
quantification from liver homogenates of APAP-treated mice.  (A-B) Gelatinase activity was determined 
from homogenates of APAP-treated wild type mice various times after APAP treatment.  (C-H) 
Gelatinase activity was determined at 6 hours in liver homogenates from (C-D) PAI-1
+/+
 and PAI-1
-/-
 
mice, (E-F) wild type mice treated with TNK or vehicle, and (G-H) wild type mice treated with TA or 
vehicle.  Data is expressed as mean + SEM.  *Significantly different from respective control mice 
(p<0.05).  n=3-5 mice per group.  
Figure 6.7 
 
Figure 6.7:  MMP-9 deficiency does not protect against APAP-induced liver injury.   
Fasted wild type (MMP-9
+/+
) and MMP-9-deficient (MMP-9
-/-
) mice were treated with APAP (300 
mg/kg) and samples were collected 24 hours later.  (A) Representative gelatin zymogram (~95 kDa) from 
liver homogenates of APAP-treated MMP-9
+/+
 or MMP-9
-/-
 mice 24 hours after APAP treatment.  (B) 
Serum ALT activity was determined 24 hours after APAP treatment. n=5-9 mice per group. 
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6.7 Supplemental Figures 
 
Supplemental Figure 6.1: PAI-1 deficiency enhances hepatic hemorrhage in APAP-treated mice.   
Fasted wild type or PAI-1
-/-
 mice were treated with APAP (300 mg/kg) and samples were collected 24 
hours later.  Representative photomicrographs of hematoxylin and eosin stained liver sections from (A) 
wild type and (B) PAI-1
-/- 
mice.   
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Chapter 7 
Conclusions and Discussion 
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Summary 
In this dissertation several components of the blood coagulation cascade were evaluated in two 
different models of hepatotoxicity initiated in separate zones of the liver lobule.  Insofar as fibrin is a 
classical downstream end product of coagulation cascade activation and is known to be present in liver 
injury induced by several models of acute liver injury, we explored the role of fibrionogen and fibrin in 
APAP- and ANIT-induced liver injuries.  Furthermore, as thrombin is generated in ANIT-induced 
hepatotoxicity, we evaluated the role of the thrombin receptors PAR-1 and PAR-4 in the acute ANIT-
induced liver injury model.  Additionally, as fibrosis develops in response to chronic injury, we evaluated 
mechanisms of liver fibrosis induced by TF and PAR-1 in the chronic model of BDEC injury elicited by 
ANIT.  Insofar as PAI-1 is protective in APAP-induced liver injury in mice we evaluated the role of 
several components of the fibrinolytic pathway in the development of liver injury.   
Coagulation in ANIT-induced liver injury. 
In the first set of studies we evaluated the role of platelets in acute ANIT-induced hepatotoxicity 
as platelets were shown to be protective in early BDL (12 hours) and ANIT-induced hepatotoxicity (24 
hours) (Bailie et al., 1994; Laschke et al., 2008).  This led us to test the hypothesis that inhibition of 
platelets could protect mice against acute ANIT-induced hepatotoxicity.  In contrast to these previously 
published results, mice depleted of platelets had increased liver injury as assessed by serum ALT levels 
24 hours after ANIT treatment and this was associated with marked pooling of blood in areas of necrosis 
(see Ch.2).  Furthermore, limiting platelet activation at the thrombin receptor on platelets both by PAR-4-
deficiency and by pretreating mice with a pharmacological inhibitor of PAR-4 increased liver injury and 
was associated with hepatic pooling of blood 24 hours after ANIT administration (see Ch. 3).  These 
results strongly suggest that platelets provide essential hemostatic function and protection in mice against 
early ANIT-induced liver injury.  This unique lesion was not reported in rats depleted of platelets and 
given ANIT, nor did rats have increased injury at the 24 hour time point (Bailie et al., 1994).  As this 
pooling of blood is a rather rare pathological lesion, it would be interesting to identify the mechanisms 
between these two species during ANIT-induced liver injury and whether this lesion can occur in human 
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patients with cholestasis having certain genetic predispositions.  Next, we further evaluated the role of 
platelets at a later time point in ANIT-induced liver injury.  Surprisingly, in direct contrast to the early 24 
hour time point, mice depleted of platelets actually had reduced liver injury 48 hours after ANIT 
administration compared to control injected animals, although pooling of blood was still evident at this 
time (see Ch. 2).  Similarly, liver injury in PAR-4-deficient mice did not further progress after 24 hours, 
while liver injury in wild type mice continued to develop and surpassed their PAR-4-deficient 
counterparts by 48 hours after ANIT treatment (see Ch. 3).  Additionally, mice treated with ANIT and 
then given a PAR-4 inhibitor 8 and 24 hours later had reduced liver injury at 48 hours, which was not 
associated with pooling of blood in the areas of necrosis (see Ch. 3).  Finally, we found that mice given 
clopidogrel, an inhibitor of platelet activation, had reduced liver injury 48 hours after ANIT 
administration (see Ch. 2).   
Taken together this series of experiments clearly identifies platelets having a biphasic role in 
cholestatic induced liver injury in mice.  Further evidence supporting a biphasic role for platelets in 
cholestatic liver injury is the fact that platelet depletion is protective against early liver injury after BDL, 
but fibrosis is enhanced by this same treatment in response to chronic injury (Laschke et al., 2008; 
Kodama et al., 2010).  Interestingly, protection afforded by platelet depletion in BDL (Laschke et al., 
2008) and clopidogrel treatment in ANIT (see Ch. 2) was associated with a reduction in hepatic 
meloperoxidase levels, a marker of neutrophil activation.  Of importance, as neutrophils promote 
chloestatic-induced liver injury, this suggests a mechanism whereby platelets may promote the 
progression of liver injury at later time points in cholestatic induced liver injury.  If fibrosis is excessive 
in certain patient populations, stimulating platelet production or other types of platelet replacement 
therapy could protect these patients from liver fibrosis and maybe cirrhosis, although, the potential 
antifibrotic properties afforded by this type of therapy could be negated by increased liver injury as 
platelets seem to play a protective role in the acute phase of cholestatic liver injury.   
It is interesting to note that TF-deficiency protected mice against ANIT-induced hepatotoxicity at 
both 24 and 48 hours, and was not associated with pooling of blood in the liver (Luyendyk et al., 2009).  
139 
 
Of importance, fibrinogen deficiency did not cause severe hepatic hemorrhage after ANIT-induced 
toxicity further suggesting a fibrin-independent mechanism for platelets preventing peliosis during ANIT-
induced hepatotoxicity (see Ch. 3).  As TF-deficiency did not precipitate the pooling of blood within the 
liver lesion of necrosis, this suggests that platelet activation at these times is not TF-dependent in this 
model.  Of importance, several other activators of PAR-4 have been found including the fibrinolytic 
enzyme plasmin and cathepsin G, a protease found in neutrophils (Sambrano et al., 2000; Quinton et al., 
2004).  As, PAI-1-deficient mice have increase uPA and tPA activity and were protected from excess 
hepatic ECM deposition, this could suggest that increased plasmin activity generated by increased uPA 
and tPA activity could protect these mice from fibrosis through PAR-4 activation on platelets (Bergheim 
et al., 2006).  Further experiments are needed to identify how platelets are activated during cholestasis 
and how they contribute to cholestatic-induced liver injury.   
Another mechanism whereby TF could promote ANIT-induced liver injury is through the 
deposition of hepatic fibrin.  In this dissertation we found that fibrinogen deficiency decreased acute liver 
injury as assessed by area of necrosis after ANIT treatment (see Ch. 3).  This could suggest that the 
protection afforded by TF-deficiency in acute ANIT-induced liver injury was by limiting fibrin deposition 
within the injured liver.  This is in complete contrast to what has been reported in the chronic model of 
ANIT-induced hepatotoxicity, where fibrinogen deficiency worsens liver injury and fibrosis (Luyendyk et 
al., 2011a).  Interestingly, fibrinogen deficiency did not affect serum bile acid levels in the acute model 
(see Ch. 3), whereas bile acid levels were elevated in the chronic model suggesting that fibrinogen or 
fibrin might play a role in preventing cholestasis during chronic BDEC injury (Luyendyk et al., 2011a).  
Insofar as patients with end stage liver disease initiated by chronic cholestasis typically have a reduced 
capacity to produce fibrinogen, are generally considered to be at risk of bleeding, and also have enhanced 
fibrinolytic capacity (Mammen, 1992; Kerr, 2003; Bernal et al., 2010), this could suggest that 
recombinant fibrinogen or plasma replacement therapy could provide a beneficial response to patients 
with end stage liver disease to prevent cholestasis, fibrosis, and hemorrhage.   
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Another way that TF could contribute to ANIT-induced liver injury is through PAR-1 activation.  
Although PAR-1 contributes to liver injury in several models of liver injury (Rondeau et al., 2001; 
Fiorucci et al., 2004; Martinelli et al., 2008; Rullier et al., 2008; Luyendyk et al., 2010), PAR-1 
deficiency did not affect the acute hepatotoxicity of ANIT (see Ch. 3).  Insofar as previous studies have 
shown that PAR-1 contributes to the development of liver fibrosis in carbon tetrachloride-induced 
hepatotoxicity (Rullier et al., 2008), we tested the hypothesis that PAR-1 could promote biliary fibrosis in 
chronic ANIT-induced BDEC injury.  Several studies have identified a role for PAR-1 on the activation 
of stellate cells, a major profibrotic cell type that contributes to liver fibrosis (Gaca et al., 2002; Fiorucci 
et al., 2004; Friedman, 2008).  Additionally, PAR-1 activation has been suggested to contribute to fibrosis 
by regulating the V 6 integrin, a cellular receptor known to promote fibrosis by activating latent TGF-β, 
a potent profibrotic cytokine (Munger et al., 1999; Jenkins et al., 2006).  In both biliary atresia and BDL 
models of cholestatic induced liver injury, induction of V 6 protein on BDECs is thought to contribute 
to the pathogenesis of liver injury by increasing the levels of local TGF-  signaling and promoting biliary 
fibrosis through ECM synthesis (Wang et al., 2007a; Nadler et al., 2009).  In the studies of Chapter 4 we 
found that both TF- and PAR-1-deficiency reduced chronic ANIT-induced fibrosis.  This led us to test the 
hypothesis that TF-dependent coagulation and subsequent PAR-1 activation contributed to liver BDEC 
injury and fibrosis by regulating the expression of the V 6 integrin.  In these studies we found that 
hepatic induction of Itgb6 mRNA was dependent on both TF and PAR-1, which was essential for the 
expression of V 6 integrin on BDECs and the development of ANIT-induced biliary fibrosis.  Further 
evaluation of the role of PAR-1 on BDECs in vitro, showed that PAR-1 stimulation alone could not alter 
Itgb6 mRNA expression in human transformed BDECs or primary rat BDECs.  However, co-stimulation 
of BDECs with agonists of PAR-1 and TGF-β1, a known molecule that promotes Itgb6 expression, 
dramatically enhanced the expression of this gene.  This suggests that while PAR-1 signaling does not 
regulate liver injury in acute BDEC injury, TF-dependent thrombin signaling can alter local profibrogenic 
signals, which contributes to disease progression.  In line with this hypothesis, we found that PAR-1-
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dependent signaling on BDECs also contributed to MCP-1 expression, an important proinflammatory 
cytokine that contributes to liver fibrosis in cholestatic liver injury (see Ch.4) (Harada et al., 2011; Baeck 
et al., 2012).  Of importance, these studies are the first to identify that PAR-1 signaling on BDECs can 
contribute to the pathogenesis of liver disease by promoting fibrosis through induction of V 6 integrin 
expression.  Furthermore, these studies identify that TF-dependent PAR-1 signaling can directly modify 
the local profibrotic response during chronic BDEC injury.  Identifying ways to selectively inhibit PAR-1 
and V 6 integrin on BDECs could help slow the development of liver fibrosis and prevent cirrhosis in 
patients with chronic cholestasis. 
Coagulation in APAP-induced hepatotoxicity 
 Altered hemostasis is seen in patients presenting with APAP overdose and several of these 
coagulation factor changes are also represented in a mouse model of APAP-induced hepatotoxicity.  Of 
importance, TF-dependent coagulation promotes liver injury in the mouse model of APAP hepatotoxicity, 
potentially through PAR-1 activation as both TF and PAR-1-deficient mice were protected against APAP-
induced hepatotoxicity (Ganey et al., 2007).  Hepatic fibrin deposition is also known to occur during 
APAP-induced hepatotoxicity (Ganey et al., 2007), while deficiency in PAI-1, the main inhibitor of 
fibrinolysis, makes liver injury and sinusoidal hemorrhage more severe, suggesting a protective effect for 
hepatic fibrin in this model (Bajt et al., 2008).  This led us to test the hypothesis in Chapter 6 that hepatic 
fibrin deposition protects against APAP-induced liver injury.  Using both genetic and pharmacologic 
strategies, we found that both fibrinogen and fibrin did not contribute to APAP-induced liver injury out to 
24 hours, a time associated with peak injury in our model.  However, we found that enhancing 
plasminogen activator activity by giving recombinant tPA (tenecteplase) recapitulated the liver injury and 
hemorrhage seen in PAI-1-deficient mice leading us to investigate fibrin-independent roles of plasmin in 
this model.  In agreement with these studies, both complete genetic deficiency and pharmacologic 
inhibition of plasmin in wild type mice by tranexamic acid reduced APAP-induced liver injury. 
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Tranexamic acid is an inexpensive drug already on the market in the United States for several 
indications and could easily be repurposed to help limit liver injury in patients suffering from APAP-
induced hepatotoxicity.  Of importance, the time course of tranexamic acid administration in our mouse 
model is in a similar time frame of when a human patient might come into the clinic.  Most admissions to 
the emergency room are after the onset of liver injury, but prior to the peak of liver injury.  In this proof 
of principle study we gave mice tranexamic acid 2 hours after APAP by i.p. injection, a time at the onset 
of liver injury, but prior to peak injury.  We did not explore the pharmacokinetics of tranexamic acid in 
this model, and in human patients the tmax could be accelerated by administering this drug by i.v. in 
combination with N-acetylcistein, the current gold standard therapy for APAP poisoning.  Furthermore, 
as patients suffering from APAP overdose are also at risk of bleeding, tranexamic acid might help prevent 
lethal bleeding events by temporarily stabilizing blood clots in these patients until coagulation factor 
levels have recovered.   
Additionally, the role of the plasmin system has also been shown to contribute to liver 
regeneration in several models of liver injury.  We have not evaluated the role of the plasminogen 
activators or plasmin in the recovery phase of APAP-induced hepatotoxicity.  However, increased 
plasminogen activator activity has been shown to promote recovery after acute carbon tetrachloride-
induced liver injury (Shanmukhappa et al., 2006; Hsiao et al., 2008).  As, liver recovery and regeneration 
is of key importance to patients suffering from APAP-toxicity, targeting these enzymes could lead to 
decreased hospitalization times by promoting liver regeneration.  However, if the function of these 
enzymes mimic the resolution phase of carbon tetrachloride-induced liver injury and accelerate hepatic 
recovery, extreme caution would have to be applied when assessing therapeutic targets for APAP-
hepatotoxicity as increased plasminogen activator activity promotes liver injury and hemorrhage in the 
development of early APAP-induced liver injury.       
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Take home message 
In summary, the coagulation cascade is a highly dynamic and regulated pathway that contributes 
to liver injury through various mechanisms which seem to be model dependent.  For example, PAR-1 
protects against early APAP-induced liver injury whereas it does not affect acute ANIT-induced BDEC 
injury.  On the contrary, fibrinogen protects against acute BDEC injury whereas this protein does not 
contribute to acute injury development in APAP-toxicity and worsens biliary fibrosis elicited by chronic 
ANIT-induced BDEC injury.  Interestingly, PAI-1 seems to serve a protective role in APAP-induced liver 
injury whereas this protein promotes liver injury after BDL.  The mechanisms whereby PAI-1 contributes 
to liver injury in these two models of liver injury are not known, but could involve plasmin and the 
plasminogen activators as these proteins have been shown to be involved in liver regeneration. 
Similarly, dual roles for platelets via the thrombin receptor can also be drawn in ANIT-induced 
cholestatic liver injury.  Our data suggest that in the acute ANIT model of BDEC injury platelets protect 
against early injury in mice, whereas they serve a protective role in the progression stage of acute liver 
injury.  Interestingly, platelets also protect against BLD-induced liver fibrosis, suggesting a more complex 
and possibly biphasic role for thrombocytes in the development of cholestatic-induced liver injury.  
Interestingly, APAP hepatotoxicity is also associated with thrombocytopenia and several molecules 
known to inhibit platelets also inhibit injury in APAP-induced hepatotoxicity.  However, a direct 
investigation on the role of platelets in APAP-induced hepatotoxicity has not been performed.  
Furthermore, as both patients suffering from APAP poisoning and end stage liver cirrhosis are at risk of 
bleeding, platelet therapy might reduce the risk of spontaneous bleeding events in these patients.   
While several models have shown roles for one or more coagulation factors in liver injury, there 
is a lack of comprehensive understanding on the mechanisms whereby these factors participate in liver 
injury and disease.  Additionally, several liver injury models have shown that components of the 
coagulation cascade contribute to liver injury in a model-dependent fashion.  Furthermore, individual 
coagulation factors reviewed and tested within this dissertation seem to have differential and sometimes 
opposing effects within the same model at different phases of the injury process.  A systematic approach 
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looking at the role of individual coagulation factors during these phases within each model could provide 
a more accurate and encompasing understanding of how these factors contribute to liver injury.  
Understanding how each of these factors contributes to the orchestra of liver injury and regeneration 
could help reveal new therapeutic targets to prevent liver injury and promote liver repair and regeneration 
in human patients.   
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